Medtronic (MDT) 10-Q 28 Feb 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jan. 24, 2020	Feb. 25, 2020
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jan. 24, 2020
Document Transition Report	false
Entity File Number	001-36820
Entity Registrant Name	Medtronic plc
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1183488
Entity Address, Address Line One	20 On Hatch, Lower Hatch Street
Entity Address, City or Town	Dublin 2
Entity Address, Country	IE
Country Region	353
City Area Code	1
Local Phone Number	438-1700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Ordinary Shares Outstanding		1,340,166,137
Entity Central Index Key	0001613103
Amendment Flag	false
Current Fiscal Year End Date	--04-24
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Address, Postal Zip Code	D02 XH02
Ordinary shares, par value $0.0001 per share
Entity Information [Line Items]
Title of 12(b) Security	Ordinary shares, par value $0.0001 per share
Trading Symbol	MDT
Security Exchange Name	NYSE
Floating Rate Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	Floating Rate Notes due 2021
Trading Symbol	MDT/21
Security Exchange Name	NYSE
0.000% Senior Notes due 2021
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2021
Trading Symbol	MDT/21A
Security Exchange Name	NYSE
0.000% Senior Notes due 2022
Entity Information [Line Items]
Title of 12(b) Security	0.000% Senior Notes due 2022
Trading Symbol	MDT/22B
Security Exchange Name	NYSE
0.375% Senior Notes due 2023
Entity Information [Line Items]
Title of 12(b) Security	0.375% Senior Notes due 2023
Trading Symbol	MDT/23B
Security Exchange Name	NYSE
0.25% Senior Notes due 2025
Entity Information [Line Items]
Title of 12(b) Security	0.25% Senior Notes due 2025
Trading Symbol	MDT/25
Security Exchange Name	NYSE
1.125% Notes due 2027
Entity Information [Line Items]
Title of 12(b) Security	1.125% Notes due 2027
Trading Symbol	MDT/27
Security Exchange Name	NYSE
1.625% Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.625% Notes due 2031
Trading Symbol	MDT/31
Security Exchange Name	NYSE
1.00% Senior Notes due 2031
Entity Information [Line Items]
Title of 12(b) Security	1.00% Senior Notes due 2031
Trading Symbol	MDT/31A
Security Exchange Name	NYSE
2.250% Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	2.250% Notes due 2039
Trading Symbol	MDT/39A
Security Exchange Name	NYSE
1.50% Senior Notes due 2039
Entity Information [Line Items]
Title of 12(b) Security	1.50% Senior Notes due 2039
Trading Symbol	MDT/39B
Security Exchange Name	NYSE
1.75% Senior Notes due 2049
Entity Information [Line Items]
Title of 12(b) Security	1.75% Senior Notes due 2049
Trading Symbol	MDT/49
Security Exchange Name	NYSE

Consolidated Statements of Inco

Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Jan. 24, 2020	Oct. 25, 2019	Jul. 26, 2019	Jan. 25, 2019	Oct. 26, 2018	Jul. 27, 2018	Jan. 24, 2020	Jan. 25, 2019
Income Statement [Abstract]
Net sales	$ 7,717			$ 7,546			$ 22,916	$ 22,411
Costs and expenses:
Cost of products sold	2,400			2,265			7,160	6,672
Research and development expense	573			561			1,763	1,736
Selling, general, and administrative expense	2,587			2,596			7,750	7,798
Amortization of intangible assets	436			436			1,317	1,327
Restructuring charges, net	13			26			87	112
Certain litigation charges	108			63			276	166
Other operating (income) expense, net	(39)			57			88	278
Operating profit (loss)	1,639			1,542			4,475	4,322
Other non-operating income, net	(96)			(71)			(305)	(309)
Interest expense	156			243			930	726
Income (loss) before income taxes	1,579			1,370			3,850	3,905
Income tax provision	(340)			99			(317)	437
Net income (loss)	1,919	$ 1,371	$ 877	1,271	$ 1,120	$ 1,077	4,167	3,468
Net income attributable to noncontrolling interests	(4)			(2)			(24)	(9)
Net income (loss) attributable to Medtronic	$ 1,915			$ 1,269			$ 4,143	$ 3,459
Basic earnings per share (usd per share)	$ 1.43			$ 0.95			$ 3.09	$ 2.57
Diluted earnings per share (usd per share)	$ 1.42			$ 0.94			$ 3.07	$ 2.54
Basic weighted average shares outstanding (shares)	1,340.5			1,342.8			1,340.7	1,348.1
Diluted weighted average shares outstanding (shares)	1,351.5			1,352.7			1,351.6	1,359.5

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Statement of Comprehensive Income [Abstract]
Net income	$ 1,919	$ 1,271	$ 4,167	$ 3,468
Other comprehensive income (loss), net of tax:
Unrealized gain on investment securities	20	32	93	23
Translation adjustment	32	128	(116)	(1,127)
Net investment hedge	35		187
Net investment hedge		0		0
Net change in retirement obligations	13	17	38	65
Unrealized (loss) gain on cash flow hedges	(35)		(37)
Unrealized (loss) gain on cash flow hedges		(23)		317
Other comprehensive income (loss)	65	154	165	(722)
Comprehensive income including noncontrolling interests	1,984	1,425	4,332	2,746
Comprehensive income attributable to noncontrolling interests	(4)	(2)	(24)	(6)
Comprehensive income attributable to Medtronic	$ 1,980	$ 1,423	$ 4,308	$ 2,740

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Current assets:
Cash and cash equivalents	$ 3,709	$ 4,393
Investments	7,919	5,455
Accounts receivable, less allowances of $205 and $190, respectively	6,248	6,222
Inventories, net	4,122	3,753
Other current assets	2,045	2,144
Total current assets	24,043	21,967
Property, plant, and equipment	11,507	10,920
Accumulated depreciation	(6,743)	(6,245)
Property, plant, and equipment, net	4,764	4,675
Goodwill	40,091	39,959
Other intangible assets, net	19,456	20,560
Tax assets	2,272	1,519
Other assets	2,196	1,014
Total assets	92,822	89,694
Current liabilities:
Current debt obligations	844	838
Accounts payable	1,945	1,953
Accrued compensation	1,909	2,189
Accrued income taxes	457	567
Other accrued expenses	3,580	2,925
Total current liabilities	8,735	8,472
Long-term debt	24,732	24,486
Accrued compensation and retirement benefits	1,598	1,651
Accrued income taxes	2,738	2,838
Deferred tax liabilities	1,282	1,278
Other liabilities	1,784	757
Total liabilities	40,869	39,482
Commitments and contingencies (Note 17)
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,340,786,042 and 1,340,697,595 shares issued and outstanding, respectively	0	0
Additional paid-in capital	26,144	26,532
Retained earnings	28,210	26,270
Accumulated other comprehensive loss	(2,546)	(2,711)
Total shareholders’ equity	51,808	50,091
Noncontrolling interests	145	121
Total equity	51,953	50,212
Total liabilities and equity	$ 92,822	$ 89,694

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 205	$ 190
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001
Ordinary shares authorized (shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (shares)	1,340,786,042	1,340,697,595
Ordinary shares outstanding (shares)	1,340,786,042	1,340,697,595

Consolidated Statements of Equi

Consolidated Statements of Equity (Unaudited) - USD ($) $ in Millions	Total	Total Shareholders’ Equity	Ordinary Shares	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Beginning balance (shares) at Apr. 27, 2018			1,354,000,000
Beginning balance at Apr. 27, 2018	$ 50,822	$ 50,720	$ 0	$ 28,127	$ 24,379	$ (1,786)	$ 102
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,077	1,075			1,075		2
Other comprehensive income (loss)	(584)	(584)				(584)
Dividends to shareholders	(677)	(677)			(677)
Issuance of shares under stock purchase and award plans (shares)			7,000,000
Issuance of shares under stock purchase and award plans	446	446		446
Repurchase of ordinary shares (shares)			(9,000,000)
Repurchase of ordinary shares	(820)	(820)		(820)
Stock-based compensation	64	64		64
Changes to noncontrolling ownership interests	1						1
Ending balance (shares) at Jul. 27, 2018			1,352,000,000
Ending balance at Jul. 27, 2018	50,329	50,224	$ 0	27,817	24,730	(2,323)	105
Beginning balance (shares) at Apr. 27, 2018			1,354,000,000
Beginning balance at Apr. 27, 2018	50,822	50,720	$ 0	28,127	24,379	(1,786)	102
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	3,468
Other comprehensive income (loss)	(722)					(719)
Ending balance (shares) at Jan. 25, 2019			1,341,000,000
Ending balance at Jan. 25, 2019	49,941	49,829	$ 0	26,518	25,769	(2,458)	112
Beginning balance (shares) at Jul. 27, 2018			1,352,000,000
Beginning balance at Jul. 27, 2018	50,329	50,224	$ 0	27,817	24,730	(2,323)	105
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,120	1,115			1,115		5
Other comprehensive income (loss)	(292)	(289)				(289)	(3)
Dividends to shareholders	(674)	(674)			(674)
Issuance of shares under stock purchase and award plans (shares)			7,000,000
Issuance of shares under stock purchase and award plans	298	298		298
Repurchase of ordinary shares (shares)			(13,000,000)
Repurchase of ordinary shares	(1,171)	(1,171)		(1,171)
Stock-based compensation	104	104		104
Ending balance (shares) at Oct. 26, 2018			1,346,000,000
Ending balance at Oct. 26, 2018	49,714	49,607	$ 0	27,048	25,171	(2,612)	107
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,271	1,269			1,269		2
Other comprehensive income (loss)	154	154				154
Dividends to shareholders	(671)	(671)			(671)
Issuance of shares under stock purchase and award plans (shares)			2,000,000
Issuance of shares under stock purchase and award plans	82	82		82
Repurchase of ordinary shares (shares)			(7,000,000)
Repurchase of ordinary shares	(672)	(672)		(672)
Stock-based compensation	60	60		60
Changes to noncontrolling ownership interests	3						3
Ending balance (shares) at Jan. 25, 2019			1,341,000,000
Ending balance at Jan. 25, 2019	$ 49,941	49,829	$ 0	26,518	25,769	(2,458)	112
Beginning balance (shares) at Apr. 26, 2019	1,340,697,595		1,341,000,000
Beginning balance at Apr. 26, 2019	$ 50,212	50,091	$ 0	26,532	26,270	(2,711)	121
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	877	864			864		13
Other comprehensive income (loss)	227	227				227
Dividends to shareholders	(724)	(724)			(724)
Issuance of shares under stock purchase and award plans (shares)			3,000,000
Issuance of shares under stock purchase and award plans	205	205		205
Repurchase of ordinary shares (shares)			(3,000,000)
Repurchase of ordinary shares	(328)	(328)		(328)
Stock-based compensation	61	61		61
Ending balance (shares) at Jul. 26, 2019			1,341,000,000
Ending balance at Jul. 26, 2019	$ 50,497	50,363	$ 0	26,470	26,377	(2,484)	134
Beginning balance (shares) at Apr. 26, 2019	1,340,697,595		1,341,000,000
Beginning balance at Apr. 26, 2019	$ 50,212	50,091	$ 0	26,532	26,270	(2,711)	121
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	4,167
Other comprehensive income (loss)	$ 165					165
Ending balance (shares) at Jan. 24, 2020	1,340,786,042		1,341,000,000
Ending balance at Jan. 24, 2020	$ 51,953	51,808	$ 0	26,144	28,210	(2,546)	145
Beginning balance (shares) at Jul. 26, 2019			1,341,000,000
Beginning balance at Jul. 26, 2019	50,497	50,363	$ 0	26,470	26,377	(2,484)	134
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,371	1,364			1,364		7
Other comprehensive income (loss)	(127)	(127)				(127)
Dividends to shareholders	(723)	(723)			(723)
Issuance of shares under stock purchase and award plans (shares)			4,000,000
Issuance of shares under stock purchase and award plans	145	145		145
Repurchase of ordinary shares (shares)			(5,000,000)
Repurchase of ordinary shares	(552)	(552)		(552)
Stock-based compensation	108	108		108
Ending balance (shares) at Oct. 25, 2019			1,340,000,000
Ending balance at Oct. 25, 2019	50,719	50,578	$ 0	26,171	27,018	(2,611)	141
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,919	1,915			1,915		4
Other comprehensive income (loss)	65	65				65
Dividends to shareholders	(723)	(723)			(723)
Issuance of shares under stock purchase and award plans (shares)			3,000,000
Issuance of shares under stock purchase and award plans	143	143		143
Repurchase of ordinary shares (shares)			(2,000,000)
Repurchase of ordinary shares	(236)	(236)		(236)
Stock-based compensation	$ 66	66		66
Ending balance (shares) at Jan. 24, 2020	1,340,786,042		1,341,000,000
Ending balance at Jan. 24, 2020	$ 51,953	$ 51,808	$ 0	$ 26,144	$ 28,210	$ (2,546)	$ 145

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Jan. 24, 2020	Oct. 25, 2019	Jul. 26, 2019	Jan. 25, 2019	Oct. 26, 2018	Jul. 27, 2018
Statement of Stockholders' Equity [Abstract]
Dividends to shareholders (usd per share)	$ 0.54	$ 0.54	$ 0.54	$ 0.50	$ 0.50	$ 0.50

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019
Operating Activities:
Net income	$ 4,167	$ 3,468
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,991	1,992
Provision for doubtful accounts	67	55
Deferred income taxes	(793)	(205)
Stock-based compensation	235	228
Loss on debt extinguishment	406	0
Other, net	140	111
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	(119)	(140)
Inventories, net	(346)	(367)
Accounts payable and accrued liabilities	103	211
Other operating assets and liabilities	(67)	(433)
Net cash provided by operating activities	5,784	4,920
Investing Activities:
Acquisitions, net of cash acquired	(199)	(1,615)
Additions to property, plant, and equipment	(877)	(799)
Purchases of investments	(8,249)	(1,987)
Sales and maturities of investments	5,791	4,159
Other investing activities	(34)	(3)
Net cash provided by (used in) investing activities	(3,568)	(245)
Financing Activities:
Change in current debt obligations, net	17	(696)
Issuance of long-term debt	5,568	3
Payments on long-term debt	(5,606)	(29)
Dividends to shareholders	(2,170)	(2,022)
Issuance of ordinary shares	585	891
Repurchase of ordinary shares	(1,208)	(2,728)
Other financing activities	(74)	10
Net cash provided by (used in) financing activities	(2,888)	(4,571)
Effect of exchange rate changes on cash and cash equivalents	(12)	(70)
Net change in cash and cash equivalents	(684)	34
Cash and cash equivalents at beginning of period	4,393	3,669
Cash and cash equivalents at end of period	3,709	3,703
Cash paid for:
Income taxes	639	1,206
Interest	$ 348	$ 540

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jan. 24, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jan. 24, 2020
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. Others In August 2017, the FASB issued guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The Company adopted this guidance in the first quarter of fiscal year 2020. The adoption of this guidance resulted in expanded disclosures and did not have an impact on the Company's consolidated financial statements. Not Yet Adopted

Revenue

Revenue	9 Months Ended
	Jan. 24, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, renal disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include hospitals, clinics, third-party health care providers, distributors, and other institutions, including governmental health care programs and group purchasing organizations. The table below illustrates net sales by segment and division for the three and nine months ended January 24, 2020 and January 25, 2019: Three months ended (1) Nine months ended (1) (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac Rhythm & Heart Failure $ 1,393 $ 1,397 $ 4,201 $ 4,295 Coronary & Structural Heart 948 913 2,844 2,736 Aortic, Peripheral, & Venous 478 476 1,420 1,424 Cardiac and Vascular Group 2,819 2,786 8,464 8,455 Surgical Innovations 1,474 1,434 4,345 4,224 Respiratory, Gastrointestinal, & Renal 702 690 2,073 1,999 Minimally Invasive Therapies Group 2,176 2,124 6,418 6,223 Brain Therapies 795 732 2,307 2,107 Spine 674 655 2,023 1,963 Specialty Therapies 340 325 996 956 Pain Therapies 303 314 910 942 Restorative Therapies Group 2,111 2,026 6,235 5,968 Diabetes Group 610 610 1,798 1,765 Total $ 7,717 $ 7,546 $ 22,916 $ 22,411 (1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for fiscal year 2019 have been recast to adjust for this realignment. The table below illustrates net sales by market geography for each segment for the three and nine months ended January 24, 2020 and January 25, 2019: U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Three months ended Three months ended Three months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 1,366 $ 1,369 $ 915 $ 924 $ 538 $ 493 Minimally Invasive Therapies Group 934 930 791 796 451 398 Restorative Therapies Group 1,409 1,354 436 435 266 237 Diabetes Group 312 348 236 213 63 49 Total $ 4,021 $ 4,001 $ 2,377 $ 2,368 $ 1,318 $ 1,177 U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Nine months ended Nine months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 4,182 $ 4,240 $ 2,735 $ 2,766 $ 1,547 $ 1,449 Minimally Invasive Therapies Group 2,769 2,659 2,364 2,396 1,285 1,168 Restorative Therapies Group 4,187 4,005 1,278 1,275 770 688 Diabetes Group 930 1,006 693 619 176 140 Total $ 12,068 $ 11,910 $ 7,069 $ 7,056 $ 3,778 $ 3,445 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. (4) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases of revenue. At January 24, 2020, $862 million of rebates were classified as other accrued expenses and $447 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. At April 26, 2019, $764 million of rebates were classified as other accrued expenses and $432 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheets. The Company includes obligations for returns in other accrued expenses in the consolidated balance sheets and the right-of-return asset in other current assets in the consolidated balance sheets. The right-of-return asset and liability at January 24, 2020 and April 26, 2019 were not material. For the three and nine months ended January 24, 2020 and January 25, 2019, adjustments to rebate and return reserves recognized in revenue that were included in the rebate and return reserves at the beginning of the period were not material. Deferred Revenue and Remaining Performance Obligations The Company records a deferred revenue liability if a customer pays consideration before the Company transfers a good or service to the customer. Deferred revenue at January 24, 2020 and April 26, 2019 was $303 million and $315 million, respectively. At January 24, 2020 and April 26, 2019, $212 million and $211 million, respectively, was included in other accrued expenses and $91 million and $104 million, respectively, was included in other liabilities . During the nine months ended January 24, 2020, the Company recognized $192 million of revenue that was included in deferred revenue as of April 26, 2019. Remaining performance obligations include deferred revenue and amounts the Company expects to receive for goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At January 24, 2020, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately $1.2 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next four years.

Acquisitions

Acquisitions	9 Months Ended
	Jan. 24, 2020
Business Combinations [Abstract]
Acquisitions	Acquisitions The Company had acquisitions during the nine months ended January 24, 2020 and January 25, 2019 that were accounted for as business combinations. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the consolidated results of the Company for the three and nine months ended January 24, 2020 and January 25, 2019. The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. Fiscal Year 2020 The acquisition date fair value of net assets acquired during the nine months ended January 24, 2020 was $272 million, consisting of $324 million of assets acquired and $52 million of liabilities assumed. Based upon preliminary valuations, assets acquired were primarily comprised of $139 million of technology-based intangible assets and $26 million of customer-related intangible assets with estimated useful lives ranging from 8 to 16 years, $92 million of goodwill, and $40 million of inventory. The goodwill is not deductible for tax purposes. The Company recognized $65 million of contingent consideration liabilities in connection with business combinations during the nine months ended January 24, 2020, which are comprised of revenue milestone-based payments. For the nine months ended January 24, 2020, purchase price allocation adjustments for fiscal year 2020 business combinations were not significant. Fiscal Year 2019 Mazor Robotics On December 18, 2018, the Company's Restorative Therapies Group acquired Mazor Robotics (Mazor), a pioneer in the field of robotic guidance systems. The acquisition of Mazor strengthened the Company's position as a global leader in enabling technologies for spine surgery. The Company offers a fully-integrated procedural solution for surgical planning, execution and confirmation by combining the Company's spine implants, navigation, and intra-operative imaging technology with Mazor's robotic-assisted surgery systems. Total consideration for the transaction, net of cash acquired, was $1.6 billion, consisting of $1.3 billion of cash and $246 million of a previously-held equity investment in Mazor. Net assets acquired includes $383 million of technology-based intangible assets and $16 million of tradenames with estimated useful lives of 10 years. Goodwill was primarily attributable to pull-through revenue, future yet to be defined technologies, and an assembled workforce and was not deductible for tax purposes. During the three and nine months ended January 25, 2019, the Company recognized $51 million of costs incurred in connection with the acquisition of Mazor, including payouts for unvested stock options and investment banker and other transaction fees, which were recognized in selling, general, and administrative expense in the consolidated statements of income. The Company made certain adjustments to the allocation of purchase price for the Mazor acquisition during the fourth quarter of fiscal year 2019 and nine months ended January 24, 2020, primarily related to estimates for certain contingent liabilities and deferred taxes, which resulted in a net increase to goodwill of $105 million. The measurement period for the Mazor acquisition closed during the quarter ended January 24, 2020. The fair values of the assets acquired and liabilities assumed were as follows: (in millions) Mazor Robotics Cash and cash equivalents $ 109 Investments 52 Accounts receivable 9 Inventory 5 Other current assets 1 Property, plant, and equipment 3 Goodwill 1,318 Other intangible assets 399 Tax assets 9 Total assets acquired 1,905 Current liabilities 210 Deferred tax liabilities 21 Total liabilities assumed 231 Net assets acquired $ 1,674 Other Fiscal Year 2019 Acquisitions The remaining acquisition date fair value of net assets acquired during the nine months ended January 25, 2019 was $377 million, consisting of $427 million of assets acquired and $50 million of liabilities assumed. Assets acquired were primarily comprised of $146 million of goodwill, $161 million of technology-based intangible assets with estimated useful lives ranging from 4 to 15 years, and $40 million of customer-related intangible assets with estimated useful lives ranging from 10 to 13 years. The Company recognized $51 million of contingent consideration liabilities in connection with business combinations during the nine months ended January 25, 2019. For the nine months ended January 25, 2019, purchase price allocation adjustments were not significant. Acquired In-Process Research & Development In-process research and development (IPR&D) acquired outside of a business combination is expensed immediately. During the three and nine months ended January 25, 2019, the Company acquired $15 million of IPR&D in connection with an asset acquisition, which was recognized in other operating (income) expense, net in the consolidated statements of income. The Company did not acquire any IPR&D in connection with an asset acquisition during the three and nine months ended January 24, 2020. Contingent Consideration Certain of the Company’s business combinations and intangible asset acquisitions involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating (income) expense, net in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of contingent consideration at January 24, 2020 and April 26, 2019 was $304 million and $222 million, respectively. At January 24, 2020, $147 million was recorded in other accrued expenses and $157 million was recorded in other liabilities in the consolidated balance sheets. At April 26, 2019, $73 million was recorded in other accrued expenses and $149 million was recorded in other liabilities in the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Beginning balance $ 260 $ 203 $ 222 $ 173 Purchase price contingent consideration 45 5 110 51 Payments (3) (1) (32) (8) Change in fair value 2 (59) 4 (68) Ending balance $ 304 $ 148 $ 304 $ 148 The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based consideration). Projected revenues are based on the Company's most recent internal operational budgets and long-range strategic plans. Changes in projected payment dates, discount rates, probabilities of payment, and projected revenues may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) January 24, 2020 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $123 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2020 - 2026 Discount rate 5.5% Product development and other milestone-based payments $181 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027

Restructuring

Restructuring	9 Months Ended
	Jan. 24, 2020
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In the third quarter of fiscal year 2018, the Company announced its Enterprise Excellence restructuring program, which is expected to leverage the Company's global size and scale, as well as enhance the customer and employee experience, with a focus on three objectives: global operations, functional optimization, and commercial optimization. Primary activities of the restructuring program include integrating and enhancing global manufacturing and supply processes, systems and site presence, enhancing and leveraging global operating models across several enabling functions, and optimizing certain commercial processes, systems, and models. The Company estimates that, in connection with its Enterprise Excellence restructuring program, it will recognize pre-tax exit and disposal costs and other costs across all segments of approximately $1.6 billion to $1.8 billion, the majority of which are expected to be incurred by the end of fiscal year 2022. Approximately half of the estimated charges are related to employee termination benefits. The remaining charges are costs associated with the restructuring program, such as salaries for employees supporting the program and consulting expenses. These charges are recognized within restructuring charges, net, cost of products sold, and selling, general, and administrative expense in the consolidated statements of income. For the three and nine months ended January 24, 2020, the Company recognized charges of $97 million and $328 million, respectively. Additionally, the Company incurred accrual adjustments of $13 million for the nine months ended January 24, 2020, related to certain employees identified for termination finding other positions within Medtronic. For the three and nine months ended January 24, 2020, charges included $50 million and $117 million, respectively, recognized within cost of products sold and $34 million and $111 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income. For the three and nine months ended January 25, 2019, the Company recognized charges of $69 million and $264 million, respectively. Additionally, the Company incurred accrual adjustments of $3 million and $8 million for the three and nine months ended January 25, 2019, respectively, related to certain employees identified for termination finding other positions within Medtronic. For the three and nine months ended January 25, 2019, charges included $21 million and $58 million, respectively, recognized within cost of products sold and $19 million and $86 million, respectively, recognized within selling, general, and administrative expense in the consolidated statements of income. The following table summarizes the activity related to the Enterprise Excellence restructuring program for the nine months ended January 24, 2020: (in millions) Employee Termination Benefits Associated Costs (1) Asset Write-Downs (2) Other Costs Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 91 223 6 8 328 Cash payments (118) (223) — (8) (349) Settled non-cash — — (6) — (6) Accrual adjustments (5) — — (8) (13) January 24, 2020 $ 69 $ 9 $ — $ 4 $ 82 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Recognized within cost of products sold in the consolidated statements of income.

Financial Instruments

Financial Instruments	9 Months Ended
	Jan. 24, 2020
Investments [Abstract]
Financial Instruments	Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at January 24, 2020 and April 26, 2019: January 24, 2020 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 623 $ 17 $ — $ 640 $ 640 $ — Level 2: Corporate debt securities 5,155 52 (8) 5,199 5,199 — U.S. government and agency securities 900 — — 900 900 — Mortgage-backed securities 655 13 (13) 655 655 — Non-U.S. government and agency securities 13 — — 13 13 — Other asset-backed securities 511 3 (2) 512 512 — Total Level 2 7,234 68 (23) 7,279 7,279 — Level 3: Auction rate securities 36 — (3) 33 — 33 Total available-for-sale debt securities $ 7,893 $ 85 $ (26) $ 7,952 $ 7,919 $ 33 April 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 529 $ 1 $ (7) $ 523 $ 523 $ — Level 2: Corporate debt securities 3,500 14 (21) 3,493 3,493 — U.S. government and agency securities 387 1 (7) 381 381 — Mortgage-backed securities 537 3 (20) 520 520 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 529 1 (3) 527 527 — Total Level 2 4,964 19 (51) 4,932 4,932 — Level 3: Auction rate securities 47 — (3) 44 — 44 Total available-for-sale debt securities $ 5,540 $ 20 $ (61) $ 5,499 $ 5,455 $ 44 The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 24, 2020 and April 26, 2019: January 24, 2020 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 96 $ — $ 40 $ — Corporate debt securities 371 (3) 65 (5) Mortgage-backed securities 82 (1) 63 (12) Other asset-backed securities 23 — 165 (2) Auction rate securities — — 33 (3) Total $ 572 $ (4) $ 366 $ (22) April 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 130 $ (1) $ 649 $ (13) Corporate debt securities 582 (5) 1,153 (16) Mortgage-backed securities 73 (1) 250 (19) Other asset-backed securities 290 (2) 85 (1) Auction rate securities — — 44 (3) Total $ 1,075 $ (9) $ 2,181 $ (52) The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and nine months ended January 24, 2020 and January 25, 2019. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. During the three and nine months ended January 24, 2020, the Company redeemed $11 million worth of level 3 investments at par value. No gain or loss was recognized on the redemption. There were no purchases, sales, settlements, or gains or losses recognized in earnings or other comprehensive income for available-for-sale securities classified as Level 3 during the three and nine months ended January 25, 2019. Activity related to the Company’s debt securities portfolio is as follows: Three months ended Nine months Ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Proceeds from sales $ 2,531 $ 1,301 $ 5,789 $ 3,217 Gross realized gains 9 9 17 17 Gross realized losses (2) (36) (13) (55) Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At January 24, 2020 and April 26, 2019, the credit loss portion of other-than-temporary impairments on debt securities was not significant. No available-for-sale securities were sold for significantly less than carrying value during the three and nine months ended January 24, 2020 and January 25, 2019. The January 24, 2020 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 24, 2020 Due in one year or less $ 3,595 Due after one year through five years 2,727 Due after five years through ten years 1,577 Due after ten years 53 Total $ 7,952 Equity Securities, Equity Method Investments, and Other Investments The Company holds investments in equity securities with and without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments and investments without readily determinable fair values are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the investees, including financial statements, market participant valuations from recent and proposed equity offerings, and other third-party data. The following table summarizes the Company's equity and other investments at January 24, 2020 and April 26, 2019, which are classified as other assets in the consolidated balance sheets: (in millions) January 24, 2020 April 26, 2019 Investments with readily determinable fair value (marketable equity securities) $ 39 $ — Investments without readily determinable fair values 373 308 Equity method and other investments 68 64 Total equity and other investments $ 480 $ 372 The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Proceeds from sales $ — $ 33 $ 2 $ 941 Gross gains 1 8 16 131 Gross losses — (1) — (30) Impairment losses recognized (1) — (5) (12)

Financing Arrangements

Financing Arrangements	9 Months Ended
	Jan. 24, 2020
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. No commercial paper was outstanding at both January 24, 2020 and April 26, 2019. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreement also contains customary covenants, all of which the Company was in compliance with at January 24, 2020. Debt Obligations The Company's debt obligations consisted of the following: (in millions) Maturity by January 24, 2020 April 26, 2019 Current debt obligations 2020 - 2021 $ 844 $ 838 Long-term debt 0.000 percent two 2021 1,662 1,681 Floating rate two 2021 831 560 4.125 percent ten 2021 — 500 3.150 percent seven 2022 1,534 2,500 3.125 percent ten 2022 — 675 3.200 percent ten 2023 650 650 0.375 percent four 2023 1,662 1,681 2.750 percent ten 2023 530 530 0.000 percent four 2023 831 — 2.950 percent ten 2024 310 310 3.625 percent ten 2024 432 850 3.500 percent ten 2025 2,700 4,000 0.250 percent seven 2026 1,108 — 1.125 percent eight 2027 1,662 1,681 3.350 percent ten 2027 368 850 1.625 percent twelve 2031 1,108 1,121 1.000 percent thirteen 2032 1,108 — 4.375 percent twenty 2035 1,931 2,382 6.550 percent thirty 2038 253 284 2.250 percent twenty 2039 1,108 1,121 6.500 percent thirty 2039 158 183 5.550 percent thirty 2040 224 306 1.500 percent twenty 2040 1,108 — 4.500 percent thirty 2042 105 129 4.000 percent thirty 2043 305 325 4.625 percent thirty 2044 127 177 4.625 percent thirty 2045 1,813 1,963 1.750 percent thirty 2050 1,108 — Bank borrowings 2021 - 2022 70 83 Debt (discount) premium, net 2020 - 2050 (15) 29 Finance lease obligations 2021 - 2033 47 10 Interest rate swaps N/A — 9 Deferred financing costs 2020 - 2050 (106) (104) Long-term debt $ 24,732 $ 24,486 Senior Notes The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at January 24, 2020. In June 2019, Medtronic Luxco issued six tranches of Euro-denominated Senior Notes with an aggregate principal of €5.0 billion, with maturities ranging from fiscal year 2021 to fiscal year 2050, resulting in cash proceeds of approximately $5.6 billion, net of discounts and issuance costs. The issuance included €250 million of floating rate Senior Notes due in fiscal year 2021, €750 million of 0.000 percent Senior Notes due in fiscal year 2023, €1.0 billion of 0.250 percent Senior Notes due in fiscal year 2026, €1.0 billion of 1.000 percent Senior Notes due in fiscal year 2032, €1.0 billion of 1.500 percent Senior Notes due in fiscal year 2040, and €1.0 billion of 1.750 percent Senior Notes due in fiscal year 2050. The Company used the net proceeds of the offering to fund the cash tender offer and early redemption, described below. The Euro-denominated debt is designated as a net investment hedge of certain of the Company's European operations. Refer to Note 8 for additional information regarding the net investment hedge. The Company completed the cash tender offer of $4.6 billion of Medtronic Inc., CIFSA, and Medtronic Luxco Senior Notes for $5.0 billion of total consideration in July 2019. The Company recognized a loss on debt extinguishment of $413 million during the first quarter of fiscal year 2020, which primarily included cash premiums and accelerated amortization of deferred financing costs and debt discounts and premiums. The loss on debt extinguishment also included a $16 million charge for the estimated early redemption premium for $533 million of senior notes which were redeemed in August 2019. The loss on debt extinguishment was recognized in interest expense in the consolidated statements of income. Financial Instruments Not Measured at Fair Value At January 24, 2020, the estimated fair value of the Company’s Senior Notes was $27.5 billion compared to a principal value of $25.2 billion. At April 26, 2019, the estimated fair value was $26.2 billion compared to a principal value of $25.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

Derivatives and Currency Exchan

Derivatives and Currency Exchange Risk Management	9 Months Ended
	Jan. 24, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Currency Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, including currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro, Japanese Yen, and British Pound. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $12.1 billion and $11.1 billion at January 24, 2020 and April 26, 2019, respectively. The Company also uses derivative and non-derivative instruments to manage the impact of currency exchange rate changes on net investments in foreign currency-denominated operations. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets and statements of income. Freestanding Derivative Contracts Freestanding derivative contracts are primarily used to offset the Company’s exposure to the change in value of specific foreign-currency-denominated assets and liabilities, and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. The gross notional amount of the Company's freestanding currency exchange rate contracts outstanding at January 24, 2020 and April 26, 2019 was $5.2 billion and $4.3 billion, respectively. The Company's freestanding currency exchange rate contracts are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign-currency-denominated assets, liabilities, and cash flows. The Company also uses total return swaps to hedge the liability of a non-qualified, deferred compensation plan. The gross notional amount of the Company's total return swaps outstanding at January 24, 2020 and April 26, 2019 was $215 million and $191 million, respectively. The Company's total return swaps are not designated as hedges, and therefore, changes in the value of these instruments are recognized in earnings. The cash flows related to the Company's freestanding derivative contracts are reported as operating activities in the consolidated statements of cash flows. The amounts and classification of the (gains) losses in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended (in millions) Classification January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Currency exchange rate contracts Other operating (income) expense, net $ 2 $ 30 $ (4) $ (171) Total return swaps Other operating (income) expense, net (17) — (22) — Total $ (15) $ 30 $ (26) $ (171) Cash Flow Hedges Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. The gross notional amount of these contracts, designated as cash flow hedges, outstanding at January 24, 2020 and April 26, 2019 was $6.9 billion and $6.8 billion, respectively, and will mature within the subsequent two accumulated other comprehensive loss . The gain or loss on the derivative instrument is reclassified into earnings and is included in other operating (income) expense, net in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings in the current period. The cash flows related to all of the Company's derivative instruments designated as cash flow hedges are reported as operating activities in the consolidated statements of cash flows. No components of the hedge contracts were excluded in the measurement of hedge effectiveness, and no forward contracts designated as cash flow hedges were derecognized or discontinued during the three and nine months ended January 24, 2020 and January 25, 2019. The amount of the (gains) losses recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Currency exchange rate contracts $ (41) $ (25) $ (144) $ (469) The amount of the (gains) losses recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 (in millions) Other operating (income) expense, net Other operating (income) expense, net Other operating (income) expense, net Other operating (income) expense, net Total amounts of income and expense line items presented in the consolidated statements of income in which the effects of cash flow hedges are recorded $ (39) $ 57 $ 88 $ 278 Currency exchange rate contracts designated as cash flow hedges: Amount of (gain) loss reclassified from AOCI into income (82) (48) (206) (56) Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. The gains or losses on forward starting interest rate derivative instruments that are designated and qualify as cash flow hedges are reported as a component of accumulated other comprehensive loss . Beginning in the period in which the planned debt issuance occurs and the related derivative instruments are terminated, the gains or losses are then reclassified into interest expense over the term of the related debt. For the three and nine months ended January 24, 2020 and January 25, 2019, the reclassifications of net (gains) losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense were not significant. At January 24, 2020 and April 26, 2019 the Company had $157 million and $194 million, respectively, in after-tax net unrealized gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $145 million of after-tax net unrealized gains at January 24, 2020 will be recognized in the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. Changes in the fair value of the derivative instrument are recognized in interest expense and are offset by changes in the fair value of the underlying debt instrument. The gains from terminated interest rate swap agreements are recognized in long-term debt , increasing the outstanding balances of the debt, and amortized as a reduction of interest expense over the remaining life of the related debt. The cash flows related to the Company's interest rate derivative instruments designated as fair value hedges are reported as operating activities in the consolidated statements of cash flows. At January 24, 2020 the Company had no interest rate swaps outstanding designated as fair value hedges, as the Company terminated previously held swaps in connection with the tender and early redemption of the underlying senior notes during the first quarter of fiscal year 2020. At April 26, 2019, the Company had interest rate swaps in gross notional amounts of $1.2 billion, designated as fair value hedges of underlying fixed-rate senior note obligations, including the Company's $500 million 4.125 percent 2011 Senior Notes due fiscal year 2021 and the $675 million 3.125 percent 2012 Senior Notes due fiscal year 2022. The gain recognized upon termination of interest rate swaps was not significant for the three and nine months ended January 24, 2020. At April 26, 2019, the market value of outstanding interest rate swap agreements was an unrealized gain of $9 million which was recorded in other assets , with the offset recorded in long-term debt on the consolidated balance sheets. The Company did not recognize any gains or losses during the three or nine months ended January 24, 2020 and January 25, 2019 on firm commitments that no longer qualify as fair value hedges. The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges: (in millions) Carrying Amount of Hedged Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities) Location on the Consolidated Balance Sheet January 24, 2020 April 26, 2019 January 24, 2020 April 26, 2019 Long-term debt $ — $ (1,175) $ — $ 9 Net Investment Hedges The Company has designated Euro-denominated debt as a net investment hedge of certain of its European operations to manage the exposure to currency and exchange rate movements for foreign currency-denominated net investments in foreign operations. At January 24, 2020, the Company had €12.0 billion, or $13.3 billion, of outstanding Euro-denominated debt designated as a hedge of its net investment in certain of its European operations, which will mature in fiscal years 2021 through 2050. Additionally, during the first quarter of fiscal year 2020, the Company entered into and settled forward currency exchange rate contracts to manage the exposure to exchange rate movements in anticipation of the issuance of Euro-denominated senior notes. Certain of these forward currency exchange rate contracts were designated as a net investment hedge of certain of the Company's European operations. These contracts matured in conjunction with the issuance of Euro-denominated debt in the first quarter of fiscal year 2020. For instruments that are designated and qualify as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss . The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in other operating (income) expense, net . The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. At January 24, 2020 and April 26, 2019 the Company had $18 million in after-tax unrealized gains, and $169 million in after-tax unrealized losses, respectively, associated with net investment hedges recorded in accumulated other comprehensive loss . The Company does not expect any of the after-tax unrealized gains at January 24, 2020 to be recognized in the consolidated statements of income over the next 12 months. The Company did not recognize any gains or losses during the three or nine months ended January 24, 2020 or January 25, 2019 on instruments that no longer qualify as net investment hedges. The amount and classifications of the (gains) losses recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows: Three months ended Nine months ended (in millions) Classification January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Net investment hedges Other operating (income) expense, net $ — $ — $ (7) $ — The amount of the (gains) losses recognized in AOCI related to instruments designated as net investment hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Net investment hedges $ (35) $ — $ (187) $ — Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 24, 2020 and April 26, 2019. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. January 24, 2020 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 183 Other accrued expenses $ 11 Currency exchange rate contracts Other assets 75 Other liabilities 12 Total derivatives designated as hedging instruments 258 23 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 9 Other accrued expenses 10 Total return swap Other current assets 16 Other accrued expenses — Cross currency interest rate contracts Other current assets 1 Other accrued expenses — Total derivatives not designated as hedging instruments 26 10 Total derivatives $ 284 $ 33 April 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 234 Other accrued expenses $ 1 Interest rate contracts Other assets 9 Other liabilities — Currency exchange rate contracts Other assets 78 Other liabilities 1 Total derivatives designated as hedging instruments 321 2 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 23 Other accrued expenses 17 Total return swaps Other current assets 15 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 44 17 Total derivatives $ 365 $ 19 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. January 24, 2020 April 26, 2019 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 267 $ 17 $ 335 $ 30 Derivative liabilities 33 — 19 — The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows. The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 24, 2020 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 267 $ (33) $ (5) $ 229 Total return swaps 16 — — 16 Cross currency interest rate contracts 1 — — 1 284 (33) (5) 246 Derivative liabilities: Currency exchange rate contracts (33) 33 — — (33) 33 — — Total $ 251 $ — $ (5) $ 246 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9) $ (43) $ 283 Interest rate contracts 9 — (1) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9) (44) 312 Derivative liabilities: Currency exchange rate contracts (19) 9 — (10) (19) 9 — (10) Total $ 346 $ — $ (44) $ 302

Inventories

Inventories	9 Months Ended
	Jan. 24, 2020
Inventory Disclosure [Abstract]
Inventories	Inventories Inventory balances, net of reserves, were as follows: (in millions) January 24, 2020 April 26, 2019 Finished goods $ 2,693 $ 2,476 Work in-process 643 572 Raw materials 786 705 Total $ 4,122 $ 3,753

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Jan. 24, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 26, 2019 $ 6,854 $ 20,381 $ 10,821 $ 1,903 $ 39,959 Goodwill as a result of acquisitions — 11 65 16 92 Purchase accounting adjustments 7 2 119 (5) 123 Currency translation and other 5 (59) (29) — (83) January 24, 2020 $ 6,866 $ 20,335 $ 10,976 $ 1,914 $ 40,091 The Company assesses goodwill for impairment annually as of the first day of the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did not recognize any goodwill impairment during the three and nine months ended January 24, 2020 or January 25, 2019. Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets: January 24, 2020 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,971 $ (4,824) $ 16,944 $ (4,095) Purchased technology and patents 10,640 (4,178) 11,405 (4,570) Trademarks and tradenames 464 (228) 570 (324) Other 83 (54) 85 (59) Total $ 28,158 $ (9,284) $ 29,004 $ (9,048) Indefinite-lived: IPR&D $ 582 $ — $ 604 $ — The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying value of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not recognize any definite-lived intangible asset charges during the three months ended January 24, 2020. During the nine months ended January 24, 2020, the Company recognized $33 million of definite-lived intangible asset charges in connection with the exit of businesses within the Restorative Therapies Group segment. During the three months ended January 25, 2019, the Company recognized $26 million of definite-lived intangible asset charges in connection with business exits within the Restorative Therapies Group segment. During the nine months ended January 25, 2019, the Company recognized $87 million of definite-lived intangible asset charges, including $26 million and $61 million of charges in connection with business exits within the Restorative Therapies Group and Cardiac and Vascular Group segments, respectively. Definite-lived intangible asset impairment charges are recognized in other operating (income) expense, net in the consolidated statements of income. The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying value may be impaired. The Company did not recognize any indefinite-lived intangible asset impairments during the three and nine months ended January 24, 2020. During the three and nine months ended January 25, 2019, the Company recognized $21 million of indefinite-lived intangible asset charges, including $11 million in connection with a business exit within the Restorative Therapies Group segment. Indefinite-lived intangible asset charges are recognized in other operating (income) expense, net in the consolidated statements of income. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three and nine months ended January 24, 2020 and January 25, 2019 was $436 million and $1.3 billion, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 24, 2020, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2020 $ 437 2021 1,741 2022 1,699 2023 1,634 2024 1,605 2025 1,576

Income Taxes

Income Taxes	9 Months Ended
	Jan. 24, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company's effective tax rate for the three and nine months ended January 24, 2020 was (21.5) percent and (8.2) percent, respectively, as compared to 7.2 percent and 11.2 percent for the three and nine months ended January 25, 2019, respectively. The decrease in the effective tax rate for the three and nine months ended January 24, 2020, as compared to the corresponding periods in the prior fiscal year, was primarily due to the impact of certain tax adjustments described below. Certain Tax Adjustments During the three months ended January 24, 2020, the benefit from certain tax adjustments of $558 million, recognized in income tax provision in the consolidated statements of income, included the following: • A benefit of $558 million related to the release of a valuation allowance previously recorded against certain net operating losses. Luxembourg enacted tax legislation during the quarter which required the Company to reassess the realizability of certain net operating losses. The Company evaluated both the positive and negative evidence and released valuation allowance equal to the expected benefit from the utilization of certain net operating losses in connection with a planned intercompany sale of intellectual property. During the nine months ended January 24, 2020, the net benefit from certain tax adjustments of $839 million, recognized in income tax provision in the consolidated statements of income, included the following: • A net benefit of $30 million related to U.S. Treasury’s issuance of certain Final Regulations associated with U.S. Tax Reform. The primary impact of these regulations resulted in the Company re-establishing its permanently reinvested assertion on certain foreign earnings and reversing the previously accrued tax liability. This benefit was partially offset by additional tax associated with a previously executed internal reorganization of certain foreign subsidiaries. • A benefit of $251 million related to tax legislative changes in Switzerland which abolished certain preferential tax regimes the Company benefited from and replaced them with a new set of internationally accepted measures. The legislation provided for higher effective tax rates but allowed for a transitional period whereby an amortizable asset was created for Swiss federal income tax purposes which will be amortized and deducted over a 10-year period. • A benefit of $558 million related to the release of a valuation allowance previously recorded against certain net operating losses. Luxembourg enacted tax legislation during the quarter which required the Company to reassess the realizability of certain net operating losses. The Company evaluated both the positive and negative evidence and released valuation allowance equal to the expected benefit from the utilization of certain net operating losses in connection with a planned intercompany sale of intellectual property. During the three months ended January 25, 2019, the net benefit from certain tax adjustments of $64 million, recognized in income tax provision in the consolidated statements of income, included the following: • A net benefit of $12 million associated with the transition tax liability and the impacts of U.S. Tax Reform on deferred tax assets, liabilities, and valuation allowances. • A benefit of $32 million related to intercompany legal entity restructuring. • A net benefit of $20 million associated with the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. During the nine months ended January 25, 2019, the net benefit from certain tax adjustments of $35 million, recognized in income tax provision in the consolidated statements of income, included the following: • A net benefit of $25 million associated with the transition tax liability and the impacts of U.S. Tax Reform on deferred tax assets, liabilities, and valuation allowances • A benefit of $32 million related to intercompany legal entity restructuring. • A net benefit of $20 million associated with the finalization of certain income tax aspects of the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. • A charge of $42 million related to the recognition of a prepaid tax expense resulting from the reduction in the U.S. statutory tax rate due to U.S. Tax Reform and the sale of U.S. manufactured inventory held as of April 27, 2018. At January 24, 2020 and April 26, 2019, the Company's gross unrecognized tax benefits were $1.8 billion. In addition, the Company had accrued gross interest and penalties of $207 million at January 24, 2020. If all of the Company’s unrecognized tax benefits were recognized, approximately $1.8 billion would impact the Company’s effective tax rate. At both January 24, 2020 and April 26, 2019, the total balance of the Company's gross unrecognized tax benefits was recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets. Refer to Note 17 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jan. 24, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended Nine months ended (in millions, except per share data) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Numerator: Net income attributable to ordinary shareholders $ 1,915 $ 1,269 $ 4,143 $ 3,459 Denominator: Basic – weighted average shares outstanding 1,340.5 1,342.8 1,340.7 1,348.1 Effect of dilutive securities: Employee stock options 8.4 6.9 7.8 7.9 Employee restricted stock units 2.6 3.0 2.9 3.2 Other — — 0.2 0.3 Diluted – weighted average shares outstanding 1,351.5 1,352.7 1,351.6 1,359.5 Basic earnings per share $ 1.43 $ 0.95 $ 3.09 $ 2.57 Diluted earnings per share $ 1.42 $ 0.94 $ 3.07 $ 2.54

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Jan. 24, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and nine months ended January 24, 2020 and January 25, 2019: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Stock options $ 12 $ 11 $ 52 $ 62 Restricted stock 46 43 159 144 Employee stock purchase plan 8 6 24 22 Total stock-based compensation expense $ 66 $ 60 $ 235 $ 228 Cost of products sold $ 6 $ 5 $ 22 $ 23 Research and development expense 9 8 29 29 Selling, general, and administrative expense 51 47 184 176 Total stock-based compensation expense 66 60 235 228 Income tax benefits (11) (8) (40) (40) Total stock-based compensation expense, net of tax $ 55 $ 52 $ 195 $ 188

Retirement Benefit Plans

Retirement Benefit Plans	9 Months Ended
	Jan. 24, 2020
Retirement Benefits [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three months and nine months ended January 24, 2020 and January 25, 2019: U.S. Non-U.S. Three months ended Three months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Service cost $ 26 $ 27 $ 15 $ 15 Interest cost 32 33 7 7 Expected return on plan assets (56) (54) (15) (14) Amortization of net actuarial loss 14 19 4 3 Net periodic benefit cost $ 16 $ 25 $ 11 $ 11 U.S. Non-U.S. Nine months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Service cost $ 78 $ 81 $ 45 $ 45 Interest cost 96 99 21 21 Expected return on plan assets (168) (162) (45) (42) Amortization of net actuarial loss 42 57 11 9 Net periodic benefit cost $ 48 $ 75 $ 32 $ 33 Components of net periodic benefit cost other than the service component are recognized in other non-operating income, net

Leases

Leases	9 Months Ended
	Jan. 24, 2020
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, and research facilities and warehouses, as well as transportation, data processing, and other equipment. The Company determines whether a contract is a lease or contains a lease at inception date. Upon commencement, the Company recognizes a right-of-use asset and lease liability. Right-of-use assets represent the Company's right to use the underlying asset for the lease term. Lease liabilities are the Company's obligation to make the lease payments arising from a lease. As the Company’s leases typically do not provide an implicit rate, the Company’s lease liabilities are measured on a discounted basis using the Company's incremental borrowing rate. Lease terms used in the recognition of right-of-use assets and lease liabilities include only options to extend the lease that are reasonably certain to be exercised. Additionally, lease terms underlying the right-of-use assets and lease liabilities consider terminations that are reasonably certain to be executed. The Company's lease agreements include leases that have both lease and associated nonlease components. The Company has elected to account for lease components and the associated nonlease components as a single lease component. The consolidated balance sheets do not include recognized assets or liabilities for leases that, at the commencement date, have a term of twelve months or less and do not include an option to purchase the underlying asset that is reasonably certain to be exercised. The Company recognizes such leases in the consolidated statements of income on a straight-line basis over the lease term. Additionally, the Company recognizes variable lease payments not included in its lease liabilities in the period in which the obligation for those payments is incurred. Variable lease payments for the three and nine months ended January 24, 2020 were not material. The Company's lease agreements include leases accounted for as operating leases and those accounted for as finance leases. The right-of-use assets, lease liabilities, lease costs, cash flows, and lease maturities associated with the Company's finance leases are not material to the consolidated financial statements at or for the three and nine months ended January 24, 2020. Finance lease right-of-use assets are included in property, plant, and equipment, net , and finance lease liabilities are included in current debt obligations and long-term debt on the consolidated balance sheets. Additionally, from time to time, the Company subleases portions of its real-estate property, resulting in sublease income. Sublease income and the related assets and cash flows were not material to the consolidated financial statements at or for the three and nine months ended January 24, 2020. The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at January 24, 2020: (in millions) Balance Sheet Classification January 24, 2020 Right-of-use assets Other assets $ 995 Current liability Other accrued expenses 169 Non-current liability Other liabilities 851 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at January 24, 2020: January 24, 2020 Weighted-average remaining lease term 7.5 years Weighted-average discount rate 3.0% The following table summarizes the components of total operating lease cost for the three and nine months ended January 24, 2020: Three months ended Nine months ended (in millions) January 24, 2020 January 24, 2020 Operating lease cost $ 59 $ 170 Short-term lease cost 10 32 Total operating lease cost $ 69 $ 202 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for the nine months ended January 24, 2020: Nine months ended (in millions) January 24, 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 167 Right-of-use assets obtained in exchange for operating lease liabilities 178 The following table summarizes the maturities of the Company's operating leases at January 24, 2020: (in millions) Operating Leases Remaining 2020 $ 81 2021 203 2022 171 2023 147 2024 125 Thereafter 448 Total expected lease payments 1,175 Less: Imputed interest (155) Total lease liability $ 1,020 The Company makes certain products available to customers under lease arrangements, including arrangements whereby equipment is placed with customers who then purchase consumable products to accompany the use of the equipment. Income arising from arrangements where the Company is the lessor is recognized within net sales in the consolidated statements of income and the Company's net investments in sales-type leases are included in other current assets and other assets in the consolidated balance sheets. Lessor income and the related assets and lease maturities were not material to the consolidated financial statements at or for the three and nine months ended January 24, 2020. As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019, minimum payments under non-cancelable operating leases at April 26, 2019 were: (in millions) Operating Leases 2020 $ 216 2021 157 2022 103 2023 61 2024 34 Thereafter 81 Total minimum lease payments $ 652

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Jan. 24, 2020
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following table provides changes in AOCI, net of tax, and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized Gain (Loss) on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45) $ (1,383) $ (169) $ (1,308) $ 194 $ (2,711) Other comprehensive income (loss) before reclassifications 94 (116) 187 (1) 106 270 Reclassifications (1) — — 39 (143) (105) Other comprehensive income (loss) 93 (116) 187 38 (37) 165 January 24, 2020 $ 48 $ (1,499) $ 18 $ (1,270) $ 157 $ (2,546) (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustment Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 27, 2018 $ (194) $ (11) $ (257) $ (1,117) $ (207) $ (1,786) Other comprehensive (loss) income before reclassifications (7) (1,124) — — 353 (778) Reclassifications 30 — — 65 (36) 59 Other comprehensive income (loss) 23 (1,124) — 65 317 (719) Cumulative effect of change in accounting principle (1) 47 — — — — 47 January 25, 2019 $ (124) $ (1,135) $ (257) $ (1,052) $ 110 $ (2,458) (1) The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018. The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the nine months ended January 24, 2020 and January 25, 2019 was an expense of $7 million and a benefit of $2 million, respectively. During the nine months ended January 24, 2020 and January 25, 2019, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of $1 million and $2 million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 6 to the consolidated financial statements for additional information. For the nine months ended January 24, 2020, there was no income tax on cumulative translation adjustments. For the nine months ended January 25, 2019, there was a $8 million income tax benefit on cumulative translation adjustments. During the nine months ended January 24, 2020 and January 25, 2019, there were no tax impacts on net investment hedges. Refer to Note 8 to the consolidated financial statements for additional information. The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the nine months ended January 24, 2020 and January 25, 2019, there were no income tax impacts on the net change in retirement obligations in other comprehensive income before reclassifications. During the nine months ended January 24, 2020 and January 25, 2019, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $9 million and $15 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within other non-operating income, net . Refer to Note 14 to the consolidated financial statements for additional information. The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the nine months ended January 24, 2020 and January 25, 2019 was an expense of $38 million and $116 million, respectively. During the nine months ended January 24, 2020 and January 25, 2019, gains and losses on cash flow hedges reclassified from AOCI were reduced by income taxes of $47 million and $16 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within other operating (income) expense, net, and gains and losses on forward starting interest rate derivatives reclassified from AOCI are recognized within interest expense. Refer to Note 8 to the consolidated financial statements for additional information.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jan. 24, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies litigation charges and gains related to significant legal matters as certain litigation charges. During the three and nine months ended January 24, 2020, the Company recognized $108 million and $276 million, respectively, of certain litigation charges related to probable and estimable damages for significant legal matters. During the three and nine months ended January 25, 2019, the Company recognized $63 million and $166 million, respectively, of certain litigation charges. At January 24, 2020 and April 26, 2019, accrued litigation was approximately $0.6 billion and $0.5 billion, respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Product Liability Matters Pelvic Mesh Litigation The Company is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 16,000 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of February 5, 2020, the Company had reached agreements to settle approximately 15,400 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed six of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Sasso The Company is involved in litigation in Indiana relating to certain patent and royalty disputes with Dr. Sasso under agreements originally entered into in 1999 and 2001. On November 28, 2018, a jury in Indiana state court returned a verdict against the Company for approximately $112 million. The Company has strong arguments to appeal the verdict and has filed post-trial motions and appeals with the appropriate appellate courts. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Shareholder Related Matters Covidien Acquisition On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstein and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On March 20, 2015, the District Court issued an order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, and reversed in part. On April 19, 2016 the Minnesota Supreme Court granted the Company’s petition to review the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings, which are ongoing. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. Environmental Proceedings The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. Since the early 2000s, the Company or its predecessors have also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring the Company's predecessor to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. Following a trial in March 2002, the Court held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that the Company’s predecessor was liable for the cost of performing a study of the River and Bay. Following a second trial in June 2014, the Court ordered that further engineering study and engineering design work was needed to determine the nature and extent of remediation in the Penobscot River and Bay. The Court also appointed an engineering firm to conduct such studies and issue a report on potential remediation alternatives. In connection with these proceedings, reports have been produced including a variety of cost estimates for a variety of potential remedial options. A third trial to determine the course of remediation to be pursued is scheduled to occur in fiscal year 2021. The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. Government Matters Since 2017, the Company has been responding to requests from the Department of Justice and U.S. Department of Health and Human Services for information about business practices relating to a neurovascular product developed and first marketed by ev3 and Covidien. The Company has provided information in response to these requests and is cooperating with the inquiry. The Company has not recognized an expense in connection with any ongoing investigation, because any such potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from the ongoing information requests. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court reviewed this dispute, and on June 9, 2016, issued its opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. Oral argument for the Appeal occurred on March 14, 2018. The 8th Circuit Court of Appeals issued their opinion on August 16, 2018, and remanded the case back to the U.S. Tax Court for additional factual findings. U.S. Tax Court trial is scheduled to occur in April of 2020. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2007 and 2008 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2009, 2010, and 2011 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level. Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2012. The statute of limitations for Covidien’s 2013 and 2014 U.S. federal income tax returns lapsed during the first quarter of fiscal years 2018 and 2019, respectively. Covidien's fiscal year 2015 U.S. federal income tax returns are currently being audited by the IRS. The statute of limitations for Covidien's 2016 U.S. federal income tax return lapsed during the third quarter of fiscal year 2020. While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Refer to Note 11 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has a guarantee commitment related to certain contingent tax liabilities as a party to the Tax Sharing Agreement that was entered into on June 29, 2007, between Covidien, Tyco International (now Johnson Controls), and Tyco Electronics (now TE Connectivity), associated with the spin-off from Tyco. The Tax Sharing Agreement covers certain income tax liabilities for periods prior to and including the spin-off. Medtronic’s share of the income tax liabilities for these periods is 42 percent, with Johnson Controls and TE Connectivity share being 27 percent, and 31 percent, respectively. If Johnson Controls and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. The most significant amounts at risk under this Tax Sharing Agreement were resolved with the U.S. Tax Court and IRS Appeals resolutions reached in May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution, including certain state and international tax matters that remain open. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to tax years that remain open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or Tyco Electronics legal entities for periods prior to the 2007 separation. Refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019 for additional information. As part of the Company’s sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates’ products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Jan. 24, 2020
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. There are certain corporate and centralized expenses that are not allocated to the segments. The Company’s management evaluates performance of the segments and allocates resources based on segment operating profit. Segment operating profit represents income before income taxes, excluding interest expense, amortization of intangible assets, centralized distribution costs, non-operating income or expense items, certain corporate charges, and other items not allocated to the segments. The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during the first quarter of fiscal year 2020 to remove the impact of non-service pension and post-retirement benefit costs from segment results. This change did not have a material impact on the segment results reviewed. As a result of the change, the Company has revised the disclosure for the prior period to align with the current presentation. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2019. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Net Sales Three months ended (1) Nine months ended (1) (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 2,819 $ 2,786 $ 8,464 $ 8,455 Minimally Invasive Therapies Group 2,176 2,124 6,418 6,223 Restorative Therapies Group 2,111 2,026 6,235 5,968 Diabetes Group 610 610 1,798 1,765 Total $ 7,717 $ 7,546 $ 22,916 $ 22,411 (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Segment Operating Profit Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 1,101 $ 1,076 $ 3,284 $ 3,262 Minimally Invasive Therapies Group 860 828 2,453 2,396 Restorative Therapies Group 898 824 2,531 2,394 Diabetes Group 158 190 456 538 Segment operating profit 3,017 2,918 8,724 8,590 Interest expense (156) (243) (930) (726) Other non-operating income, net 96 71 305 309 Amortization of intangible assets (436) (436) (1,317) (1,327) Corporate (348) (331) (1,005) (974) Centralized distribution costs (348) (383) (1,117) (1,313) Restructuring and associated costs (97) (66) (315) (256) Acquisition-related items (28) (17) (74) (57) Certain litigation charges (108) (63) (276) (166) IPR&D charges — (11) — (26) Exit of businesses — (69) (41) (149) Debt tender premium and other charges — — 7 — Medical device regulations (13) — (31) — Contribution to Medtronic Foundation — — (80) — Income before income taxes $ 1,579 $ 1,370 $ 3,850 $ 3,905 Geographic Information Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and nine months ended January 24, 2020 and January 25, 2019 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Ireland $ 22 $ 24 $ 66 $ 68 United States 4,021 4,001 12,068 11,910 Rest of world 3,674 3,521 10,782 10,433 Total other countries, excluding Ireland 7,695 7,522 22,850 22,343 Total $ 7,717 $ 7,546 $ 22,916 $ 22,411

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Jan. 24, 2020
Condensed Financial Information Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Additionally, Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. The following is a summary of these guarantees: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of Medtronic Luxco Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic Luxco • Subsidiary Guarantor - Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors) The following presents the Company’s consolidating statements of comprehensive income for the three and nine months ended January 24, 2020 and January 25, 2019, condensed consolidating balance sheets at January 24, 2020 and April 26, 2019, and condensed consolidating statements of cash flows for the nine months ended January 24, 2020 and January 25, 2019. The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Consolidating Statement of Comprehensive Income Three Months Ended January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 344 $ — $ 7,717 $ (344) $ 7,717 Costs and expenses: Cost of products sold — 337 — 2,294 (231) 2,400 Research and development expense — 154 — 419 — 573 Selling, general, and administrative expense 3 432 — 2,152 — 2,587 Amortization of intangible assets — 6 — 430 — 436 Restructuring charges, net — 3 — 10 — 13 Certain litigation charges — — — 108 — 108 Other operating expense (income), net 12 (569) — 624 (106) (39) Operating profit (loss) (15) (19) — 1,680 (7) 1,639 Other non-operating (income) expense, net — (50) (174) (415) 543 (96) Interest expense 66 316 141 176 (543) 156 Equity in net (income) loss of subsidiaries (1,994) (1,707) (1,961) — 5,662 — Income (loss) before income taxes 1,913 1,422 1,994 1,919 (5,669) 1,579 Income tax provision (2) (40) — (298) — (340) Net income (loss) 1,915 1,462 1,994 2,217 (5,669) 1,919 Net income attributable to noncontrolling interests — — — (4) — (4) Net income (loss) attributable to Medtronic 1,915 1,462 1,994 2,213 (5,669) 1,915 Other comprehensive income (loss), net of tax 65 58 65 18 (141) 65 Comprehensive income attributable to — — — (4) — (4) Total comprehensive income (loss) $ 1,980 $ 1,520 $ 2,059 $ 2,231 $ (5,810) $ 1,980 Consolidating Statement of Comprehensive Income Nine Months Ended January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 1,155 $ — $ 22,916 $ (1,155) $ 22,916 Costs and expenses: Cost of products sold — 1,013 — 6,999 (852) 7,160 Research and development expense — 500 — 1,263 — 1,763 Selling, general, and administrative expense 9 1,241 1 6,499 — 7,750 Amortization of intangible assets — 12 — 1,305 — 1,317 Restructuring charges, net — 13 — 74 — 87 Certain litigation charges — 5 — 271 — 276 Other operating expense (income), net 39 (1,637) (7) 1,977 (284) 88 Operating profit (loss) (48) 8 6 4,528 (19) 4,475 Other non-operating (income) expense, net — (184) (660) (1,245) 1,784 (305) Interest expense 350 1,372 424 568 (1,784) 930 Equity in net (income) loss of subsidiaries (4,535) (2,899) (4,293) — 11,727 — Income (loss) before income taxes 4,137 1,719 4,535 5,205 (11,746) 3,850 Income tax provision (6) (199) — (112) — (317) Net income (loss) 4,143 1,918 4,535 5,317 (11,746) 4,167 Net income attributable to noncontrolling interests — — — (24) — (24) Net income (loss) attributable to Medtronic 4,143 1,918 4,535 5,293 (11,746) 4,143 Other comprehensive income (loss), net of tax 165 29 165 (65) (129) 165 Comprehensive income attributable to — — — (24) — (24) Total comprehensive income (loss) $ 4,308 $ 1,947 $ 4,700 $ 5,228 $ (11,875) $ 4,308 Consolidating Statement of Comprehensive Income Three Months Ended January 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 281 $ — $ 7,546 $ (281) $ 7,546 Costs and expenses: Cost of products sold — 223 — 2,206 (164) 2,265 Research and development expense — 152 — 409 — 561 Selling, general, and administrative expense 2 362 — 2,232 — 2,596 Amortization of intangible assets — 2 — 434 — 436 Restructuring charges, net — 3 — 23 — 26 Certain litigation charges — 12 — 51 — 63 Other operating expense (income), net 15 (827) — 987 (118) 57 Operating profit (loss) (17) 354 — 1,204 1 1,542 Other non-operating (income) expense, net — (151) (200) (480) 760 (71) Interest expense 125 501 133 244 (760) 243 Equity in net (income) loss of subsidiaries (1,410) (678) (1,343) — 3,431 — Income (loss) before income taxes 1,268 682 1,410 1,440 (3,430) 1,370 Income tax provision (1) 40 — 60 — 99 Net income (loss) 1,269 642 1,410 1,380 (3,430) 1,271 Net income attributable to noncontrolling interests — — — (2) — (2) Net income (loss) attributable to Medtronic 1,269 642 1,410 1,378 (3,430) 1,269 Other comprehensive income (loss), net of tax 154 45 154 132 (331) 154 Comprehensive income attributable to noncontrolling interests — — — (2) — (2) Total comprehensive income (loss) $ 1,423 $ 687 $ 1,564 $ 1,510 $ (3,761) $ 1,423 Consolidating Statement of Comprehensive Income Nine Months Ended January 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 1,007 $ — $ 22,411 $ (1,007) $ 22,411 Costs and expenses: Cost of products sold — 776 — 6,538 (642) 6,672 Research and development expense — 496 — 1,240 — 1,736 Selling, general, and administrative expense 8 1,142 — 6,648 — 7,798 Amortization of intangible assets — 6 — 1,321 — 1,327 Restructuring charges, net — 14 — 98 — 112 Certain litigation charges — 90 — 76 — 166 Other operating expense (income), net 40 (1,759) — 2,336 (339) 278 Operating profit (loss) (48) 242 — 4,154 (26) 4,322 Other non-operating (income) expense, net — (445) (539) (1,411) 2,086 (309) Interest expense 333 1,444 349 686 (2,086) 726 Equity in net (income) loss of subsidiaries (3,835) (2,176) (3,645) — 9,656 — Income (loss) before income taxes 3,454 1,419 3,835 4,879 (9,682) 3,905 Income tax provision (5) (79) — 521 — 437 Net income (loss) 3,459 1,498 3,835 4,358 (9,682) 3,468 Net income attributable to noncontrolling interests — — — (9) — (9) Net income (loss) attributable to Medtronic 3,459 1,498 3,835 4,349 (9,682) 3,459 Other comprehensive income (loss), net of tax (719) (965) (719) (779) 2,460 (722) Comprehensive income attributable to noncontrolling interests — — — (6) — (6) Total comprehensive income (loss) $ 2,740 $ 533 $ 3,116 $ 3,573 $ (7,222) $ 2,740 Condensed Consolidating Balance Sheet January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 185 $ 3,524 $ — $ 3,709 Investments — — — 7,919 — 7,919 Accounts receivable, net — — — 6,248 — 6,248 Inventories, net — 211 — 4,159 (248) 4,122 Intercompany receivable 42 8,807 5 34,982 (43,836) — Other current assets 10 195 2 1,838 — 2,045 Total current assets 52 9,213 192 58,670 (44,084) 24,043 Property, plant, and equipment, net — 1,536 — 3,228 — 4,764 Goodwill — 2,009 — 38,082 — 40,091 Other intangible assets, net — 197 — 19,259 — 19,456 Tax assets — 508 — 1,764 — 2,272 Investment in subsidiaries 58,753 75,008 77,989 — (211,750) — Intercompany loans receivable — 22 18,296 21,072 (39,390) — Other assets — 377 — 1,819 — 2,196 Total assets $ 58,805 $ 88,870 $ 96,477 $ 143,894 $ (295,224) $ 92,822 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 344 $ — $ 844 Accounts payable — 507 — 1,438 — 1,945 Intercompany payable — 21,383 13,599 8,854 (43,836) — Accrued compensation 20 785 — 1,104 — 1,909 Accrued income taxes — — — 457 — 457 Other accrued expenses 25 287 98 3,170 — 3,580 Total current liabilities 45 23,462 13,697 15,367 (43,836) 8,735 Long-term debt — 9,786 13,522 1,424 — 24,732 Accrued compensation and retirement benefits — 1,025 — 573 — 1,598 Accrued income taxes 10 760 — 1,968 — 2,738 Intercompany loans payable 6,942 9,012 9,729 13,707 (39,390) — Deferred tax liabilities — — — 1,282 — 1,282 Other liabilities — 262 — 1,522 — 1,784 Total liabilities 6,997 44,307 36,948 35,843 (83,226) 40,869 Shareholders’ equity 51,808 44,563 59,529 107,906 (211,998) 51,808 Noncontrolling interests — — — 145 — 145 Total equity 51,808 44,563 59,529 108,051 (211,998) 51,953 Total liabilities and equity $ 58,805 $ 88,870 $ 96,477 $ 143,894 $ (295,224) $ 92,822 Condensed Consolidating Balance Sheet April 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 18 $ 1 $ 4,374 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — 188 — 3,792 (227) 3,753 Intercompany receivable 40 9,407 6 19,170 (28,623) — Other current assets 10 190 3 1,941 — 2,144 Total current assets 50 9,803 10 40,954 (28,850) 21,967 Property, plant, and equipment, net — 1,480 — 3,195 — 4,675 Goodwill — 2,009 — 37,950 — 39,959 Other intangible assets, net — 99 — 20,461 — 20,560 Tax assets — 568 — 951 — 1,519 Investment in subsidiaries 64,352 71,123 65,012 — (200,487) — Intercompany loans receivable 3,000 21 27,858 35,398 (66,277) — Other assets — 216 — 798 — 1,014 Total assets $ 67,402 $ 85,319 $ 92,880 $ 139,707 $ (295,614) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 338 $ — $ 838 Accounts payable — 481 — 1,472 — 1,953 Intercompany payable — 11,971 7,200 9,452 (28,623) — Accrued compensation 3 913 — 1,273 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 331 53 2,521 — 2,925 Total current liabilities 23 14,196 7,253 15,623 (28,623) 8,472 Long-term debt — 14,418 8,621 1,447 — 24,486 Accrued compensation and retirement benefits — 1,069 — 582 — 1,651 Accrued income taxes 10 692 — 2,136 — 2,838 Intercompany loans payable 17,278 12,613 19,682 16,704 (66,277) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — 133 — 624 — 757 Total liabilities 17,311 43,121 35,556 38,394 (94,900) 39,482 Shareholders' equity 50,091 42,198 57,324 101,192 (200,714) 50,091 Noncontrolling interests — — — 121 — 121 Total equity 50,091 42,198 57,324 101,313 (200,714) 50,212 Total liabilities and equity $ 67,402 $ 85,319 $ 92,880 $ 139,707 $ (295,614) $ 89,694 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 130 $ (1,315) $ 365 $ 6,604 $ — $ 5,784 Investing Activities: Acquisitions, net of cash acquired — 2 — (201) — (199) Additions to property, plant, and equipment — (236) — (641) — (877) Purchases of investments — — — (8,249) — (8,249) Sales and maturities of investments — 12 — 5,779 — 5,791 Capital contribution paid — — (9,000) (800) 9,800 — Return of capital 10,000 — (3,000) (7,000) — — Other investing activities — (56) (5) 27 — (34) Net cash provided by (used in) investing activities 10,000 (278) (12,005) (11,085) 9,800 (3,568) Financing Activities: Change in current debt obligations, net — — — 17 — 17 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (5,016) (515) (75) — (5,606) Dividends to shareholders (2,170) — — — — (2,170) Issuance of ordinary shares 585 — — — — 585 Repurchase of ordinary shares (1,208) — — — — (1,208) Net intercompany loan borrowings (repayments) (7,337) 6,591 6,010 (5,264) — — Capital contribution received — — 800 9,000 (9,800) — Other financing activities — — (38) (36) — (74) Net cash provided by (used in) financing activities (10,130) 1,575 11,824 3,643 (9,800) (2,888) Effect of exchange rate changes on cash and cash equivalents — — — (12) — (12) Net change in cash and cash equivalents — (18) 184 (850) — (684) Cash and cash equivalents at beginning of period — 18 1 4,374 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 185 $ 3,524 $ — $ 3,709 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 100 $ (619) $ 200 $ 5,239 $ — $ 4,920 Investing Activities: Acquisitions, net of cash acquired — — — (1,615) — (1,615) Additions to property, plant, and equipment — (207) — (592) — (799) Purchases of investments — — — (1,987) — (1,987) Sales and maturities of investments — 76 — 4,083 — 4,159 Capital contribution paid (18) (47) — — 65 — Other investing activities — — — (3) — (3) Net cash provided by (used in) investing activities (18) (178) — (114) 65 (245) Financing Activities: Change in current debt obligations, net — — (696) — — (696) Issuance of long-term debt — — — 3 — 3 Payments on long-term debt — — — (29) — (29) Dividends to shareholders (2,022) — — — — (2,022) Issuance of ordinary shares 891 — — — — 891 Repurchase of ordinary shares (2,728) — — — — (2,728) Net intercompany loan borrowings (repayments) 3,777 793 814 (5,384) — — Capital contribution received — — — 65 (65) — Other financing activities — — 17 (7) — 10 Net cash provided by (used in) financing activities (82) 793 135 (5,352) (65) (4,571) Effect of exchange rate changes on cash and cash equivalents — — — (70) — (70) Net change in cash and cash equivalents — (4) 335 (297) — 34 Cash and cash equivalents at beginning of period — 20 1 3,648 — 3,669 Cash and cash equivalents at end of period $ — $ 16 $ 336 $ 3,351 $ — $ 3,703 Consolidating Statement of Comprehensive Income Three Months Ended January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,717 $ — $ 7,717 Costs and expenses: Cost of products sold — — — 2,400 — 2,400 Research and development expense — — — 573 — 573 Selling, general, and administrative expense 3 — 1 2,583 — 2,587 Amortization of intangible assets — — — 436 — 436 Restructuring charges, net — — — 13 — 13 Certain litigation charges — — — 108 — 108 Other operating expense (income), net 12 — — (51) — (39) Operating profit (loss) (15) — (1) 1,655 — 1,639 Other non-operating (income) expense, net — (27) (179) (372) 482 (96) Interest expense 66 189 141 242 (482) 156 Equity in net (income) loss of subsidiaries (1,994) (448) (1,957) — 4,399 — Income (loss) before income taxes 1,913 286 1,994 1,785 (4,399) 1,579 Income tax provision (2) — — (338) — (340) Net income (loss) 1,915 286 1,994 2,123 (4,399) 1,919 Net income attributable to noncontrolling interests — — — (4) — (4) Net income (loss) attributable to Medtronic 1,915 286 1,994 2,119 (4,399) 1,915 Other comprehensive income (loss), net of tax 65 (35) 65 30 (60) 65 Comprehensive income attributable to — — — (4) — (4) Total comprehensive income (loss) $ 1,980 $ 251 $ 2,059 $ 2,149 $ (4,459) $ 1,980 Consolidating Statement of Comprehensive Income Nine Months Ended January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 22,916 $ — $ 22,916 Costs and expenses: Cost of products sold — — — 7,160 — 7,160 Research and development expense — — — 1,763 — 1,763 Selling, general, and administrative expense 9 1 2 7,738 — 7,750 Amortization of intangible assets — — — 1,317 — 1,317 Restructuring charges, net — — — 87 — 87 Certain litigation charges — — — 276 — 276 Other operating expense (income), net 39 — (7) 56 — 88 Operating profit (loss) (48) (1) 5 4,519 — 4,475 Other non-operating (income) expense, net — (122) (680) (1,132) 1,629 (305) Interest expense 350 601 424 1,184 (1,629) 930 Equity in net (income) loss of subsidiaries (4,535) (2,635) (4,274) — 11,444 — Income (loss) before income taxes 4,137 2,155 4,535 4,467 (11,444) 3,850 Income tax provision (6) — — (311) — (317) Net income (loss) 4,143 2,155 4,535 4,778 (11,444) 4,167 Net income attributable to noncontrolling interests — — — (24) — (24) Net income (loss) attributable to Medtronic 4,143 2,155 4,535 4,754 (11,444) 4,143 Other comprehensive income (loss), net of tax 165 (46) 165 (23) (96) 165 Comprehensive income attributable to — — — (24) — (24) Total comprehensive income (loss) $ 4,308 $ 2,109 $ 4,700 $ 4,731 $ (11,540) $ 4,308 Consolidating Statement of Comprehensive Income Three Months Ended January 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,546 $ — $ 7,546 Costs and expenses: Cost of products sold — — — 2,265 — 2,265 Research and development expense — — — 561 — 561 Selling, general, and administrative expense 2 — 1 2,593 — 2,596 Amortization of intangible assets — — — 436 — 436 Restructuring charges, net — — — 26 — 26 Certain litigation charges — — — 63 — 63 Other operating expense, net 15 — — 42 — 57 Operating profit (loss) (17) — (1) 1,560 — 1,542 Other non-operating (income) expense, net — (9) (207) (190) 335 (71) Interest expense 125 23 132 298 (335) 243 Equity in net (income) loss of subsidiaries (1,410) (656) (1,336) — 3,402 — Income (loss) before income taxes 1,268 642 1,410 1,452 (3,402) 1,370 Income tax provision (1) — — 100 — 99 Net income (loss) 1,269 642 1,410 1,352 (3,402) 1,271 Net income attributable to noncontrolling interests — — — (2) — (2) Net income (loss) attributable to Medtronic 1,269 642 1,410 1,350 (3,402) 1,269 Other comprehensive income (loss), net of tax 154 104 154 154 (412) 154 Comprehensive income attributable to — — — (2) — (2) Total comprehensive income (loss) $ 1,423 $ 746 $ 1,564 $ 1,504 $ (3,814) $ 1,423 Consolidating Statement of Comprehensive Income Nine Months Ended January 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 22,411 $ — $ 22,411 Costs and expenses: Cost of products sold — — — 6,672 — 6,672 Research and development expense — — — 1,736 — 1,736 Selling, general, and administrative expense 8 1 2 7,787 — 7,798 Amortization of intangible assets — — — 1,327 — 1,327 Restructuring charges, net — — — 112 — 112 Certain litigation charges — — — 166 — 166 Other operating expense, net 40 — — 238 — 278 Operating profit (loss) (48) (1) (2) 4,373 — 4,322 Other non-operating (income) expense, net — (29) (559) (614) 893 (309) Interest expense 333 66 348 872 (893) 726 Equity in net (income) loss of subsidiaries (3,835) (2,277) (3,626) — 9,738 — Income (loss) before income taxes 3,454 2,239 3,835 4,115 (9,738) 3,905 Income tax provision (5) — — 442 — 437 Net income (loss) 3,459 2,239 3,835 3,673 (9,738) 3,468 Net income attributable to noncontrolling interests — — — (9) — (9) Net income (loss) attributable to Medtronic 3,459 2,239 3,835 3,664 (9,738) 3,459 Other comprehensive income (loss), net of tax (719) 287 (719) (722) 1,151 (722) Comprehensive income attributable to — — — (6) — (6) Total comprehensive income (loss) $ 2,740 $ 2,526 $ 3,116 $ 2,945 $ (8,587) $ 2,740 Condensed Consolidating Balance Sheet January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 185 $ 3,524 $ — $ 3,709 Investments — — — 7,919 — 7,919 Accounts receivable, net — — — 6,248 — 6,248 Inventories, net — — — 4,122 — 4,122 Intercompany receivable 42 — 1,333 13,623 (14,998) — Other current assets 10 — 3 2,032 — 2,045 Total current assets 52 — 1,521 37,468 (14,998) 24,043 Property, plant, and equipment, net — — — 4,764 — 4,764 Goodwill — — — 40,091 — 40,091 Other intangible assets, net — — — 19,456 — 19,456 Tax assets — — — 2,272 — 2,272 Investment in subsidiaries 58,753 68,723 76,908 — (204,384) — Intercompany loans receivable — 3,545 18,296 37,018 (58,859) — Other assets — — — 2,196 — 2,196 Total assets $ 58,805 $ 72,268 $ 96,725 $ 143,265 $ (278,241) $ 92,822 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 844 $ — $ 844 Accounts payable — — — 1,945 — 1,945 Intercompany payable — 1,327 13,599 72 (14,998) — Accrued compensation 20 — — 1,889 — 1,909 Accrued income taxes — — — 457 — 457 Other accrued expenses 25 8 104 3,443 — 3,580 Total current liabilities 45 1,335 13,703 8,650 (14,998) 8,735 Long-term debt — 1,307 13,522 9,903 — 24,732 Accrued compensation and retirement benefits — — — 1,598 — 1,598 Accrued income taxes 10 — — 2,728 — 2,738 Intercompany loans payable 6,942 27,048 9,970 14,899 (58,859) — Deferred tax liabilities — — — 1,282 — 1,282 Other liabilities — — 1 1,783 — 1,784 Total liabilities 6,997 29,690 37,196 40,843 (73,857) 40,869 Shareholders’ equity 51,808 42,578 59,529 102,277 (204,384) 51,808 Noncontrolling interests — — — 145 — 145 Total equity 51,808 42,578 59,529 102,422 (204,384) 51,953 Total liabilities and equity $ 58,805 $ 72,268 $ 96,725 $ 143,265 $ (278,241) $ 92,822 Condensed Consolidating Balance Sheet April 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 1 $ 4,392 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — — — 3,753 — 3,753 Intercompany receivable 40 — 1,374 7,212 (8,626) — Other current assets 10 — 3 2,131 — 2,144 Total current assets 50 — 1,378 29,165 (8,626) 21,967 Property, plant, and equipment, net — — — 4,675 — 4,675 Goodwill — — — 39,959 — 39,959 Other intangible assets, net — — — 20,560 — 20,560 Tax assets — — — 1,519 — 1,519 Investment in subsidiaries 64,352 39,563 63,651 — (167,566) — Intercompany loans receivable 3,000 4,119 27,858 29,002 (63,979) — Other assets — — — 1,014 — 1,014 Total assets $ 67,402 $ 43,682 $ 92,887 $ 125,894 $ (240,171) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 838 $ — $ 838 Accounts payable — — — 1,953 — 1,953 Intercompany payable — 1,308 7,199 119 (8,626) — Accrued compensation 3 — — 2,186 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 11 60 2,834 — 2,925 Total current liabilities 23 1,319 7,259 8,497 (8,626) 8,472 Long-term debt — 1,354 8,621 14,511 — 24,486 Accrued compensation and retirement benefits — — — 1,651 — 1,651 Accrued income taxes 10 — — 2,828 — 2,838 Intercompany loans payable 17,278 9,320 19,682 17,699 (63,979) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — — 1 756 — 757 Total liabilities 17,311 11,993 35,563 47,220 (72,605) 39,482 Shareholders' equity 50,091 31,689 57,324 78,553 (167,566) 50,091 Noncontrolling interests — — — 121 — 121 Total Equity 50,091 31,689 57,324 78,674 (167,566) 50,212 Total liabilities and equity $ 67,402 $ 43,682 $ 92,887 $ 125,894 $ (240,171) $ 89,694 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 130 $ (497) $ 441 $ 5,710 $ — $ 5,784 Investing Activities: Acquisitions, net of cash acquired — — — (199) — (199) Additions to property, plant, and equipment — — — (877) — (877) Purchases of investments — — — (8,249) — (8,249) Sales and maturities of investments — — — 5,791 — 5,791 Capital contribution paid — (9,348) (9,301) (800) 19,449 — Return of capital 10,000 — (3,000) (7,000) — — Other investing activities — — (5) (29) — (34) Net cash provided by (used in) investing activities 10,000 (9,348) (12,306) (11,363) 19,449 (3,568) Financing Activities: Change in current debt obligations, net — — — 17 — 17 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (44) (515) (5,047) — (5,606) Dividends to shareholders (2,170) — — — — (2,170) Issuance of ordinary shares 585 — — — — 585 Repurchase of ordinary shares (1,208) — — — — (1,208) Net intercompany loan borrowings (repayments) (7,337) 588 6,231 518 — — Capital contribution received — 9,301 800 9,348 (19,449) — Other financing activities — — (34) (40) — (74) Net cash provided by (used in) financing activities (10,130) 9,845 12,049 4,797 (19,449) (2,888) Effect of exchange rate changes on cash and cash equivalents — — — (12) — (12) Net change in cash and cash equivalents — — 184 (868) — (684) Cash and cash equivalents at beginning of period — — 1 4,392 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 185 $ 3,524 $ — $ 3,709 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 100 $ (62) $ 219 $ 4,663 $ — $ 4,920 Investing Activities: Acquisitions, net of cash acquired — — — (1,615) — (1,615) Additions to property, plant, and equipment — — — (799) — (799) Purchases of investments — — — (1,987) — (1,987) Sales and maturities of investments — — — 4,159 — 4,159 Capital contributions paid (18) (187) — — 205 — Other investing activities — — — (3) — (3) Net cash provided by (used in) investing activities (18) (187) — (245) 205 (245) Financing Activities: Change in current debt obligations, net — — (696) — — (696) Issuance of long-term debt — — — 3 — 3 Payments on long-term debt — — — (29) — (29) Dividends to shareholders (2,022) — — — — (2,022) Issuance of ordinary shares 891 — — — — 891 Repurchase of ordinary shares (2,728) — — — — (2,728) Net intercompany loan borrowings (repayments) 3,777 249 795 (4,821) — — Capital contributions received — — — 205 (205) — Other financing activities — — 17 (7) — 10 Net cash provided by (used in) financing activities (82) 249 116 (4,649) (205) (4,571) Effect of exchange rate changes on cash and cash equivalents — — — (70) — (70) Net change in cash and cash equivalents — — 335 (301) — 34 Cash and cash equivalents at beginning of period — — 1 3,668 — 3,669 Cash and cash equivalents at end of period $ — $ — $ 336 $ 3,367 $ — $ 3,703

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Jan. 24, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2020, 2019, and 2018 will end or ended on April 24, 2020, April 26, 2019, and April 27, 2018, respectively. The Company's fiscal year 2021 is a 53-week year, with the extra week occurring during the first quarter, and will end on April 30, 2021.
New Accounting Pronouncements	Recently Adopted Leases In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. This guidance also requires additional qualitative and quantitative lease related disclosures in the notes to the consolidated financial statements. The Company adopted this guidance using the modified retrospective method in the first quarter of fiscal year 2020. During the implementation of this recently adopted accounting standard, the Company elected the package of practical expedients available under the transition guidance that allowed an entity not to reassess whether any expired or existing contracts are or contain leases, the classification for any expired or existing leases or any initial direct costs for existing leases. Further, the Company made accounting policy elections to not apply the recognition requirements to short-term leases and to account for lease and nonlease components as a single lease component. The adoption of this guidance resulted in the recognition of right-of-use assets and lease liabilities in an amount of approximately $1.0 billion, an immaterial cumulative-effect adjustment to retained earnings as of April 27, 2019, and expansion of lease related disclosures . The adoption of this guidance did not have a material impact on the Company's consolidated statements of income or consolidated statements of cash flows. Others In August 2017, the FASB issued guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. The Company adopted this guidance in the first quarter of fiscal year 2020. The adoption of this guidance resulted in expanded disclosures and did not have an impact on the Company's consolidated financial statements. Not Yet Adopted

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Jan. 24, 2020
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The table below illustrates net sales by segment and division for the three and nine months ended January 24, 2020 and January 25, 2019: Three months ended (1) Nine months ended (1) (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac Rhythm & Heart Failure $ 1,393 $ 1,397 $ 4,201 $ 4,295 Coronary & Structural Heart 948 913 2,844 2,736 Aortic, Peripheral, & Venous 478 476 1,420 1,424 Cardiac and Vascular Group 2,819 2,786 8,464 8,455 Surgical Innovations 1,474 1,434 4,345 4,224 Respiratory, Gastrointestinal, & Renal 702 690 2,073 1,999 Minimally Invasive Therapies Group 2,176 2,124 6,418 6,223 Brain Therapies 795 732 2,307 2,107 Spine 674 655 2,023 1,963 Specialty Therapies 340 325 996 956 Pain Therapies 303 314 910 942 Restorative Therapies Group 2,111 2,026 6,235 5,968 Diabetes Group 610 610 1,798 1,765 Total $ 7,717 $ 7,546 $ 22,916 $ 22,411 (1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. During the first quarter of fiscal year 2020, the Company realigned its divisions within the Restorative Therapies Group, which included a movement of revenue from Transformative Solutions product lines previously included in Specialty Therapies to a product line under Brain Therapies. As a result, net sales for fiscal year 2019 have been recast to adjust for this realignment. The table below illustrates net sales by market geography for each segment for the three and nine months ended January 24, 2020 and January 25, 2019: U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Three months ended Three months ended Three months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 1,366 $ 1,369 $ 915 $ 924 $ 538 $ 493 Minimally Invasive Therapies Group 934 930 791 796 451 398 Restorative Therapies Group 1,409 1,354 436 435 266 237 Diabetes Group 312 348 236 213 63 49 Total $ 4,021 $ 4,001 $ 2,377 $ 2,368 $ 1,318 $ 1,177 U.S. (1)(4) Non-U.S. Developed Markets (2)(4) Emerging Markets (3)(4) Nine months ended Nine months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 4,182 $ 4,240 $ 2,735 $ 2,766 $ 1,547 $ 1,449 Minimally Invasive Therapies Group 2,769 2,659 2,364 2,396 1,285 1,168 Restorative Therapies Group 4,187 4,005 1,278 1,275 770 688 Diabetes Group 930 1,006 693 619 176 140 Total $ 12,068 $ 11,910 $ 7,069 $ 7,056 $ 3,778 $ 3,445 (1) U.S. includes the United States and U.S. territories. (2) Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3) Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Jan. 24, 2020
Business Combinations [Abstract]
Schedule of Fair Value of the Assets Acquired and Liabilities Assumed	The fair values of the assets acquired and liabilities assumed were as follows: (in millions) Mazor Robotics Cash and cash equivalents $ 109 Investments 52 Accounts receivable 9 Inventory 5 Other current assets 1 Property, plant, and equipment 3 Goodwill 1,318 Other intangible assets 399 Tax assets 9 Total assets acquired 1,905 Current liabilities 210 Deferred tax liabilities 21 Total liabilities assumed 231 Net assets acquired $ 1,674
Reconciliation of Beginning and Ending Balances of Contingent Consideration	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Beginning balance $ 260 $ 203 $ 222 $ 173 Purchase price contingent consideration 45 5 110 51 Payments (3) (1) (32) (8) Change in fair value 2 (59) 4 (68) Ending balance $ 304 $ 148 $ 304 $ 148
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) January 24, 2020 Valuation Technique Unobservable Input Range Discount rate 11.5% - 32.5% Revenue and other performance-based payments $123 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2020 - 2026 Discount rate 5.5% Product development and other milestone-based payments $181 Discounted cash flow Probability of payment 75% - 100% Projected fiscal year of payment 2020 - 2027

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Jan. 24, 2020
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	The following table summarizes the activity related to the Enterprise Excellence restructuring program for the nine months ended January 24, 2020: (in millions) Employee Termination Benefits Associated Costs (1) Asset Write-Downs (2) Other Costs Total April 26, 2019 $ 101 $ 9 $ — $ 12 $ 122 Charges 91 223 6 8 328 Cash payments (118) (223) — (8) (349) Settled non-cash — — (6) — (6) Accrual adjustments (5) — — (8) (13) January 24, 2020 $ 69 $ 9 $ — $ 4 $ 82 (1) Associated costs include costs incurred as a direct result of the restructuring program, such as salaries for employees supporting the program and consulting expenses. (2) Recognized within cost of products sold in the consolidated statements of income.

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Jan. 24, 2020
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification, Debt Securities	The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at January 24, 2020 and April 26, 2019: January 24, 2020 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 623 $ 17 $ — $ 640 $ 640 $ — Level 2: Corporate debt securities 5,155 52 (8) 5,199 5,199 — U.S. government and agency securities 900 — — 900 900 — Mortgage-backed securities 655 13 (13) 655 655 — Non-U.S. government and agency securities 13 — — 13 13 — Other asset-backed securities 511 3 (2) 512 512 — Total Level 2 7,234 68 (23) 7,279 7,279 — Level 3: Auction rate securities 36 — (3) 33 — 33 Total available-for-sale debt securities $ 7,893 $ 85 $ (26) $ 7,952 $ 7,919 $ 33 April 26, 2019 Valuation Balance Sheet Classification (in millions) Cost Unrealized Unrealized Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 529 $ 1 $ (7) $ 523 $ 523 $ — Level 2: Corporate debt securities 3,500 14 (21) 3,493 3,493 — U.S. government and agency securities 387 1 (7) 381 381 — Mortgage-backed securities 537 3 (20) 520 520 — Non-U.S. government and agency securities 11 — — 11 11 — Other asset-backed securities 529 1 (3) 527 527 — Total Level 2 4,964 19 (51) 4,932 4,932 — Level 3: Auction rate securities 47 — (3) 44 — 44 Total available-for-sale debt securities $ 5,540 $ 20 $ (61) $ 5,499 $ 5,455 $ 44
Available-For-Sale Debt Securities in Continuous Unrealized Loss Position	The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at January 24, 2020 and April 26, 2019: January 24, 2020 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 96 $ — $ 40 $ — Corporate debt securities 371 (3) 65 (5) Mortgage-backed securities 82 (1) 63 (12) Other asset-backed securities 23 — 165 (2) Auction rate securities — — 33 (3) Total $ 572 $ (4) $ 366 $ (22) April 26, 2019 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Fair Value Unrealized U.S. government and agency securities $ 130 $ (1) $ 649 $ (13) Corporate debt securities 582 (5) 1,153 (16) Mortgage-backed securities 73 (1) 250 (19) Other asset-backed securities 290 (2) 85 (1) Auction rate securities — — 44 (3) Total $ 1,075 $ (9) $ 2,181 $ (52)
Activity Related to the Company's Debt Securities Portfolio	Activity related to the Company’s debt securities portfolio is as follows: Three months ended Nine months Ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Proceeds from sales $ 2,531 $ 1,301 $ 5,789 $ 3,217 Gross realized gains 9 9 17 17 Gross realized losses (2) (36) (13) (55)
Available-for-sale Debt Securities Contractual Maturities	The January 24, 2020 balance of available-for-sale debt securities by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) January 24, 2020 Due in one year or less $ 3,595 Due after one year through five years 2,727 Due after five years through ten years 1,577 Due after ten years 53 Total $ 7,952
Summary of Equity and Other Investments	The following table summarizes the Company's equity and other investments at January 24, 2020 and April 26, 2019, which are classified as other assets in the consolidated balance sheets: (in millions) January 24, 2020 April 26, 2019 Investments with readily determinable fair value (marketable equity securities) $ 39 $ — Investments without readily determinable fair values 373 308 Equity method and other investments 68 64 Total equity and other investments $ 480 $ 372
Activity Related to the Company's Equity and Other Investments Portfolio	The table below includes activity related to the Company’s portfolio of equity and other investments. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Proceeds from sales $ — $ 33 $ 2 $ 941 Gross gains 1 8 16 131 Gross losses — (1) — (30) Impairment losses recognized (1) — (5) (12)

Financing Arrangements (Tables)

Financing Arrangements (Tables)	9 Months Ended
	Jan. 24, 2020
Debt Disclosure [Abstract]
Long-term Debt	The Company's debt obligations consisted of the following: (in millions) Maturity by January 24, 2020 April 26, 2019 Current debt obligations 2020 - 2021 $ 844 $ 838 Long-term debt 0.000 percent two 2021 1,662 1,681 Floating rate two 2021 831 560 4.125 percent ten 2021 — 500 3.150 percent seven 2022 1,534 2,500 3.125 percent ten 2022 — 675 3.200 percent ten 2023 650 650 0.375 percent four 2023 1,662 1,681 2.750 percent ten 2023 530 530 0.000 percent four 2023 831 — 2.950 percent ten 2024 310 310 3.625 percent ten 2024 432 850 3.500 percent ten 2025 2,700 4,000 0.250 percent seven 2026 1,108 — 1.125 percent eight 2027 1,662 1,681 3.350 percent ten 2027 368 850 1.625 percent twelve 2031 1,108 1,121 1.000 percent thirteen 2032 1,108 — 4.375 percent twenty 2035 1,931 2,382 6.550 percent thirty 2038 253 284 2.250 percent twenty 2039 1,108 1,121 6.500 percent thirty 2039 158 183 5.550 percent thirty 2040 224 306 1.500 percent twenty 2040 1,108 — 4.500 percent thirty 2042 105 129 4.000 percent thirty 2043 305 325 4.625 percent thirty 2044 127 177 4.625 percent thirty 2045 1,813 1,963 1.750 percent thirty 2050 1,108 — Bank borrowings 2021 - 2022 70 83 Debt (discount) premium, net 2020 - 2050 (15) 29 Finance lease obligations 2021 - 2033 47 10 Interest rate swaps N/A — 9 Deferred financing costs 2020 - 2050 (106) (104) Long-term debt $ 24,732 $ 24,486

Derivatives and Currency Exch_2

Derivatives and Currency Exchange Risk Management (Tables)	9 Months Ended
	Jan. 24, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of (Gains) Losses in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the (gains) losses in the consolidated statements of income related to derivative instruments not designated as hedging instruments for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended (in millions) Classification January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Currency exchange rate contracts Other operating (income) expense, net $ 2 $ 30 $ (4) $ (171) Total return swaps Other operating (income) expense, net (17) — (22) — Total $ (15) $ 30 $ (26) $ (171)
Amounts of (Gains) Losses Recognized in AOCI	The amount of the (gains) losses recognized in AOCI related to the currency exchange rate contract derivative instruments designated as cash flow hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Currency exchange rate contracts $ (41) $ (25) $ (144) $ (469)
Amount and Location of (Gains) Losses in Statements of Income	The amount of the (gains) losses recognized in the consolidated statements of income related to derivative instruments designated as cash flow hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 (in millions) Other operating (income) expense, net Other operating (income) expense, net Other operating (income) expense, net Other operating (income) expense, net Total amounts of income and expense line items presented in the consolidated statements of income in which the effects of cash flow hedges are recorded $ (39) $ 57 $ 88 $ 278 Currency exchange rate contracts designated as cash flow hedges: Amount of (gain) loss reclassified from AOCI into income (82) (48) (206) (56)
Schedule of Amounts Recorded on Consolidated Balance Sheet Related to Cumulative Basis Adjustments for Fair Value Hedges	The following amounts were recorded on the consolidated balance sheet related to the cumulative basis adjustments for fair value hedges: (in millions) Carrying Amount of Hedged Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities) Location on the Consolidated Balance Sheet January 24, 2020 April 26, 2019 January 24, 2020 April 26, 2019 Long-term debt $ — $ (1,175) $ — $ 9
Amount and Location of (Gains) Losses in Statements of Income, Derivative Instruments Designated as Net Investment Hedges	The amount and classifications of the (gains) losses recognized in the consolidated statements of income for the portion of the net investment hedges excluded from the measurement of hedge effectiveness were as follows: Three months ended Nine months ended (in millions) Classification January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Net investment hedges Other operating (income) expense, net $ — $ — $ (7) $ —
Amounts of (Gains) Losses Recognized in AOCI for Net Investment Hedges	The amount of the (gains) losses recognized in AOCI related to instruments designated as net investment hedges for the three and nine months ended January 24, 2020 and January 25, 2019 were as follows: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Net investment hedges $ (35) $ — $ (187) $ —
Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at January 24, 2020 and April 26, 2019. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments and are further segregated by type of contract within those two categories. January 24, 2020 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 183 Other accrued expenses $ 11 Currency exchange rate contracts Other assets 75 Other liabilities 12 Total derivatives designated as hedging instruments 258 23 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 9 Other accrued expenses 10 Total return swap Other current assets 16 Other accrued expenses — Cross currency interest rate contracts Other current assets 1 Other accrued expenses — Total derivatives not designated as hedging instruments 26 10 Total derivatives $ 284 $ 33 April 26, 2019 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets $ 234 Other accrued expenses $ 1 Interest rate contracts Other assets 9 Other liabilities — Currency exchange rate contracts Other assets 78 Other liabilities 1 Total derivatives designated as hedging instruments 321 2 Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets 23 Other accrued expenses 17 Total return swaps Other current assets 15 Other accrued expenses — Cross currency interest rate contracts Other current assets 6 Other accrued expenses — Total derivatives not designated as hedging instruments 44 17 Total derivatives $ 365 $ 19
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. January 24, 2020 April 26, 2019 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 267 $ 17 $ 335 $ 30 Derivative liabilities 33 — 19 —
Offsetting Assets	The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 24, 2020 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 267 $ (33) $ (5) $ 229 Total return swaps 16 — — 16 Cross currency interest rate contracts 1 — — 1 284 (33) (5) 246 Derivative liabilities: Currency exchange rate contracts (33) 33 — — (33) 33 — — Total $ 251 $ — $ (5) $ 246 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9) $ (43) $ 283 Interest rate contracts 9 — (1) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9) (44) 312 Derivative liabilities: Currency exchange rate contracts (19) 9 — (10) (19) 9 — (10) Total $ 346 $ — $ (44) $ 302
Offsetting Liabilities	The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. January 24, 2020 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 267 $ (33) $ (5) $ 229 Total return swaps 16 — — 16 Cross currency interest rate contracts 1 — — 1 284 (33) (5) 246 Derivative liabilities: Currency exchange rate contracts (33) 33 — — (33) 33 — — Total $ 251 $ — $ (5) $ 246 April 26, 2019 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Cash Collateral Posted (Received) Net Amount Derivative assets: Currency exchange rate contracts $ 335 $ (9) $ (43) $ 283 Interest rate contracts 9 — (1) 8 Total return swaps 15 — — 15 Cross currency interest rate contracts 6 — — 6 365 (9) (44) 312 Derivative liabilities: Currency exchange rate contracts (19) 9 — (10) (19) 9 — (10) Total $ 346 $ — $ (44) $ 302

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jan. 24, 2020
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances, net of reserves, were as follows: (in millions) January 24, 2020 April 26, 2019 Finished goods $ 2,693 $ 2,476 Work in-process 643 572 Raw materials 786 705 Total $ 4,122 $ 3,753

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Jan. 24, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The following table presents the changes in the carrying amount of goodwill by segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 26, 2019 $ 6,854 $ 20,381 $ 10,821 $ 1,903 $ 39,959 Goodwill as a result of acquisitions — 11 65 16 92 Purchase accounting adjustments 7 2 119 (5) 123 Currency translation and other 5 (59) (29) — (83) January 24, 2020 $ 6,866 $ 20,335 $ 10,976 $ 1,914 $ 40,091
Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: January 24, 2020 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,971 $ (4,824) $ 16,944 $ (4,095) Purchased technology and patents 10,640 (4,178) 11,405 (4,570) Trademarks and tradenames 464 (228) 570 (324) Other 83 (54) 85 (59) Total $ 28,158 $ (9,284) $ 29,004 $ (9,048) Indefinite-lived: IPR&D $ 582 $ — $ 604 $ —
Gross Carrying Amount of Indefinite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: January 24, 2020 April 26, 2019 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,971 $ (4,824) $ 16,944 $ (4,095) Purchased technology and patents 10,640 (4,178) 11,405 (4,570) Trademarks and tradenames 464 (228) 570 (324) Other 83 (54) 85 (59) Total $ 28,158 $ (9,284) $ 29,004 $ (9,048) Indefinite-lived: IPR&D $ 582 $ — $ 604 $ —
Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets	Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 24, 2020, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2020 $ 437 2021 1,741 2022 1,699 2023 1,634 2024 1,605 2025 1,576

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jan. 24, 2020
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended Nine months ended (in millions, except per share data) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Numerator: Net income attributable to ordinary shareholders $ 1,915 $ 1,269 $ 4,143 $ 3,459 Denominator: Basic – weighted average shares outstanding 1,340.5 1,342.8 1,340.7 1,348.1 Effect of dilutive securities: Employee stock options 8.4 6.9 7.8 7.9 Employee restricted stock units 2.6 3.0 2.9 3.2 Other — — 0.2 0.3 Diluted – weighted average shares outstanding 1,351.5 1,352.7 1,351.6 1,359.5 Basic earnings per share $ 1.43 $ 0.95 $ 3.09 $ 2.57 Diluted earnings per share $ 1.42 $ 0.94 $ 3.07 $ 2.54

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Jan. 24, 2020
Share-based Payment Arrangement [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and nine months ended January 24, 2020 and January 25, 2019: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Stock options $ 12 $ 11 $ 52 $ 62 Restricted stock 46 43 159 144 Employee stock purchase plan 8 6 24 22 Total stock-based compensation expense $ 66 $ 60 $ 235 $ 228 Cost of products sold $ 6 $ 5 $ 22 $ 23 Research and development expense 9 8 29 29 Selling, general, and administrative expense 51 47 184 176 Total stock-based compensation expense 66 60 235 228 Income tax benefits (11) (8) (40) (40) Total stock-based compensation expense, net of tax $ 55 $ 52 $ 195 $ 188

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	9 Months Ended
	Jan. 24, 2020
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three months and nine months ended January 24, 2020 and January 25, 2019: U.S. Non-U.S. Three months ended Three months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Service cost $ 26 $ 27 $ 15 $ 15 Interest cost 32 33 7 7 Expected return on plan assets (56) (54) (15) (14) Amortization of net actuarial loss 14 19 4 3 Net periodic benefit cost $ 16 $ 25 $ 11 $ 11 U.S. Non-U.S. Nine months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Service cost $ 78 $ 81 $ 45 $ 45 Interest cost 96 99 21 21 Expected return on plan assets (168) (162) (45) (42) Amortization of net actuarial loss 42 57 11 9 Net periodic benefit cost $ 48 $ 75 $ 32 $ 33

Leases (Tables)

Leases (Tables)	9 Months Ended
	Jan. 24, 2020
Leases [Abstract]
Summary of Balance Sheet Classification of Operating Leases and Amounts of Right-of-Use Assets and Lease Liabilities	The following table summarizes the balance sheet classification of the Company's operating leases and amounts of the right-of-use assets and lease liabilities at January 24, 2020: (in millions) Balance Sheet Classification January 24, 2020 Right-of-use assets Other assets $ 995 Current liability Other accrued expenses 169 Non-current liability Other liabilities 851
Schedule of Components of Total Operating Lease Cost and Supplemental Lease Information	The following table summarizes the weighted-average remaining lease term and weighted-average discount rate for the Company's operating leases at January 24, 2020: January 24, 2020 Weighted-average remaining lease term 7.5 years Weighted-average discount rate 3.0% The following table summarizes the components of total operating lease cost for the three and nine months ended January 24, 2020: Three months ended Nine months ended (in millions) January 24, 2020 January 24, 2020 Operating lease cost $ 59 $ 170 Short-term lease cost 10 32 Total operating lease cost $ 69 $ 202 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for operating lease liabilities for the nine months ended January 24, 2020: Nine months ended (in millions) January 24, 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 167 Right-of-use assets obtained in exchange for operating lease liabilities 178
Maturities of Operating Leases	The following table summarizes the maturities of the Company's operating leases at January 24, 2020: (in millions) Operating Leases Remaining 2020 $ 81 2021 203 2022 171 2023 147 2024 125 Thereafter 448 Total expected lease payments 1,175 Less: Imputed interest (155) Total lease liability $ 1,020
Minimum Payments Under Non-Cancelable Operating Leases	As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 26, 2019, minimum payments under non-cancelable operating leases at April 26, 2019 were: (in millions) Operating Leases 2020 $ 216 2021 157 2022 103 2023 61 2024 34 Thereafter 81 Total minimum lease payments $ 652

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Jan. 24, 2020
Equity [Abstract]
Changes in AOCI by Component	The following table provides changes in AOCI, net of tax, and by component: (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustments Net Investment Hedges Net Change in Retirement Obligations Unrealized Gain (Loss) on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 26, 2019 $ (45) $ (1,383) $ (169) $ (1,308) $ 194 $ (2,711) Other comprehensive income (loss) before reclassifications 94 (116) 187 (1) 106 270 Reclassifications (1) — — 39 (143) (105) Other comprehensive income (loss) 93 (116) 187 38 (37) 165 January 24, 2020 $ 48 $ (1,499) $ 18 $ (1,270) $ 157 $ (2,546) (in millions) Unrealized (Loss) Gain on Investment Securities Cumulative Translation Adjustment Net Investment Hedges Net Change in Retirement Obligations Unrealized (Loss) Gain on Cash Flow Hedges Total Accumulated Other Comprehensive (Loss) Income April 27, 2018 $ (194) $ (11) $ (257) $ (1,117) $ (207) $ (1,786) Other comprehensive (loss) income before reclassifications (7) (1,124) — — 353 (778) Reclassifications 30 — — 65 (36) 59 Other comprehensive income (loss) 23 (1,124) — 65 317 (719) Cumulative effect of change in accounting principle (1) 47 — — — — 47 January 25, 2019 $ (124) $ (1,135) $ (257) $ (1,052) $ 110 $ (2,458)

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Jan. 24, 2020
Segment Reporting [Abstract]
Net Sales by Segment	The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Net Sales Three months ended (1) Nine months ended (1) (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 2,819 $ 2,786 $ 8,464 $ 8,455 Minimally Invasive Therapies Group 2,176 2,124 6,418 6,223 Restorative Therapies Group 2,111 2,026 6,235 5,968 Diabetes Group 610 610 1,798 1,765 Total $ 7,717 $ 7,546 $ 22,916 $ 22,411 (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Segment Operating Profit Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Cardiac and Vascular Group $ 1,101 $ 1,076 $ 3,284 $ 3,262 Minimally Invasive Therapies Group 860 828 2,453 2,396 Restorative Therapies Group 898 824 2,531 2,394 Diabetes Group 158 190 456 538 Segment operating profit 3,017 2,918 8,724 8,590 Interest expense (156) (243) (930) (726) Other non-operating income, net 96 71 305 309 Amortization of intangible assets (436) (436) (1,317) (1,327) Corporate (348) (331) (1,005) (974) Centralized distribution costs (348) (383) (1,117) (1,313) Restructuring and associated costs (97) (66) (315) (256) Acquisition-related items (28) (17) (74) (57) Certain litigation charges (108) (63) (276) (166) IPR&D charges — (11) — (26) Exit of businesses — (69) (41) (149) Debt tender premium and other charges — — 7 — Medical device regulations (13) — (31) — Contribution to Medtronic Foundation — — (80) — Income before income taxes $ 1,579 $ 1,370 $ 3,850 $ 3,905
Net Sales to External Customers by Geography	The following table presents net sales for the three and nine months ended January 24, 2020 and January 25, 2019 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended Nine months ended (in millions) January 24, 2020 January 25, 2019 January 24, 2020 January 25, 2019 Ireland $ 22 $ 24 $ 66 $ 68 United States 4,021 4,001 12,068 11,910 Rest of world 3,674 3,521 10,782 10,433 Total other countries, excluding Ireland 7,695 7,522 22,850 22,343 Total $ 7,717 $ 7,546 $ 22,916 $ 22,411

Guarantor Financial Informati_2

Guarantor Financial Information (Tables)	9 Months Ended
	Jan. 24, 2020
Condensed Financial Information Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 344 $ — $ 7,717 $ (344) $ 7,717 Costs and expenses: Cost of products sold — 337 — 2,294 (231) 2,400 Research and development expense — 154 — 419 — 573 Selling, general, and administrative expense 3 432 — 2,152 — 2,587 Amortization of intangible assets — 6 — 430 — 436 Restructuring charges, net — 3 — 10 — 13 Certain litigation charges — — — 108 — 108 Other operating expense (income), net 12 (569) — 624 (106) (39) Operating profit (loss) (15) (19) — 1,680 (7) 1,639 Other non-operating (income) expense, net — (50) (174) (415) 543 (96) Interest expense 66 316 141 176 (543) 156 Equity in net (income) loss of subsidiaries (1,994) (1,707) (1,961) — 5,662 — Income (loss) before income taxes 1,913 1,422 1,994 1,919 (5,669) 1,579 Income tax provision (2) (40) — (298) — (340) Net income (loss) 1,915 1,462 1,994 2,217 (5,669) 1,919 Net income attributable to noncontrolling interests — — — (4) — (4) Net income (loss) attributable to Medtronic 1,915 1,462 1,994 2,213 (5,669) 1,915 Other comprehensive income (loss), net of tax 65 58 65 18 (141) 65 Comprehensive income attributable to — — — (4) — (4) Total comprehensive income (loss) $ 1,980 $ 1,520 $ 2,059 $ 2,231 $ (5,810) $ 1,980 Consolidating Statement of Comprehensive Income Nine Months Ended January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 1,155 $ — $ 22,916 $ (1,155) $ 22,916 Costs and expenses: Cost of products sold — 1,013 — 6,999 (852) 7,160 Research and development expense — 500 — 1,263 — 1,763 Selling, general, and administrative expense 9 1,241 1 6,499 — 7,750 Amortization of intangible assets — 12 — 1,305 — 1,317 Restructuring charges, net — 13 — 74 — 87 Certain litigation charges — 5 — 271 — 276 Other operating expense (income), net 39 (1,637) (7) 1,977 (284) 88 Operating profit (loss) (48) 8 6 4,528 (19) 4,475 Other non-operating (income) expense, net — (184) (660) (1,245) 1,784 (305) Interest expense 350 1,372 424 568 (1,784) 930 Equity in net (income) loss of subsidiaries (4,535) (2,899) (4,293) — 11,727 — Income (loss) before income taxes 4,137 1,719 4,535 5,205 (11,746) 3,850 Income tax provision (6) (199) — (112) — (317) Net income (loss) 4,143 1,918 4,535 5,317 (11,746) 4,167 Net income attributable to noncontrolling interests — — — (24) — (24) Net income (loss) attributable to Medtronic 4,143 1,918 4,535 5,293 (11,746) 4,143 Other comprehensive income (loss), net of tax 165 29 165 (65) (129) 165 Comprehensive income attributable to — — — (24) — (24) Total comprehensive income (loss) $ 4,308 $ 1,947 $ 4,700 $ 5,228 $ (11,875) $ 4,308 Consolidating Statement of Comprehensive Income Three Months Ended January 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 281 $ — $ 7,546 $ (281) $ 7,546 Costs and expenses: Cost of products sold — 223 — 2,206 (164) 2,265 Research and development expense — 152 — 409 — 561 Selling, general, and administrative expense 2 362 — 2,232 — 2,596 Amortization of intangible assets — 2 — 434 — 436 Restructuring charges, net — 3 — 23 — 26 Certain litigation charges — 12 — 51 — 63 Other operating expense (income), net 15 (827) — 987 (118) 57 Operating profit (loss) (17) 354 — 1,204 1 1,542 Other non-operating (income) expense, net — (151) (200) (480) 760 (71) Interest expense 125 501 133 244 (760) 243 Equity in net (income) loss of subsidiaries (1,410) (678) (1,343) — 3,431 — Income (loss) before income taxes 1,268 682 1,410 1,440 (3,430) 1,370 Income tax provision (1) 40 — 60 — 99 Net income (loss) 1,269 642 1,410 1,380 (3,430) 1,271 Net income attributable to noncontrolling interests — — — (2) — (2) Net income (loss) attributable to Medtronic 1,269 642 1,410 1,378 (3,430) 1,269 Other comprehensive income (loss), net of tax 154 45 154 132 (331) 154 Comprehensive income attributable to noncontrolling interests — — — (2) — (2) Total comprehensive income (loss) $ 1,423 $ 687 $ 1,564 $ 1,510 $ (3,761) $ 1,423 Consolidating Statement of Comprehensive Income Nine Months Ended January 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 1,007 $ — $ 22,411 $ (1,007) $ 22,411 Costs and expenses: Cost of products sold — 776 — 6,538 (642) 6,672 Research and development expense — 496 — 1,240 — 1,736 Selling, general, and administrative expense 8 1,142 — 6,648 — 7,798 Amortization of intangible assets — 6 — 1,321 — 1,327 Restructuring charges, net — 14 — 98 — 112 Certain litigation charges — 90 — 76 — 166 Other operating expense (income), net 40 (1,759) — 2,336 (339) 278 Operating profit (loss) (48) 242 — 4,154 (26) 4,322 Other non-operating (income) expense, net — (445) (539) (1,411) 2,086 (309) Interest expense 333 1,444 349 686 (2,086) 726 Equity in net (income) loss of subsidiaries (3,835) (2,176) (3,645) — 9,656 — Income (loss) before income taxes 3,454 1,419 3,835 4,879 (9,682) 3,905 Income tax provision (5) (79) — 521 — 437 Net income (loss) 3,459 1,498 3,835 4,358 (9,682) 3,468 Net income attributable to noncontrolling interests — — — (9) — (9) Net income (loss) attributable to Medtronic 3,459 1,498 3,835 4,349 (9,682) 3,459 Other comprehensive income (loss), net of tax (719) (965) (719) (779) 2,460 (722) Comprehensive income attributable to noncontrolling interests — — — (6) — (6) Total comprehensive income (loss) $ 2,740 $ 533 $ 3,116 $ 3,573 $ (7,222) $ 2,740 Consolidating Statement of Comprehensive Income Three Months Ended January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,717 $ — $ 7,717 Costs and expenses: Cost of products sold — — — 2,400 — 2,400 Research and development expense — — — 573 — 573 Selling, general, and administrative expense 3 — 1 2,583 — 2,587 Amortization of intangible assets — — — 436 — 436 Restructuring charges, net — — — 13 — 13 Certain litigation charges — — — 108 — 108 Other operating expense (income), net 12 — — (51) — (39) Operating profit (loss) (15) — (1) 1,655 — 1,639 Other non-operating (income) expense, net — (27) (179) (372) 482 (96) Interest expense 66 189 141 242 (482) 156 Equity in net (income) loss of subsidiaries (1,994) (448) (1,957) — 4,399 — Income (loss) before income taxes 1,913 286 1,994 1,785 (4,399) 1,579 Income tax provision (2) — — (338) — (340) Net income (loss) 1,915 286 1,994 2,123 (4,399) 1,919 Net income attributable to noncontrolling interests — — — (4) — (4) Net income (loss) attributable to Medtronic 1,915 286 1,994 2,119 (4,399) 1,915 Other comprehensive income (loss), net of tax 65 (35) 65 30 (60) 65 Comprehensive income attributable to — — — (4) — (4) Total comprehensive income (loss) $ 1,980 $ 251 $ 2,059 $ 2,149 $ (4,459) $ 1,980 Consolidating Statement of Comprehensive Income Nine Months Ended January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 22,916 $ — $ 22,916 Costs and expenses: Cost of products sold — — — 7,160 — 7,160 Research and development expense — — — 1,763 — 1,763 Selling, general, and administrative expense 9 1 2 7,738 — 7,750 Amortization of intangible assets — — — 1,317 — 1,317 Restructuring charges, net — — — 87 — 87 Certain litigation charges — — — 276 — 276 Other operating expense (income), net 39 — (7) 56 — 88 Operating profit (loss) (48) (1) 5 4,519 — 4,475 Other non-operating (income) expense, net — (122) (680) (1,132) 1,629 (305) Interest expense 350 601 424 1,184 (1,629) 930 Equity in net (income) loss of subsidiaries (4,535) (2,635) (4,274) — 11,444 — Income (loss) before income taxes 4,137 2,155 4,535 4,467 (11,444) 3,850 Income tax provision (6) — — (311) — (317) Net income (loss) 4,143 2,155 4,535 4,778 (11,444) 4,167 Net income attributable to noncontrolling interests — — — (24) — (24) Net income (loss) attributable to Medtronic 4,143 2,155 4,535 4,754 (11,444) 4,143 Other comprehensive income (loss), net of tax 165 (46) 165 (23) (96) 165 Comprehensive income attributable to — — — (24) — (24) Total comprehensive income (loss) $ 4,308 $ 2,109 $ 4,700 $ 4,731 $ (11,540) $ 4,308 Consolidating Statement of Comprehensive Income Three Months Ended January 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,546 $ — $ 7,546 Costs and expenses: Cost of products sold — — — 2,265 — 2,265 Research and development expense — — — 561 — 561 Selling, general, and administrative expense 2 — 1 2,593 — 2,596 Amortization of intangible assets — — — 436 — 436 Restructuring charges, net — — — 26 — 26 Certain litigation charges — — — 63 — 63 Other operating expense, net 15 — — 42 — 57 Operating profit (loss) (17) — (1) 1,560 — 1,542 Other non-operating (income) expense, net — (9) (207) (190) 335 (71) Interest expense 125 23 132 298 (335) 243 Equity in net (income) loss of subsidiaries (1,410) (656) (1,336) — 3,402 — Income (loss) before income taxes 1,268 642 1,410 1,452 (3,402) 1,370 Income tax provision (1) — — 100 — 99 Net income (loss) 1,269 642 1,410 1,352 (3,402) 1,271 Net income attributable to noncontrolling interests — — — (2) — (2) Net income (loss) attributable to Medtronic 1,269 642 1,410 1,350 (3,402) 1,269 Other comprehensive income (loss), net of tax 154 104 154 154 (412) 154 Comprehensive income attributable to — — — (2) — (2) Total comprehensive income (loss) $ 1,423 $ 746 $ 1,564 $ 1,504 $ (3,814) $ 1,423 Consolidating Statement of Comprehensive Income Nine Months Ended January 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 22,411 $ — $ 22,411 Costs and expenses: Cost of products sold — — — 6,672 — 6,672 Research and development expense — — — 1,736 — 1,736 Selling, general, and administrative expense 8 1 2 7,787 — 7,798 Amortization of intangible assets — — — 1,327 — 1,327 Restructuring charges, net — — — 112 — 112 Certain litigation charges — — — 166 — 166 Other operating expense, net 40 — — 238 — 278 Operating profit (loss) (48) (1) (2) 4,373 — 4,322 Other non-operating (income) expense, net — (29) (559) (614) 893 (309) Interest expense 333 66 348 872 (893) 726 Equity in net (income) loss of subsidiaries (3,835) (2,277) (3,626) — 9,738 — Income (loss) before income taxes 3,454 2,239 3,835 4,115 (9,738) 3,905 Income tax provision (5) — — 442 — 437 Net income (loss) 3,459 2,239 3,835 3,673 (9,738) 3,468 Net income attributable to noncontrolling interests — — — (9) — (9) Net income (loss) attributable to Medtronic 3,459 2,239 3,835 3,664 (9,738) 3,459 Other comprehensive income (loss), net of tax (719) 287 (719) (722) 1,151 (722) Comprehensive income attributable to — — — (6) — (6) Total comprehensive income (loss) $ 2,740 $ 2,526 $ 3,116 $ 2,945 $ (8,587) $ 2,740
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 185 $ 3,524 $ — $ 3,709 Investments — — — 7,919 — 7,919 Accounts receivable, net — — — 6,248 — 6,248 Inventories, net — 211 — 4,159 (248) 4,122 Intercompany receivable 42 8,807 5 34,982 (43,836) — Other current assets 10 195 2 1,838 — 2,045 Total current assets 52 9,213 192 58,670 (44,084) 24,043 Property, plant, and equipment, net — 1,536 — 3,228 — 4,764 Goodwill — 2,009 — 38,082 — 40,091 Other intangible assets, net — 197 — 19,259 — 19,456 Tax assets — 508 — 1,764 — 2,272 Investment in subsidiaries 58,753 75,008 77,989 — (211,750) — Intercompany loans receivable — 22 18,296 21,072 (39,390) — Other assets — 377 — 1,819 — 2,196 Total assets $ 58,805 $ 88,870 $ 96,477 $ 143,894 $ (295,224) $ 92,822 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 344 $ — $ 844 Accounts payable — 507 — 1,438 — 1,945 Intercompany payable — 21,383 13,599 8,854 (43,836) — Accrued compensation 20 785 — 1,104 — 1,909 Accrued income taxes — — — 457 — 457 Other accrued expenses 25 287 98 3,170 — 3,580 Total current liabilities 45 23,462 13,697 15,367 (43,836) 8,735 Long-term debt — 9,786 13,522 1,424 — 24,732 Accrued compensation and retirement benefits — 1,025 — 573 — 1,598 Accrued income taxes 10 760 — 1,968 — 2,738 Intercompany loans payable 6,942 9,012 9,729 13,707 (39,390) — Deferred tax liabilities — — — 1,282 — 1,282 Other liabilities — 262 — 1,522 — 1,784 Total liabilities 6,997 44,307 36,948 35,843 (83,226) 40,869 Shareholders’ equity 51,808 44,563 59,529 107,906 (211,998) 51,808 Noncontrolling interests — — — 145 — 145 Total equity 51,808 44,563 59,529 108,051 (211,998) 51,953 Total liabilities and equity $ 58,805 $ 88,870 $ 96,477 $ 143,894 $ (295,224) $ 92,822 Condensed Consolidating Balance Sheet April 26, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 18 $ 1 $ 4,374 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — 188 — 3,792 (227) 3,753 Intercompany receivable 40 9,407 6 19,170 (28,623) — Other current assets 10 190 3 1,941 — 2,144 Total current assets 50 9,803 10 40,954 (28,850) 21,967 Property, plant, and equipment, net — 1,480 — 3,195 — 4,675 Goodwill — 2,009 — 37,950 — 39,959 Other intangible assets, net — 99 — 20,461 — 20,560 Tax assets — 568 — 951 — 1,519 Investment in subsidiaries 64,352 71,123 65,012 — (200,487) — Intercompany loans receivable 3,000 21 27,858 35,398 (66,277) — Other assets — 216 — 798 — 1,014 Total assets $ 67,402 $ 85,319 $ 92,880 $ 139,707 $ (295,614) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 500 $ — $ 338 $ — $ 838 Accounts payable — 481 — 1,472 — 1,953 Intercompany payable — 11,971 7,200 9,452 (28,623) — Accrued compensation 3 913 — 1,273 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 331 53 2,521 — 2,925 Total current liabilities 23 14,196 7,253 15,623 (28,623) 8,472 Long-term debt — 14,418 8,621 1,447 — 24,486 Accrued compensation and retirement benefits — 1,069 — 582 — 1,651 Accrued income taxes 10 692 — 2,136 — 2,838 Intercompany loans payable 17,278 12,613 19,682 16,704 (66,277) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — 133 — 624 — 757 Total liabilities 17,311 43,121 35,556 38,394 (94,900) 39,482 Shareholders' equity 50,091 42,198 57,324 101,192 (200,714) 50,091 Noncontrolling interests — — — 121 — 121 Total equity 50,091 42,198 57,324 101,313 (200,714) 50,212 Total liabilities and equity $ 67,402 $ 85,319 $ 92,880 $ 139,707 $ (295,614) $ 89,694 Condensed Consolidating Balance Sheet January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 185 $ 3,524 $ — $ 3,709 Investments — — — 7,919 — 7,919 Accounts receivable, net — — — 6,248 — 6,248 Inventories, net — — — 4,122 — 4,122 Intercompany receivable 42 — 1,333 13,623 (14,998) — Other current assets 10 — 3 2,032 — 2,045 Total current assets 52 — 1,521 37,468 (14,998) 24,043 Property, plant, and equipment, net — — — 4,764 — 4,764 Goodwill — — — 40,091 — 40,091 Other intangible assets, net — — — 19,456 — 19,456 Tax assets — — — 2,272 — 2,272 Investment in subsidiaries 58,753 68,723 76,908 — (204,384) — Intercompany loans receivable — 3,545 18,296 37,018 (58,859) — Other assets — — — 2,196 — 2,196 Total assets $ 58,805 $ 72,268 $ 96,725 $ 143,265 $ (278,241) $ 92,822 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 844 $ — $ 844 Accounts payable — — — 1,945 — 1,945 Intercompany payable — 1,327 13,599 72 (14,998) — Accrued compensation 20 — — 1,889 — 1,909 Accrued income taxes — — — 457 — 457 Other accrued expenses 25 8 104 3,443 — 3,580 Total current liabilities 45 1,335 13,703 8,650 (14,998) 8,735 Long-term debt — 1,307 13,522 9,903 — 24,732 Accrued compensation and retirement benefits — — — 1,598 — 1,598 Accrued income taxes 10 — — 2,728 — 2,738 Intercompany loans payable 6,942 27,048 9,970 14,899 (58,859) — Deferred tax liabilities — — — 1,282 — 1,282 Other liabilities — — 1 1,783 — 1,784 Total liabilities 6,997 29,690 37,196 40,843 (73,857) 40,869 Shareholders’ equity 51,808 42,578 59,529 102,277 (204,384) 51,808 Noncontrolling interests — — — 145 — 145 Total equity 51,808 42,578 59,529 102,422 (204,384) 51,953 Total liabilities and equity $ 58,805 $ 72,268 $ 96,725 $ 143,265 $ (278,241) $ 92,822 Condensed Consolidating Balance Sheet April 26, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 1 $ 4,392 $ — $ 4,393 Investments — — — 5,455 — 5,455 Accounts receivable, net — — — 6,222 — 6,222 Inventories, net — — — 3,753 — 3,753 Intercompany receivable 40 — 1,374 7,212 (8,626) — Other current assets 10 — 3 2,131 — 2,144 Total current assets 50 — 1,378 29,165 (8,626) 21,967 Property, plant, and equipment, net — — — 4,675 — 4,675 Goodwill — — — 39,959 — 39,959 Other intangible assets, net — — — 20,560 — 20,560 Tax assets — — — 1,519 — 1,519 Investment in subsidiaries 64,352 39,563 63,651 — (167,566) — Intercompany loans receivable 3,000 4,119 27,858 29,002 (63,979) — Other assets — — — 1,014 — 1,014 Total assets $ 67,402 $ 43,682 $ 92,887 $ 125,894 $ (240,171) $ 89,694 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ — $ 838 $ — $ 838 Accounts payable — — — 1,953 — 1,953 Intercompany payable — 1,308 7,199 119 (8,626) — Accrued compensation 3 — — 2,186 — 2,189 Accrued income taxes — — — 567 — 567 Other accrued expenses 20 11 60 2,834 — 2,925 Total current liabilities 23 1,319 7,259 8,497 (8,626) 8,472 Long-term debt — 1,354 8,621 14,511 — 24,486 Accrued compensation and retirement benefits — — — 1,651 — 1,651 Accrued income taxes 10 — — 2,828 — 2,838 Intercompany loans payable 17,278 9,320 19,682 17,699 (63,979) — Deferred tax liabilities — — — 1,278 — 1,278 Other liabilities — — 1 756 — 757 Total liabilities 17,311 11,993 35,563 47,220 (72,605) 39,482 Shareholders' equity 50,091 31,689 57,324 78,553 (167,566) 50,091 Noncontrolling interests — — — 121 — 121 Total Equity 50,091 31,689 57,324 78,674 (167,566) 50,212 Total liabilities and equity $ 67,402 $ 43,682 $ 92,887 $ 125,894 $ (240,171) $ 89,694
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Nine Months Ended January 24, 2020 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 130 $ (1,315) $ 365 $ 6,604 $ — $ 5,784 Investing Activities: Acquisitions, net of cash acquired — 2 — (201) — (199) Additions to property, plant, and equipment — (236) — (641) — (877) Purchases of investments — — — (8,249) — (8,249) Sales and maturities of investments — 12 — 5,779 — 5,791 Capital contribution paid — — (9,000) (800) 9,800 — Return of capital 10,000 — (3,000) (7,000) — — Other investing activities — (56) (5) 27 — (34) Net cash provided by (used in) investing activities 10,000 (278) (12,005) (11,085) 9,800 (3,568) Financing Activities: Change in current debt obligations, net — — — 17 — 17 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (5,016) (515) (75) — (5,606) Dividends to shareholders (2,170) — — — — (2,170) Issuance of ordinary shares 585 — — — — 585 Repurchase of ordinary shares (1,208) — — — — (1,208) Net intercompany loan borrowings (repayments) (7,337) 6,591 6,010 (5,264) — — Capital contribution received — — 800 9,000 (9,800) — Other financing activities — — (38) (36) — (74) Net cash provided by (used in) financing activities (10,130) 1,575 11,824 3,643 (9,800) (2,888) Effect of exchange rate changes on cash and cash equivalents — — — (12) — (12) Net change in cash and cash equivalents — (18) 184 (850) — (684) Cash and cash equivalents at beginning of period — 18 1 4,374 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 185 $ 3,524 $ — $ 3,709 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 25, 2019 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 100 $ (619) $ 200 $ 5,239 $ — $ 4,920 Investing Activities: Acquisitions, net of cash acquired — — — (1,615) — (1,615) Additions to property, plant, and equipment — (207) — (592) — (799) Purchases of investments — — — (1,987) — (1,987) Sales and maturities of investments — 76 — 4,083 — 4,159 Capital contribution paid (18) (47) — — 65 — Other investing activities — — — (3) — (3) Net cash provided by (used in) investing activities (18) (178) — (114) 65 (245) Financing Activities: Change in current debt obligations, net — — (696) — — (696) Issuance of long-term debt — — — 3 — 3 Payments on long-term debt — — — (29) — (29) Dividends to shareholders (2,022) — — — — (2,022) Issuance of ordinary shares 891 — — — — 891 Repurchase of ordinary shares (2,728) — — — — (2,728) Net intercompany loan borrowings (repayments) 3,777 793 814 (5,384) — — Capital contribution received — — — 65 (65) — Other financing activities — — 17 (7) — 10 Net cash provided by (used in) financing activities (82) 793 135 (5,352) (65) (4,571) Effect of exchange rate changes on cash and cash equivalents — — — (70) — (70) Net change in cash and cash equivalents — (4) 335 (297) — 34 Cash and cash equivalents at beginning of period — 20 1 3,648 — 3,669 Cash and cash equivalents at end of period $ — $ 16 $ 336 $ 3,351 $ — $ 3,703 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 24, 2020 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 130 $ (497) $ 441 $ 5,710 $ — $ 5,784 Investing Activities: Acquisitions, net of cash acquired — — — (199) — (199) Additions to property, plant, and equipment — — — (877) — (877) Purchases of investments — — — (8,249) — (8,249) Sales and maturities of investments — — — 5,791 — 5,791 Capital contribution paid — (9,348) (9,301) (800) 19,449 — Return of capital 10,000 — (3,000) (7,000) — — Other investing activities — — (5) (29) — (34) Net cash provided by (used in) investing activities 10,000 (9,348) (12,306) (11,363) 19,449 (3,568) Financing Activities: Change in current debt obligations, net — — — 17 — 17 Issuance of long-term debt — — 5,567 1 — 5,568 Payments on long-term debt — (44) (515) (5,047) — (5,606) Dividends to shareholders (2,170) — — — — (2,170) Issuance of ordinary shares 585 — — — — 585 Repurchase of ordinary shares (1,208) — — — — (1,208) Net intercompany loan borrowings (repayments) (7,337) 588 6,231 518 — — Capital contribution received — 9,301 800 9,348 (19,449) — Other financing activities — — (34) (40) — (74) Net cash provided by (used in) financing activities (10,130) 9,845 12,049 4,797 (19,449) (2,888) Effect of exchange rate changes on cash and cash equivalents — — — (12) — (12) Net change in cash and cash equivalents — — 184 (868) — (684) Cash and cash equivalents at beginning of period — — 1 4,392 — 4,393 Cash and cash equivalents at end of period $ — $ — $ 185 $ 3,524 $ — $ 3,709 Condensed Consolidating Statement of Cash Flows Nine Months Ended January 25, 2019 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 100 $ (62) $ 219 $ 4,663 $ — $ 4,920 Investing Activities: Acquisitions, net of cash acquired — — — (1,615) — (1,615) Additions to property, plant, and equipment — — — (799) — (799) Purchases of investments — — — (1,987) — (1,987) Sales and maturities of investments — — — 4,159 — 4,159 Capital contributions paid (18) (187) — — 205 — Other investing activities — — — (3) — (3) Net cash provided by (used in) investing activities (18) (187) — (245) 205 (245) Financing Activities: Change in current debt obligations, net — — (696) — — (696) Issuance of long-term debt — — — 3 — 3 Payments on long-term debt — — — (29) — (29) Dividends to shareholders (2,022) — — — — (2,022) Issuance of ordinary shares 891 — — — — 891 Repurchase of ordinary shares (2,728) — — — — (2,728) Net intercompany loan borrowings (repayments) 3,777 249 795 (4,821) — — Capital contributions received — — — 205 (205) — Other financing activities — — 17 (7) — 10 Net cash provided by (used in) financing activities (82) 249 116 (4,649) (205) (4,571) Effect of exchange rate changes on cash and cash equivalents — — — (70) — (70) Net change in cash and cash equivalents — — 335 (301) — 34 Cash and cash equivalents at beginning of period — — 1 3,668 — 3,669 Cash and cash equivalents at end of period $ — $ — $ 336 $ 3,367 $ — $ 3,703

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 27, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets	$ 995
Total lease liability	$ 1,020
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right-of-use assets		$ 1,000
Total lease liability		$ 1,000

Revenue - Disaggregation of Net

Revenue - Disaggregation of Net Sales by Segment and Division (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 7,717	$ 7,546	$ 22,916	$ 22,411
Cardiac and Vascular Group
Disaggregation of Revenue [Line Items]
Net sales	2,819	2,786	8,464	8,455
Cardiac and Vascular Group | Cardiac Rhythm & Heart Failure
Disaggregation of Revenue [Line Items]
Net sales	1,393	1,397	4,201	4,295
Cardiac and Vascular Group | Coronary & Structural Heart
Disaggregation of Revenue [Line Items]
Net sales	948	913	2,844	2,736
Cardiac and Vascular Group | Aortic, Peripheral, & Venous
Disaggregation of Revenue [Line Items]
Net sales	478	476	1,420	1,424
Minimally Invasive Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,176	2,124	6,418	6,223
Minimally Invasive Therapies Group | Surgical Innovations
Disaggregation of Revenue [Line Items]
Net sales	1,474	1,434	4,345	4,224
Minimally Invasive Therapies Group | Respiratory, Gastrointestinal, & Renal
Disaggregation of Revenue [Line Items]
Net sales	702	690	2,073	1,999
Restorative Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,111	2,026	6,235	5,968
Restorative Therapies Group | Brain Therapies
Disaggregation of Revenue [Line Items]
Net sales	795	732	2,307	2,107
Restorative Therapies Group | Spine
Disaggregation of Revenue [Line Items]
Net sales	674	655	2,023	1,963
Restorative Therapies Group | Specialty Therapies
Disaggregation of Revenue [Line Items]
Net sales	340	325	996	956
Restorative Therapies Group | Pain Therapies
Disaggregation of Revenue [Line Items]
Net sales	303	314	910	942
Diabetes Group
Disaggregation of Revenue [Line Items]
Net sales	$ 610	$ 610	$ 1,798	$ 1,765

Revenue - Disaggregation of N_2

Revenue - Disaggregation of Net Sales by Market Geography for Each Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Disaggregation of Revenue [Line Items]
Net sales	$ 7,717	$ 7,546	$ 22,916	$ 22,411
U.S.
Disaggregation of Revenue [Line Items]
Net sales	4,021	4,001	12,068	11,910
Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	2,377	2,368	7,069	7,056
Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	1,318	1,177	3,778	3,445
Cardiac and Vascular Group
Disaggregation of Revenue [Line Items]
Net sales	2,819	2,786	8,464	8,455
Cardiac and Vascular Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,366	1,369	4,182	4,240
Cardiac and Vascular Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	915	924	2,735	2,766
Cardiac and Vascular Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	538	493	1,547	1,449
Minimally Invasive Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,176	2,124	6,418	6,223
Minimally Invasive Therapies Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	934	930	2,769	2,659
Minimally Invasive Therapies Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	791	796	2,364	2,396
Minimally Invasive Therapies Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	451	398	1,285	1,168
Restorative Therapies Group
Disaggregation of Revenue [Line Items]
Net sales	2,111	2,026	6,235	5,968
Restorative Therapies Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	1,409	1,354	4,187	4,005
Restorative Therapies Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	436	435	1,278	1,275
Restorative Therapies Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	266	237	770	688
Diabetes Group
Disaggregation of Revenue [Line Items]
Net sales	610	610	1,798	1,765
Diabetes Group | U.S.
Disaggregation of Revenue [Line Items]
Net sales	312	348	930	1,006
Diabetes Group | Non-U.S. Developed Markets
Disaggregation of Revenue [Line Items]
Net sales	236	213	693	619
Diabetes Group | Emerging Markets
Disaggregation of Revenue [Line Items]
Net sales	$ 63	$ 49	$ 176	$ 140

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 24, 2020	Apr. 26, 2019
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 303	$ 315
Revenue recognized that was previously included in deferred revenue	192
Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations	$ 1,200
Period over which remaining performance obligations are expected to be recognized as revenue	four years
Other accrued expenses
Disaggregation of Revenue [Line Items]
Rebate obligations	$ 862	764
Deferred revenue	212	211
Reduction of accounts receivable
Disaggregation of Revenue [Line Items]
Rebate obligations	447	432
Other liabilities
Disaggregation of Revenue [Line Items]
Deferred revenue	$ 91	$ 104

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($)	Dec. 18, 2018	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Oct. 25, 2019	Apr. 26, 2019	Oct. 26, 2018	Apr. 27, 2018
Business Acquisition [Line Items]
Goodwill		$ 40,091,000,000		$ 40,091,000,000		$ 40,091,000,000		$ 39,959,000,000
Purchase price contingent consideration		45,000,000	$ 5,000,000	110,000,000	$ 51,000,000
Purchase accounting adjustments. net increase to goodwill				123,000,000
Contingent consideration liabilities		304,000,000	148,000,000	304,000,000	148,000,000	304,000,000	$ 260,000,000	222,000,000	$ 203,000,000	$ 173,000,000
Other accrued expenses
Business Acquisition [Line Items]
Contingent consideration liabilities		147,000,000		147,000,000		147,000,000		73,000,000
Other liabilities
Business Acquisition [Line Items]
Contingent consideration liabilities		157,000,000		157,000,000		157,000,000		$ 149,000,000
IPR&D
Business Acquisition [Line Items]
In-process research and development acquired in connection with asset acquisition		0	15,000,000	0	15,000,000
All Business Acquisitions
Business Acquisition [Line Items]
Net assets acquired		272,000,000		272,000,000		272,000,000
Total assets acquired		324,000,000		324,000,000		324,000,000
Total liabilities assumed		52,000,000		52,000,000		52,000,000
Goodwill		92,000,000		92,000,000		92,000,000
Inventory		40,000,000		40,000,000		40,000,000
Purchase price contingent consideration				65,000,000
All Business Acquisitions | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired		139,000,000		$ 139,000,000		139,000,000
All Business Acquisitions | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life				8 years
All Business Acquisitions | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life				16 years
All Business Acquisitions | Customer-Related Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired		$ 26,000,000		$ 26,000,000		26,000,000
All Business Acquisitions | Customer-Related Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life				8 years
All Business Acquisitions | Customer-Related Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life				16 years
Mazor Robotics
Business Acquisition [Line Items]
Net assets acquired	$ 1,674,000,000
Total assets acquired	1,905,000,000
Total liabilities assumed	231,000,000
Intangible assets acquired	399,000,000
Goodwill	1,318,000,000
Inventory	5,000,000
Cash consideration	1,300,000,000
Total consideration for the transaction, net of cash acquired, including previously-held equity investment	1,600,000,000
Previously-held equity investment	246,000,000
Costs incurred in connection with acquisition			51,000,000		51,000,000
Purchase accounting adjustments. net increase to goodwill						$ 105,000,000
Mazor Robotics | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired	$ 383,000,000
Estimated useful life	10 years
Mazor Robotics | Tradenames
Business Acquisition [Line Items]
Intangible assets acquired	$ 16,000,000
Estimated useful life	10 years
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Net assets acquired			377,000,000		377,000,000
Total assets acquired			427,000,000		427,000,000
Total liabilities assumed			50,000,000		50,000,000
Goodwill			146,000,000		146,000,000
Purchase price contingent consideration					51,000,000
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired			161,000,000		$ 161,000,000
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life					4 years
Series of Individually Immaterial Business Acquisitions | Technology-Based Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life					15 years
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired			$ 40,000,000		$ 40,000,000
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets | Minimum
Business Acquisition [Line Items]
Estimated useful life					10 years
Series of Individually Immaterial Business Acquisitions | Customer-Related Intangible Assets | Maximum
Business Acquisition [Line Items]
Estimated useful life					13 years

Acquisitions - Assets Acquired

Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019	Dec. 18, 2018
Business Acquisition [Line Items]
Goodwill	$ 40,091	$ 39,959
Mazor Robotics
Business Acquisition [Line Items]
Cash and cash equivalents			$ 109
Investments			52
Accounts receivable			9
Inventory			5
Other current assets			1
Property, plant, and equipment			3
Goodwill			1,318
Other intangible assets			399
Tax assets			9
Total assets acquired			1,905
Current liabilities			210
Deferred tax liabilities			21
Total liabilities assumed			231
Net assets acquired			$ 1,674

Acquisitions - Reconciliation o

Acquisitions - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]
Beginning balance	$ 260	$ 203	$ 222	$ 173
Purchase price contingent consideration	45	5	110	51
Payments	(3)	(1)	(32)	(8)
Change in fair value	2	(59)	4	(68)
Ending balance	$ 304	$ 148	$ 304	$ 148

Acquisitions - Fair Value Measu

Acquisitions - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) $ in Millions	Jan. 24, 2020USD ($)	Oct. 25, 2019USD ($)	Apr. 26, 2019USD ($)	Jan. 25, 2019USD ($)	Oct. 26, 2018USD ($)	Apr. 27, 2018USD ($)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 304	$ 260	$ 222	$ 148	$ 203	$ 173
Revenue and other performance-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 123
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.115
Revenue and other performance-based payments | Minimum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.30
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.325
Revenue and other performance-based payments | Maximum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	1
Product development and other milestone-based payments | Recurring | Level 3
Fair Value Inputs, Liabilities, Quantitative Information [Line Items] (Deprecated 2018-01-31)
Contingent consideration, fair value	$ 181
Product development and other milestone-based payments | Recurring | Level 3 | Discount rate
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.055
Product development and other milestone-based payments | Minimum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	0.75
Product development and other milestone-based payments | Maximum | Recurring | Level 3 | Probability of payment
Fair Value Inputs
Contingent consideration, significant unobservable inputs	1

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - Enterprise Excellence - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Restructuring Cost and Reserve [Line Items]
Charges	$ 97	$ 69	$ 328	$ 264
Accrual adjustments		3	13	8
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges	50	21	117	58
Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Charges	34	$ 19	111	$ 86
Minimum | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Expected cost	1,600		1,600
Maximum | Pre-tax exit and disposal costs and other
Restructuring Cost and Reserve [Line Items]
Expected cost	$ 1,800		$ 1,800

Restructuring - Termination Lia

Restructuring - Termination Liability and Restructuring Reserve (Details) - Enterprise Excellence - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Restructuring Reserve [Roll Forward]
Beginning balance			$ 122
Charges	$ 97	$ 69	328	$ 264
Cash payments			(349)
Settled non-cash			(6)
Accrual adjustments		$ (3)	(13)	$ (8)
Ending balance	82		82
Employee Termination Benefits
Restructuring Reserve [Roll Forward]
Beginning balance			101
Charges			91
Cash payments			(118)
Settled non-cash			0
Accrual adjustments			(5)
Ending balance	69		69
Associated Costs
Restructuring Reserve [Roll Forward]
Beginning balance			9
Charges			223
Cash payments			(223)
Settled non-cash			0
Accrual adjustments			0
Ending balance	9		9
Asset Write-Downs
Restructuring Reserve [Roll Forward]
Beginning balance			0
Charges			6
Cash payments			0
Settled non-cash			(6)
Accrual adjustments			0
Ending balance	0		0
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance			12
Charges			8
Cash payments			(8)
Settled non-cash			0
Accrual adjustments			(8)
Ending balance	$ 4		$ 4

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Schedule of Investments [Line Items]
Cost	$ 7,893	$ 5,540
Unrealized Gains	85	20
Unrealized Losses	(26)	(61)
Fair Value	7,952	5,499
Investments
Schedule of Investments [Line Items]
Fair Value	7,919	5,455
Other Assets
Schedule of Investments [Line Items]
Fair Value	33	44
Level 2
Schedule of Investments [Line Items]
Cost	7,234	4,964
Unrealized Gains	68	19
Unrealized Losses	(23)	(51)
Fair Value	7,279	4,932
Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	7,279	4,932
Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Corporate debt securities | Level 2
Schedule of Investments [Line Items]
Cost	5,155	3,500
Unrealized Gains	52	14
Unrealized Losses	(8)	(21)
Fair Value	5,199	3,493
Corporate debt securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	5,199	3,493
Corporate debt securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 1
Schedule of Investments [Line Items]
Cost	623	529
Unrealized Gains	17	1
Unrealized Losses	0	(7)
Fair Value	640	523
U.S. government and agency securities | Level 1 | Investments
Schedule of Investments [Line Items]
Fair Value	640	523
U.S. government and agency securities | Level 1 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	900	387
Unrealized Gains	0	1
Unrealized Losses	0	(7)
Fair Value	900	381
U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	900	381
U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Mortgage-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	655	537
Unrealized Gains	13	3
Unrealized Losses	(13)	(20)
Fair Value	655	520
Mortgage-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	655	520
Mortgage-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Non-U.S. government and agency securities | Level 2
Schedule of Investments [Line Items]
Cost	13	11
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	13	11
Non-U.S. government and agency securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	13	11
Non-U.S. government and agency securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Other asset-backed securities | Level 2
Schedule of Investments [Line Items]
Cost	511	529
Unrealized Gains	3	1
Unrealized Losses	(2)	(3)
Fair Value	512	527
Other asset-backed securities | Level 2 | Investments
Schedule of Investments [Line Items]
Fair Value	512	527
Other asset-backed securities | Level 2 | Other Assets
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3
Schedule of Investments [Line Items]
Cost	36	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	33	44
Auction rate securities | Level 3 | Investments
Schedule of Investments [Line Items]
Fair Value	0	0
Auction rate securities | Level 3 | Other Assets
Schedule of Investments [Line Items]
Fair Value	$ 33	$ 44

Financial Instruments - Availab

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	$ 572	$ 1,075
Less than 12 months, Unrealized Losses	(4)	(9)
More than 12 months, Fair Value	366	2,181
More than 12 months, Unrealized Losses	(22)	(52)
U.S. government and agency securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	96	130
Less than 12 months, Unrealized Losses	0	(1)
More than 12 months, Fair Value	40	649
More than 12 months, Unrealized Losses	0	(13)
Corporate debt securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	371	582
Less than 12 months, Unrealized Losses	(3)	(5)
More than 12 months, Fair Value	65	1,153
More than 12 months, Unrealized Losses	(5)	(16)
Mortgage-backed securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	82	73
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	63	250
More than 12 months, Unrealized Losses	(12)	(19)
Other asset-backed securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	23	290
Less than 12 months, Unrealized Losses	0	(2)
More than 12 months, Fair Value	165	85
More than 12 months, Unrealized Losses	(2)	(1)
Auction rate securities
Debt Securities, Available-for-sale [Line Items]
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	33	44
More than 12 months, Unrealized Losses	$ (3)	$ (3)

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019	Apr. 26, 2019
Gain (Loss) on Securities [Line Items]
Redemption of investments	$ 2,531,000,000	$ 1,301,000,000	$ 5,789,000,000	$ 3,217,000,000
Credit loss portion of other-than-temporary impairments	0		0		$ 0
Reductions for available-for-sale securities sold	0	0	0	0
Equity and Other Investments
Gain (Loss) on Securities [Line Items]
Net gains recognized	1,000,000	7,000,000	16,000,000	101,000,000
Net realized gains on equity and other investments sold during the period		1,000,000		71,000,000
Net unrealized gains on equity and other investments still held	1,000,000	$ 6,000,000	16,000,000	$ 30,000,000
Level 3
Gain (Loss) on Securities [Line Items]
Redemption of investments	11,000,000		11,000,000
Gain or loss recognized on redemption	$ 0		$ 0

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019	Apr. 26, 2019
Activities Related to Debt Securities Portfolio
Proceeds from sales	$ 2,531	$ 1,301	$ 5,789	$ 3,217
Gross realized gains	9	9	17	17
Gross realized losses	(2)	$ (36)	(13)	$ (55)
AFS Debt Maturities
Due in one year or less	3,595		3,595
Due after one year through five years	2,727		2,727
Due after five years through ten years	1,577		1,577
Due after ten years	53		53
Fair Value	$ 7,952		$ 7,952		$ 5,499

Financial Instruments - Summary

Financial Instruments - Summary of Equity and Other Investments (Details) - Other Assets - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Investment [Line Items]
Investments with readily determinable fair value (marketable equity securities)	$ 39	$ 0
Investments without readily determinable fair values	373	308
Equity method and other investments	68	64
Total equity and other investments	$ 480	$ 372

Financial Instruments - Activ_2

Financial Instruments - Activity Related to the Company's Investment Portfolio, Equity and Other Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Investment [Line Items]
Proceeds from sales			$ 5,791	$ 4,159
Equity and Other Investments
Investment [Line Items]
Proceeds from sales	$ 0	$ 33	2	941
Gross gains	1	8	16	131
Gross losses	0	(1)	0	(30)
Impairment losses recognized	$ (1)	$ 0	$ (5)	$ (12)

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details)	1 Months Ended			3 Months Ended	9 Months Ended
	Aug. 30, 2019USD ($)	Jul. 31, 2019USD ($)	Jun. 30, 2019USD ($)	Jul. 26, 2019USD ($)	Jan. 24, 2020USD ($)	Jan. 25, 2019USD ($)	Jun. 30, 2019EUR (€)tranche	Apr. 26, 2019USD ($)
Senior Notes
Principal value					$ 25,200,000,000			$ 25,000,000,000
Cash proceeds, net of discounts and issuance costs					5,568,000,000	$ 3,000,000
Loss on extinguishment of debt					406,000,000	$ 0
Financial Instruments Not Measured at Fair Value
Long-term debt, including the current portion, fair value					27,500,000,000			26,200,000,000
Commercial Paper Program | Commercial Paper
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount					3,500,000,000
Commercial paper, amount outstanding					0			0
Credit Facility | Line of Credit
Line of Credit Facility
Line of credit, maximum capacity					$ 3,500,000,000
Term of debt instrument					5 years
Line of credit, amount outstanding					$ 0			$ 0
Senior Notes 2019 | Senior notes | Medtronic Luxco
Senior Notes
Number of tranches | tranche							6
Principal value | €							€ 5,000,000,000
Cash proceeds, net of discounts and issuance costs			$ 5,600,000,000
Floating Rate Notes due 2021 | Senior notes
Line of Credit Facility
Term of debt instrument					2 years
Floating Rate Notes due 2021 | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							250,000,000
0.000 percent four-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					4 years
Senior Notes
Stated interest rate					0.00%
0.000 percent four-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 750,000,000
Stated interest rate							0.00%
0.250 percent seven-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					7 years
Senior Notes
Stated interest rate					0.25%
0.250 percent seven-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							0.25%
1.000 percent thirteen-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					13 years
Senior Notes
Stated interest rate					1.00%
1.000 percent thirteen-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.00%
1.500 percent twenty-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					20 years
Senior Notes
Stated interest rate					1.50%
1.500 percent twenty-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.50%
1.750 percent thirty-year 2019 senior notes | Senior notes
Line of Credit Facility
Term of debt instrument					30 years
Senior Notes
Stated interest rate					1.75%
1.750 percent thirty-year 2019 senior notes | Senior notes | Medtronic Luxco
Senior Notes
Principal value | €							€ 1,000,000,000
Stated interest rate							1.75%
Medtronic Inc, CIFSA, and Medtronic Luxco Senior Notes | Senior notes
Senior Notes
Extinguishment of debt	$ 533,000,000	$ 4,600,000,000
Total consideration		$ 5,000,000,000
Loss on extinguishment of debt				$ 413,000,000
Early redemption premium	$ 16,000,000

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 24, 2020	Apr. 26, 2019
Debt Instrument [Line Items]
Current debt obligations	$ 844	$ 838
Long-term debt
Debt (discount) premium, net	(15)	29
Deferred financing costs	(106)	(104)
Long-term debt	$ 24,732	24,486
Senior notes | 0.000 percent two-year 2019 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	2 years
Long-term debt, gross	$ 1,662	1,681
Senior notes | Floating rate two-year 2019 senior notes
Long-term debt
Term of debt instrument	2 years
Long-term debt, gross	$ 831	560
Senior notes | 4.125 percent ten-year 2011 senior notes
Long-term debt
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 0	500
Senior notes | 3.150 percent seven-year 2015 senior notes
Long-term debt
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term debt, gross	$ 1,534	2,500
Senior notes | 3.125 percent ten-year 2012 senior notes
Long-term debt
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 0	675
Senior notes | 3.200 percent ten-year 2012 CIFSA senior notes
Long-term debt
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 650	650
Senior notes | 0.375 percent four-year 2019 senior notes
Long-term debt
Stated interest rate	0.375%
Term of debt instrument	4 years
Long-term debt, gross	$ 1,662	1,681
Senior notes | 2.750 percent ten-year 2013 senior notes
Long-term debt
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term debt, gross	$ 530	530
Senior notes | 0.000 percent four-year 2019 senior notes
Long-term debt
Stated interest rate	0.00%
Term of debt instrument	4 years
Long-term debt, gross	$ 831	0
Senior notes | 2.950 percent ten-year 2013 CIFSA senior notes
Long-term debt
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term debt, gross	$ 310	310
Senior notes | 3.625 percent ten-year 2014 senior notes
Long-term debt
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term debt, gross	$ 432	850
Senior notes | 3.500 percent ten-year 2015 senior notes
Long-term debt
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term debt, gross	$ 2,700	4,000
Senior notes | 0.250 percent seven-year 2019 senior notes
Long-term debt
Stated interest rate	0.25%
Term of debt instrument	7 years
Long-term debt, gross	$ 1,108	0
Senior notes | 1.125 percent eight-year 2019 senior notes
Long-term debt
Stated interest rate	1.125%
Term of debt instrument	8 years
Long-term debt, gross	$ 1,662	1,681
Senior notes | 3.350 percent ten-year 2017 senior notes
Long-term debt
Stated interest rate	3.35%
Term of debt instrument	10 years
Long-term debt, gross	$ 368	850
Senior notes | 1.625 percent twelve-year 2019 senior notes
Long-term debt
Stated interest rate	1.625%
Term of debt instrument	12 years
Long-term debt, gross	$ 1,108	1,121
Senior notes | 1.000 percent thirteen-year 2019 senior notes
Long-term debt
Stated interest rate	1.00%
Term of debt instrument	13 years
Long-term debt, gross	$ 1,108	0
Senior notes | 4.375 percent twenty-year 2015 senior notes
Long-term debt
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,931	2,382
Senior notes | 6.550 percent thirty-year 2007 CIFSA senior notes
Long-term debt
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 253	284
Senior notes | 2.250 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	2.25%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,108	1,121
Senior notes | 6.500 percent thirty-year 2009 senior notes
Long-term debt
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 158	183
Senior notes | 5.550 percent thirty-year 2010 senior notes
Long-term debt
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 224	306
Senior notes | 1.500 percent twenty-year 2019 senior notes
Long-term debt
Stated interest rate	1.50%
Term of debt instrument	20 years
Long-term debt, gross	$ 1,108	0
Senior notes | 4.500 percent thirty-year 2012 senior notes
Long-term debt
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 105	129
Senior notes | 4.000 percent thirty-year 2013 senior notes
Long-term debt
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term debt, gross	$ 305	325
Senior notes | 4.625 percent thirty-year 2014 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 127	177
Senior notes | 4.625 percent thirty-year 2015 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 1,813	1,963
Senior notes | 1.750 percent thirty-year 2019 senior notes
Long-term debt
Stated interest rate	1.75%
Term of debt instrument	30 years
Long-term debt, gross	$ 1,108	0
Bank borrowings
Long-term debt
Long-term debt, gross	70	83
Finance lease obligations
Long-term debt
Finance lease obligations	47
Finance lease obligations		10
Interest rate swaps
Long-term debt
Interest rate swaps	$ 0	$ 9

Derivatives and Currency Exch_3

Derivatives and Currency Exchange Risk Management - Narrative (Details) € in Billions	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 24, 2020USD ($)	Jan. 25, 2019USD ($)	Jan. 24, 2020USD ($)	Jan. 25, 2019USD ($)	Apr. 26, 2019USD ($)	Jan. 24, 2020EUR (€)derivative	Jan. 24, 2020USD ($)derivative
Derivative Instruments and Hedging Activities Disclosures [Line Items]
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI					$ 194,000,000		$ 157,000,000
Cash flow hedge unrealized gains to be reclassified over the next 12 months			$ 145,000,000
Debt, face amount					25,000,000,000		$ 25,200,000,000
Gains (losses) on firm commitments that no longer qualify as fair value hedges	$ 0	$ 0	0	$ 0
After-tax net unrealized gains (losses) associated with net investment hedging instruments recorded in AOCI			18,000,000		169,000,000
Net investment hedge unrealized gains or losses to be reclassified over the next twelve months, net of tax			0
Gains (losses) on firm commitments that no longer qualify as net investment hedges	$ 0	$ 0	$ 0	$ 0
4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate						4.125%	4.125%
3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate						3.125%	3.125%
Currency exchange rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount					11,100,000,000		$ 12,100,000,000
Currency exchange rate contracts | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount					4,300,000,000		5,200,000,000
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount					6,800,000,000		6,900,000,000
Maximum remaining maturity of foreign currency derivatives			2 years
Currency exchange rate contracts | Derivatives designated as hedging instruments | Net investment hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount						€ 12	13,300,000,000
Total return swaps | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount					191,000,000		$ 215,000,000
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gross notional amount					1,200,000,000
Number of interest rate swaps outstanding | derivative						0	0
Market value of outstanding interest rate swap agreements - net unrealized gain					9,000,000
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging | 4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount					$ 500,000,000
Stated interest rate					4.125%
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging | 3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount					$ 675,000,000
Stated interest rate					3.125%

Derivatives and Currency Exch_4

Derivatives and Currency Exchange Risk Management - Derivative (Gains) Losses Not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Derivative Instruments, (Gain) Loss [Line Items]
Total	$ (15)	$ 30	$ (26)	$ (171)
Other operating (income) expense, net | Currency exchange rate contracts
Derivative Instruments, (Gain) Loss [Line Items]
Total	2	30	(4)	(171)
Other operating (income) expense, net | Total return swaps
Derivative Instruments, (Gain) Loss [Line Items]
Total	$ (17)	$ 0	$ (22)	$ 0

Derivatives and Currency Exch_5

Derivatives and Currency Exchange Risk Management - (Gains) Losses Recognized in AOCI, Cash Flow Hedges (Details) - Currency exchange rate contracts - Cash flow hedging - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, Cash flow hedges	$ (41)		$ (144)
Recognized in AOCI, Cash flow hedges		$ (25)		$ (469)

Derivatives and Currency Exch_6

Derivatives and Currency Exchange Risk Management - Amount of (Gains) Losses Recognized in Consolidated Statements of Income, Cash Flow Hedges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Other operating (income) expense, net	$ (39)	$ 57	$ 88	$ 278
Cash flow hedging | Currency exchange rate contracts | Other operating (income) expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Amount of (gain) loss reclassified from AOCI into income	$ (82)		$ (206)
Amount of (gain) loss reclassified from AOCI into income		$ (48)		$ (56)

Derivatives and Currency Exch_7

Derivatives and Currency Exchange Risk Management - Schedule of Amounts Recorded on Consolidated Balance Sheet Related to Cumulative Basis Adjustments for Fair Value Hedges (Details) - Long-term debt - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Derivatives, Fair Value [Line Items]
Carrying Amount of Hedged Assets/(Liabilities)	$ 0	$ (1,175)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Assets/(Liabilities)	$ 0	$ 9

Derivatives and Currency Exch_8

Derivatives and Currency Exchange Risk Management - (Gains) Losses Recognized in Income, Net Investment Hedges (Details) - Currency exchange rate contracts - Other operating (income) expense, net - Net investment hedges - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in Income, Net investment hedges	$ 0		$ (7)
Recognized in Income, Net investment hedges		$ 0		$ 0

Derivatives and Currency Exch_9

Derivatives and Currency Exchange Risk Management - (Gains) Losses Recognized in AOCI, Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, Net investment hedges	$ (35)		$ (187)
Recognized in AOCI, Net investment hedges		$ 0		$ 0
Currency exchange rate contracts | Net investment hedges
Derivative Instruments, (Gain) Loss [Line Items]
Recognized in AOCI, Net investment hedges	$ (35)		$ (187)
Recognized in AOCI, Net investment hedges		$ 0		$ 0

Derivatives and Currency Exc_10

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	$ 284	$ 365
Derivative Liabilities, Fair Value	33	19
Currency exchange rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	267	335
Derivative Liabilities, Fair Value	33	19
Interest rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value		9
Total return swaps
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	16	15
Cross currency interest rate contracts
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	1	6
Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	258	321
Derivative Liabilities, Fair Value	23	2
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	183	234
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	75	78
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	11	1
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	12	1
Derivatives designated as hedging instruments | Interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value		9
Derivatives designated as hedging instruments | Interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value		0
Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	26	44
Derivative Liabilities, Fair Value	10	17
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	9	23
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	10	17
Derivatives not designated as hedging instruments | Total return swaps | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	16	15
Derivatives not designated as hedging instruments | Total return swaps | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	0	0
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other current assets
Derivatives, Fair Value [Line Items]
Derivative Assets, Fair Value	1	6
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Derivative Liabilities, Fair Value	$ 0	$ 0

Derivatives and Currency Exc_11

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 267	$ 335
Derivative liabilities	33	19
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	17	30
Derivative liabilities	$ 0	$ 0

Derivatives and Currency Exc_12

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	$ 284	$ 365
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(33)	(9)
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(5)	(44)
Net Amount	246	312
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	(33)	(19)
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	33	9
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	0	(10)
Total
Gross Amount of Recorded Assets (Liabilities)	251	346
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(5)	(44)
Net Amount	246	302
Currency exchange rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	267	335
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(33)	(9)
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	(5)	(43)
Net Amount	229	283
Derivative liabilities:
Gross Amount of Recorded Assets (Liabilities)	(33)	(19)
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	33	9
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	0	(10)
Interest rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)		9
Gross Amount Not Offset on the Balance Sheet, Financial Instruments		0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)		(1)
Net Amount		8
Total return swaps
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	16	15
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	16	15
Cross currency interest rate contracts
Derivative assets:
Gross Amount of Recorded Assets (Liabilities)	1	6
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Cash Collateral Posted (Received)	0	0
Net Amount	$ 1	$ 6

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 2,693	$ 2,476
Work in-process	643	572
Raw materials	786	705
Total	$ 4,122	$ 3,753

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	9 Months Ended
	Jan. 24, 2020USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 39,959
Goodwill as a result of acquisitions	92
Purchase accounting adjustments	123
Currency translation and other	(83)
Ending balance	40,091
Cardiac and Vascular Group
Goodwill [Roll Forward]
Beginning balance	6,854
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	7
Currency translation and other	5
Ending balance	6,866
Minimally Invasive Therapies Group
Goodwill [Roll Forward]
Beginning balance	20,381
Goodwill as a result of acquisitions	11
Purchase accounting adjustments	2
Currency translation and other	(59)
Ending balance	20,335
Restorative Therapies Group
Goodwill [Roll Forward]
Beginning balance	10,821
Goodwill as a result of acquisitions	65
Purchase accounting adjustments	119
Currency translation and other	(29)
Ending balance	10,976
Diabetes Group
Goodwill [Roll Forward]
Beginning balance	1,903
Goodwill as a result of acquisitions	16
Purchase accounting adjustments	(5)
Currency translation and other	0
Ending balance	$ 1,914

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0	$ 0
Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible asset charges	0			87,000,000
Impairment of indefinite-lived intangible assets	0	21,000,000	0	21,000,000
Amortization expense	$ 436,000,000	436,000,000	1,317,000,000	1,327,000,000
Restorative Therapies Group
Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible asset charges		26,000,000	$ 33,000,000	26,000,000
Impairment of indefinite-lived intangible assets		$ 11,000,000		11,000,000
Cardiac and Vascular Group
Finite-Lived Intangible Assets [Line Items]
Definite-lived intangible asset charges				$ 61,000,000

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Jan. 24, 2020	Apr. 26, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 28,158	$ 29,004
Accumulated Amortization	(9,284)	(9,048)
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Indefinite-lived	582	604
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	16,971	16,944
Accumulated Amortization	(4,824)	(4,095)
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,640	11,405
Accumulated Amortization	(4,178)	(4,570)
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	464	570
Accumulated Amortization	(228)	(324)
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	83	85
Accumulated Amortization	$ (54)	$ (59)

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Jan. 24, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2020	$ 437
2021	1,741
2022	1,699
2023	1,634
2024	1,605
2025	$ 1,576

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019	Apr. 26, 2019
Income Tax Disclosure [Abstract]
Effective tax rate	(21.50%)	7.20%	(8.20%)	11.20%
Certain tax adjustments	$ (558)	$ (64)	$ (839)	$ (35)
Benefit related to release of valuation allowance	558		558
Net benefit related to measurement period adjustment related to U.S. Tax Reform		12	30	25
Benefit related to tax legislative changes in Switzerland			251
Finite-Lived Intangible Assets [Line Items]
Benefit related to intercompany legal entity restructuring		32		32
Net benefit associated with finalization of certain income tax aspects of divestiture		$ 20		20
Charge related to recognition of prepaid tax expense				$ 42
Gross unrecognized tax benefits	1,800		1,800		$ 1,800
Accrued gross interest and penalties	207		207
Unrecognized tax benefits that would impact effective tax rate	$ 1,800		$ 1,800
Amortizable Asset Created for Swiss Federal Income Tax Purposes
Finite-Lived Intangible Assets [Line Items]
Period over which amortizable asset will be amortized and deducted			10 years

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Basic and Diluted Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Numerator:
Net income attributable to ordinary shareholders	$ 1,915	$ 1,269	$ 4,143	$ 3,459
Denominator:
Basic - weighted average shares outstanding (shares)	1,340.5	1,342.8	1,340.7	1,348.1
Effect of dilutive securities:
Employee stock options (shares)	8.4	6.9	7.8	7.9
Employee restricted stock units (shares)	2.6	3	2.9	3.2
Other (shares)	0	0	0.2	0.3
Diluted - weighted average shares outstanding (shares)	1,351.5	1,352.7	1,351.6	1,359.5
Basic earnings per share (usd per share)	$ 1.43	$ 0.95	$ 3.09	$ 2.57
Diluted earnings per share (usd per share)	$ 1.42	$ 0.94	$ 3.07	$ 2.54

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	3	7	3	7

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 66	$ 60	$ 235	$ 228
Income tax benefits	(11)	(8)	(40)	(40)
Total stock-based compensation expense, net of tax	55	52	195	188
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6	5	22	23
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	9	8	29	29
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	51	47	184	176
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	11	52	62
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	46	43	159	144
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 8	$ 6	$ 24	$ 22

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - Pension plans - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
U.S.
Net Periodic Benefit Cost
Service cost	$ 26	$ 27	$ 78	$ 81
Interest cost	32	33	96	99
Expected return on plan assets	(56)	(54)	(168)	(162)
Amortization of net actuarial loss	14	19	42	57
Net periodic benefit cost	16	25	48	75
Non-U.S.
Net Periodic Benefit Cost
Service cost	15	15	45	45
Interest cost	7	7	21	21
Expected return on plan assets	(15)	(14)	(45)	(42)
Amortization of net actuarial loss	4	3	11	9
Net periodic benefit cost	$ 11	$ 11	$ 32	$ 33

Leases - Balance Sheet Classifi

Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Details) $ in Millions	Jan. 24, 2020USD ($)
Leases [Abstract]
Right-of-use assets	$ 995
Current liability	169
Non-current liability	$ 851

Leases - Weighted-Average Remai

Leases - Weighted-Average Remaining Lease Term and Weighted-Average Discount Rate for Operating Leases (Details)	Jan. 24, 2020
Leases [Abstract]
Weighted-average remaining lease term	7 years 6 months
Weighted-average discount rate	3.00%

Leases - Components of Total Op

Leases - Components of Total Operating Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Jan. 24, 2020	Jan. 24, 2020
Leases [Abstract]
Operating lease cost	$ 59	$ 170
Short-term lease cost	10	32
Total operating lease cost	$ 69	$ 202

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information (Details) $ in Millions	9 Months Ended
	Jan. 24, 2020USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 167
Right-of-use assets obtained in exchange for operating lease liabilities	$ 178

Leases - Maturities of Operatin

Leases - Maturities of Operating Leases (Details) $ in Millions	Jan. 24, 2020USD ($)
Leases [Abstract]
Remaining 2020	$ 81
2021	203
2022	171
2023	147
2024	125
Thereafter	448
Total expected lease payments	1,175
Less: Imputed interest	(155)
Total lease liability	$ 1,020

Leases - Minimum Payments Under

Leases - Minimum Payments Under Non-Cancelable Operating Leases (Details) $ in Millions	Apr. 26, 2019USD ($)
Leases [Abstract]
2020	$ 216
2021	157
2022	103
2023	61
2024	34
Thereafter	81
Total minimum lease payments	$ 652

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Changes in AOCI (Details) - USD ($)		3 Months Ended						9 Months Ended
		Jan. 24, 2020	Oct. 25, 2019	Jul. 26, 2019	Jan. 25, 2019	Oct. 26, 2018	Jul. 27, 2018	Jan. 24, 2020	Jan. 25, 2019	Apr. 27, 2019	[1]	Apr. 28, 2018
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		$ 50,719,000,000	$ 50,497,000,000	$ 50,212,000,000	$ 49,714,000,000	$ 50,329,000,000	$ 50,822,000,000	$ 50,212,000,000	$ 50,822,000,000
Other comprehensive income (loss)		65,000,000	(127,000,000)	227,000,000	154,000,000	(292,000,000)	(584,000,000)	165,000,000	(722,000,000)
Cumulative effect of change in accounting principle										$ (33,000,000)		$ 0	[2]
Ending balance		51,953,000,000	50,719,000,000	50,497,000,000	49,941,000,000	49,714,000,000	50,329,000,000	51,953,000,000	49,941,000,000
Unrealized (Loss) Gain on Investment Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				(45,000,000)			(194,000,000)	(45,000,000)	(194,000,000)
Other comprehensive income (loss) before reclassifications								94,000,000	(7,000,000)
Reclassifications								(1,000,000)	30,000,000
Other comprehensive income (loss)								93,000,000	23,000,000
Cumulative effect of change in accounting principle												47,000,000
Ending balance		48,000,000			(124,000,000)			48,000,000	(124,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)								7,000,000	(2,000,000)
Reclassifications, tax expense (benefit)								1,000,000	(2,000,000)
Cumulative Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				(1,383,000,000)			(11,000,000)	(1,383,000,000)	(11,000,000)
Other comprehensive income (loss) before reclassifications								(116,000,000)	(1,124,000,000)
Reclassifications								0	0
Other comprehensive income (loss)								(116,000,000)	(1,124,000,000)
Cumulative effect of change in accounting principle												0
Ending balance		(1,499,000,000)			(1,135,000,000)			(1,499,000,000)	(1,135,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)								0	(8,000,000)
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				(169,000,000)				(169,000,000)
Other comprehensive income (loss) before reclassifications								187,000,000	0
Reclassifications								0	0
Other comprehensive income (loss)								187,000,000
Ending balance		18,000,000						18,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)								0
Net Investment Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance							(257,000,000)		(257,000,000)
Other comprehensive income (loss)									0
Cumulative effect of change in accounting principle												0
Ending balance					(257,000,000)				(257,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)									0
Net Change in Retirement Obligations
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				(1,308,000,000)			(1,117,000,000)	(1,308,000,000)	(1,117,000,000)
Other comprehensive income (loss) before reclassifications								(1,000,000)	0
Reclassifications								39,000,000	65,000,000
Other comprehensive income (loss)								38,000,000	65,000,000
Cumulative effect of change in accounting principle												0
Ending balance		(1,270,000,000)			(1,052,000,000)			(1,270,000,000)	(1,052,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)								0	0
Reclassifications, tax expense (benefit)								(9,000,000)	(15,000,000)
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance				194,000,000				194,000,000
Other comprehensive income (loss) before reclassifications								106,000,000
Reclassifications								(143,000,000)
Other comprehensive income (loss)								(37,000,000)
Ending balance		157,000,000						157,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)								38,000,000
Reclassifications, tax expense (benefit)								47,000,000
Unrealized (Loss) Gain on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance							(207,000,000)		(207,000,000)
Other comprehensive income (loss) before reclassifications									353,000,000
Reclassifications									(36,000,000)
Other comprehensive income (loss)									317,000,000
Cumulative effect of change in accounting principle												0
Ending balance					110,000,000				110,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)									116,000,000
Reclassifications, tax expense (benefit)									16,000,000
Total Accumulated Other Comprehensive (Loss) Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		(2,611,000,000)	(2,484,000,000)	(2,711,000,000)	(2,612,000,000)	(2,323,000,000)	(1,786,000,000)	(2,711,000,000)	(1,786,000,000)
Other comprehensive income (loss) before reclassifications								270,000,000	(778,000,000)
Reclassifications								(105,000,000)	59,000,000
Other comprehensive income (loss)		65,000,000	(127,000,000)	227,000,000	154,000,000	(289,000,000)	(584,000,000)	165,000,000	(719,000,000)
Cumulative effect of change in accounting principle	[2]											47,000,000
Ending balance		(2,546,000,000)	(2,611,000,000)	(2,484,000,000)	(2,458,000,000)	(2,612,000,000)	(2,323,000,000)	(2,546,000,000)	(2,458,000,000)
Retained Earnings
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance		27,018,000,000	26,377,000,000	26,270,000,000	25,171,000,000	24,730,000,000	24,379,000,000	26,270,000,000	24,379,000,000
Cumulative effect of change in accounting principle										$ (33,000,000)		$ (47,000,000)	[2]
Ending balance		$ 28,210,000,000	$ 27,018,000,000	$ 26,377,000,000	$ 25,769,000,000	$ 25,171,000,000	$ 24,730,000,000	$ 28,210,000,000	$ 25,769,000,000
[1]	See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter of fiscal year 2020.
[2]	The cumulative effect of change in accounting principle during the first quarter of fiscal year 2019 resulted from the adoption of accounting guidance that requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. As a result of the adoption, the Company reclassified $47 million from accumulated other comprehensive loss to the opening balance of retained earnings as of April 28, 2018.

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Feb. 05, 2020claim	Nov. 28, 2018USD ($)	Dec. 14, 2011patent	Jun. 29, 2007	May 31, 2017claim	Jan. 24, 2020USD ($)claim	Jan. 25, 2019USD ($)	Jan. 24, 2020USD ($)manufacturersubsidiaryclaimlandfill	Jan. 25, 2019USD ($)	Apr. 29, 2016USD ($)claim	Apr. 26, 2019USD ($)
Loss Contingencies [Line Items]
Certain litigation charges						$ 108	$ 63	$ 276	$ 166
Accrued litigation charges						$ 600		$ 600			$ 500
Covidien
Loss Contingencies [Line Items]
Tax sharing percentage, parent				42.00%
Tax sharing percentage, former parent				27.00%
Tax sharing percentage, former affiliate				31.00%
Orrington, Maine chemical manufacturing facility
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill								2
Number of landfills requiring capping and installation of groundwater extraction systems | landfill								3
Pelvic mesh | Product liability litigation
Loss Contingencies [Line Items]
Number of subsidiaries | subsidiary								2
Number of manufacturers | manufacturer								1
Amount of settlement received										$ 121
Number of claims settled | claim					5,000					11,000
Number of pending claims | claim						16,000		16,000
Pelvic mesh | Product liability litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of claims settled | claim	15,400
Ethicon
Loss Contingencies [Line Items]
Patents infringed | patent			1
Patents not infringed upon | patent			6
Sasso
Loss Contingencies [Line Items]
Approximate amount of verdict returned against the Company		$ 112

Segment and Geographic Inform_3

Segment and Geographic Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019	Jan. 24, 2020	Jan. 25, 2019
Segment Reporting Information [Line Items]
Net sales	$ 7,717	$ 7,546	$ 22,916	$ 22,411
Income before Income Taxes by Reportable Segment
Segment operating profit	1,639	1,542	4,475	4,322
Interest expense	(156)	(243)	(930)	(726)
Amortization of intangible assets	(436)	(436)	(1,317)	(1,327)
Restructuring and associated costs	(13)	(26)	(87)	(112)
Certain litigation charges	(108)	(63)	(276)	(166)
Income (loss) before income taxes	1,579	1,370	3,850	3,905
Ireland
Segment Reporting Information [Line Items]
Net sales	22	24	66	68
United States
Segment Reporting Information [Line Items]
Net sales	4,021	4,001	12,068	11,910
Rest of world
Segment Reporting Information [Line Items]
Net sales	3,674	3,521	10,782	10,433
Total other countries, excluding Ireland
Segment Reporting Information [Line Items]
Net sales	7,695	7,522	22,850	22,343
Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	3,017	2,918	8,724	8,590
Segment Reconciling Items
Income before Income Taxes by Reportable Segment
Interest expense	(156)	(243)	(930)	(726)
Other non-operating income, net	96	71	305	309
Amortization of intangible assets	(436)	(436)	(1,317)	(1,327)
Corporate	(348)	(331)	(1,005)	(974)
Centralized distribution costs	(348)	(383)	(1,117)	(1,313)
Restructuring and associated costs	(97)	(66)	(315)	(256)
Acquisition-related items	(28)	(17)	(74)	(57)
Certain litigation charges	(108)	(63)	(276)	(166)
IPR&D charges	0	(11)	0	(26)
Exit of businesses	0	(69)	(41)	(149)
Debt tender premium and other charges	0	0	7	0
Medical device regulations	(13)	0	(31)	0
Contribution to Medtronic Foundation	0	0	(80)	0
Cardiac and Vascular Group
Segment Reporting Information [Line Items]
Net sales	2,819	2,786	8,464	8,455
Cardiac and Vascular Group | United States
Segment Reporting Information [Line Items]
Net sales	1,366	1,369	4,182	4,240
Cardiac and Vascular Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	1,101	1,076	3,284	3,262
Minimally Invasive Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,176	2,124	6,418	6,223
Minimally Invasive Therapies Group | United States
Segment Reporting Information [Line Items]
Net sales	934	930	2,769	2,659
Minimally Invasive Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	860	828	2,453	2,396
Restorative Therapies Group
Segment Reporting Information [Line Items]
Net sales	2,111	2,026	6,235	5,968
Restorative Therapies Group | United States
Segment Reporting Information [Line Items]
Net sales	1,409	1,354	4,187	4,005
Restorative Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	898	824	2,531	2,394
Diabetes Group
Segment Reporting Information [Line Items]
Net sales	610	610	1,798	1,765
Diabetes Group | United States
Segment Reporting Information [Line Items]
Net sales	312	348	930	1,006
Diabetes Group | Operating Segments
Income before Income Taxes by Reportable Segment
Segment operating profit	$ 158	$ 190	$ 456	$ 538

Guarantor Financial Informati_3

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Jan. 24, 2020	Oct. 25, 2019	Jul. 26, 2019	Jan. 25, 2019	Oct. 26, 2018	Jul. 27, 2018	Jan. 24, 2020	Jan. 25, 2019
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,717			$ 7,546			$ 22,916	$ 22,411
Costs and expenses:
Cost of products sold	2,400			2,265			7,160	6,672
Research and development expense	573			561			1,763	1,736
Selling, general, and administrative expense	2,587			2,596			7,750	7,798
Amortization of intangible assets	436			436			1,317	1,327
Restructuring charges, net	13			26			87	112
Certain litigation charges	108			63			276	166
Other operating (income) expense, net	(39)			57			88	278
Operating profit (loss)	1,639			1,542			4,475	4,322
Other non-operating (income) expense, net	(96)			(71)			(305)	(309)
Interest expense	156			243			930	726
Equity in net (income) loss of subsidiaries	0			0			0	0
Income (loss) before income taxes	1,579			1,370			3,850	3,905
Income tax provision	(340)			99			(317)	437
Net income (loss)	1,919	$ 1,371	$ 877	1,271	$ 1,120	$ 1,077	4,167	3,468
Net income attributable to noncontrolling interests	(4)			(2)			(24)	(9)
Net income (loss) attributable to Medtronic	1,915			1,269			4,143	3,459
Other comprehensive income (loss), net of tax	65	$ (127)	$ 227	154	$ (292)	$ (584)	165	(722)
Comprehensive income attributable to noncontrolling interests	(4)			(2)			(24)	(6)
Comprehensive income attributable to Medtronic	1,980			1,423			4,308	2,740
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	(344)			(281)			(1,155)	(1,007)
Costs and expenses:
Cost of products sold	(231)			(164)			(852)	(642)
Research and development expense	0			0			0	0
Selling, general, and administrative expense	0			0			0	0
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	(106)			(118)			(284)	(339)
Operating profit (loss)	(7)			1			(19)	(26)
Other non-operating (income) expense, net	543			760			1,784	2,086
Interest expense	(543)			(760)			(1,784)	(2,086)
Equity in net (income) loss of subsidiaries	5,662			3,431			11,727	9,656
Income (loss) before income taxes	(5,669)			(3,430)			(11,746)	(9,682)
Income tax provision	0			0			0	0
Net income (loss)	(5,669)			(3,430)			(11,746)	(9,682)
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	(5,669)			(3,430)			(11,746)	(9,682)
Other comprehensive income (loss), net of tax	(141)			(331)			(129)	2,460
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	(5,810)			(3,761)			(11,875)	(7,222)
Consolidating Adjustments | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0			0			0	0
Costs and expenses:
Cost of products sold	0			0			0	0
Research and development expense	0			0			0	0
Selling, general, and administrative expense	0			0			0	0
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	0			0			0	0
Operating profit (loss)	0			0			0	0
Other non-operating (income) expense, net	482			335			1,629	893
Interest expense	(482)			(335)			(1,629)	(893)
Equity in net (income) loss of subsidiaries	4,399			3,402			11,444	9,738
Income (loss) before income taxes	(4,399)			(3,402)			(11,444)	(9,738)
Income tax provision	0			0			0	0
Net income (loss)	(4,399)			(3,402)			(11,444)	(9,738)
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	(4,399)			(3,402)			(11,444)	(9,738)
Other comprehensive income (loss), net of tax	(60)			(412)			(96)	1,151
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	(4,459)			(3,814)			(11,540)	(8,587)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0			0			0	0
Costs and expenses:
Cost of products sold	0			0			0	0
Research and development expense	0			0			0	0
Selling, general, and administrative expense	3			2			9	8
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	12			15			39	40
Operating profit (loss)	(15)			(17)			(48)	(48)
Other non-operating (income) expense, net	0			0			0	0
Interest expense	66			125			350	333
Equity in net (income) loss of subsidiaries	(1,994)			(1,410)			(4,535)	(3,835)
Income (loss) before income taxes	1,913			1,268			4,137	3,454
Income tax provision	(2)			(1)			(6)	(5)
Net income (loss)	1,915			1,269			4,143	3,459
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	1,915			1,269			4,143	3,459
Other comprehensive income (loss), net of tax	65			154			165	(719)
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	1,980			1,423			4,308	2,740
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0			0			0	0
Costs and expenses:
Cost of products sold	0			0			0	0
Research and development expense	0			0			0	0
Selling, general, and administrative expense	3			2			9	8
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	12			15			39	40
Operating profit (loss)	(15)			(17)			(48)	(48)
Other non-operating (income) expense, net	0			0			0	0
Interest expense	66			125			350	333
Equity in net (income) loss of subsidiaries	(1,994)			(1,410)			(4,535)	(3,835)
Income (loss) before income taxes	1,913			1,268			4,137	3,454
Income tax provision	(2)			(1)			(6)	(5)
Net income (loss)	1,915			1,269			4,143	3,459
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	1,915			1,269			4,143	3,459
Other comprehensive income (loss), net of tax	65			154			165	(719)
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	1,980			1,423			4,308	2,740
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	344			281			1,155	1,007
Costs and expenses:
Cost of products sold	337			223			1,013	776
Research and development expense	154			152			500	496
Selling, general, and administrative expense	432			362			1,241	1,142
Amortization of intangible assets	6			2			12	6
Restructuring charges, net	3			3			13	14
Certain litigation charges	0			12			5	90
Other operating (income) expense, net	(569)			(827)			(1,637)	(1,759)
Operating profit (loss)	(19)			354			8	242
Other non-operating (income) expense, net	(50)			(151)			(184)	(445)
Interest expense	316			501			1,372	1,444
Equity in net (income) loss of subsidiaries	(1,707)			(678)			(2,899)	(2,176)
Income (loss) before income taxes	1,422			682			1,719	1,419
Income tax provision	(40)			40			(199)	(79)
Net income (loss)	1,462			642			1,918	1,498
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	1,462			642			1,918	1,498
Other comprehensive income (loss), net of tax	58			45			29	(965)
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	1,520			687			1,947	533
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0			0			0	0
Costs and expenses:
Cost of products sold	0			0			0	0
Research and development expense	0			0			0	0
Selling, general, and administrative expense	0			0			1	1
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	0			0			0	0
Operating profit (loss)	0			0			(1)	(1)
Other non-operating (income) expense, net	(27)			(9)			(122)	(29)
Interest expense	189			23			601	66
Equity in net (income) loss of subsidiaries	(448)			(656)			(2,635)	(2,277)
Income (loss) before income taxes	286			642			2,155	2,239
Income tax provision	0			0			0	0
Net income (loss)	286			642			2,155	2,239
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	286			642			2,155	2,239
Other comprehensive income (loss), net of tax	(35)			104			(46)	287
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	251			746			2,109	2,526
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0			0			0	0
Costs and expenses:
Cost of products sold	0			0			0	0
Research and development expense	0			0			0	0
Selling, general, and administrative expense	0			0			1	0
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	0			0			(7)	0
Operating profit (loss)	0			0			6	0
Other non-operating (income) expense, net	(174)			(200)			(660)	(539)
Interest expense	141			133			424	349
Equity in net (income) loss of subsidiaries	(1,961)			(1,343)			(4,293)	(3,645)
Income (loss) before income taxes	1,994			1,410			4,535	3,835
Income tax provision	0			0			0	0
Net income (loss)	1,994			1,410			4,535	3,835
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	1,994			1,410			4,535	3,835
Other comprehensive income (loss), net of tax	65			154			165	(719)
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	2,059			1,564			4,700	3,116
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0			0			0	0
Costs and expenses:
Cost of products sold	0			0			0	0
Research and development expense	0			0			0	0
Selling, general, and administrative expense	1			1			2	2
Amortization of intangible assets	0			0			0	0
Restructuring charges, net	0			0			0	0
Certain litigation charges	0			0			0	0
Other operating (income) expense, net	0			0			(7)	0
Operating profit (loss)	(1)			(1)			5	(2)
Other non-operating (income) expense, net	(179)			(207)			(680)	(559)
Interest expense	141			132			424	348
Equity in net (income) loss of subsidiaries	(1,957)			(1,336)			(4,274)	(3,626)
Income (loss) before income taxes	1,994			1,410			4,535	3,835
Income tax provision	0			0			0	0
Net income (loss)	1,994			1,410			4,535	3,835
Net income attributable to noncontrolling interests	0			0			0	0
Net income (loss) attributable to Medtronic	1,994			1,410			4,535	3,835
Other comprehensive income (loss), net of tax	65			154			165	(719)
Comprehensive income attributable to noncontrolling interests	0			0			0	0
Comprehensive income attributable to Medtronic	2,059			1,564			4,700	3,116
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,717			7,546			22,916	22,411
Costs and expenses:
Cost of products sold	2,294			2,206			6,999	6,538
Research and development expense	419			409			1,263	1,240
Selling, general, and administrative expense	2,152			2,232			6,499	6,648
Amortization of intangible assets	430			434			1,305	1,321
Restructuring charges, net	10			23			74	98
Certain litigation charges	108			51			271	76
Other operating (income) expense, net	624			987			1,977	2,336
Operating profit (loss)	1,680			1,204			4,528	4,154
Other non-operating (income) expense, net	(415)			(480)			(1,245)	(1,411)
Interest expense	176			244			568	686
Equity in net (income) loss of subsidiaries	0			0			0	0
Income (loss) before income taxes	1,919			1,440			5,205	4,879
Income tax provision	(298)			60			(112)	521
Net income (loss)	2,217			1,380			5,317	4,358
Net income attributable to noncontrolling interests	(4)			(2)			(24)	(9)
Net income (loss) attributable to Medtronic	2,213			1,378			5,293	4,349
Other comprehensive income (loss), net of tax	18			132			(65)	(779)
Comprehensive income attributable to noncontrolling interests	(4)			(2)			(24)	(6)
Comprehensive income attributable to Medtronic	2,231			1,510			5,228	3,573
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,717			7,546			22,916	22,411
Costs and expenses:
Cost of products sold	2,400			2,265			7,160	6,672
Research and development expense	573			561			1,763	1,736
Selling, general, and administrative expense	2,583			2,593			7,738	7,787
Amortization of intangible assets	436			436			1,317	1,327
Restructuring charges, net	13			26			87	112
Certain litigation charges	108			63			276	166
Other operating (income) expense, net	(51)			42			56	238
Operating profit (loss)	1,655			1,560			4,519	4,373
Other non-operating (income) expense, net	(372)			(190)			(1,132)	(614)
Interest expense	242			298			1,184	872
Equity in net (income) loss of subsidiaries	0			0			0	0
Income (loss) before income taxes	1,785			1,452			4,467	4,115
Income tax provision	(338)			100			(311)	442
Net income (loss)	2,123			1,352			4,778	3,673
Net income attributable to noncontrolling interests	(4)			(2)			(24)	(9)
Net income (loss) attributable to Medtronic	2,119			1,350			4,754	3,664
Other comprehensive income (loss), net of tax	30			154			(23)	(722)
Comprehensive income attributable to noncontrolling interests	(4)			(2)			(24)	(6)
Comprehensive income attributable to Medtronic	$ 2,149			$ 1,504			$ 4,731	$ 2,945

Guarantor Financial Informati_4

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Jan. 24, 2020	Oct. 25, 2019	Jul. 26, 2019	Apr. 26, 2019	Jan. 25, 2019	Oct. 26, 2018	Jul. 27, 2018	Apr. 27, 2018
Current assets:
Cash and cash equivalents	$ 3,709			$ 4,393
Investments	7,919			5,455
Accounts receivable, net	6,248			6,222
Inventories, net	4,122			3,753
Intercompany receivable	0			0
Other current assets	2,045			2,144
Total current assets	24,043			21,967
Property, plant, and equipment, net	4,764			4,675
Goodwill	40,091			39,959
Other intangible assets, net	19,456			20,560
Tax assets	2,272			1,519
Investment in subsidiaries	0			0
Intercompany loans receivable	0			0
Other assets	2,196			1,014
Total assets	92,822			89,694
Current liabilities:
Current debt obligations	844			838
Accounts payable	1,945			1,953
Intercompany payable	0			0
Accrued compensation	1,909			2,189
Accrued income taxes	457			567
Other accrued expenses	3,580			2,925
Total current liabilities	8,735			8,472
Long-term debt	24,732			24,486
Accrued compensation and retirement benefits	1,598			1,651
Accrued income taxes	2,738			2,838
Intercompany loans payable	0			0
Deferred tax liabilities	1,282			1,278
Other liabilities	1,784			757
Total liabilities	40,869			39,482
Shareholders’ equity	51,808			50,091
Noncontrolling interests	145			121
Total equity	51,953	$ 50,719	$ 50,497	50,212	$ 49,941	$ 49,714	$ 50,329	$ 50,822
Total liabilities and equity	92,822			89,694
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0			0
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	(248)			(227)
Intercompany receivable	(43,836)			(28,623)
Other current assets	0			0
Total current assets	(44,084)			(28,850)
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	(211,750)			(200,487)
Intercompany loans receivable	(39,390)			(66,277)
Other assets	0			0
Total assets	(295,224)			(295,614)
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	(43,836)			(28,623)
Accrued compensation	0			0
Accrued income taxes	0			0
Other accrued expenses	0			0
Total current liabilities	(43,836)			(28,623)
Long-term debt	0			0
Accrued compensation and retirement benefits	0			0
Accrued income taxes	0			0
Intercompany loans payable	(39,390)			(66,277)
Deferred tax liabilities	0			0
Other liabilities	0			0
Total liabilities	(83,226)			(94,900)
Shareholders’ equity	(211,998)			(200,714)
Noncontrolling interests	0			0
Total equity	(211,998)			(200,714)
Total liabilities and equity	(295,224)			(295,614)
Consolidating Adjustments | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0			0
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	0			0
Intercompany receivable	(14,998)			(8,626)
Other current assets	0			0
Total current assets	(14,998)			(8,626)
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	(204,384)			(167,566)
Intercompany loans receivable	(58,859)			(63,979)
Other assets	0			0
Total assets	(278,241)			(240,171)
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	(14,998)			(8,626)
Accrued compensation	0			0
Accrued income taxes	0			0
Other accrued expenses	0			0
Total current liabilities	(14,998)			(8,626)
Long-term debt	0			0
Accrued compensation and retirement benefits	0			0
Accrued income taxes	0			0
Intercompany loans payable	(58,859)			(63,979)
Deferred tax liabilities	0			0
Other liabilities	0			0
Total liabilities	(73,857)			(72,605)
Shareholders’ equity	(204,384)			(167,566)
Noncontrolling interests	0			0
Total equity	(204,384)			(167,566)
Total liabilities and equity	(278,241)			(240,171)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0			0
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	0			0
Intercompany receivable	42			40
Other current assets	10			10
Total current assets	52			50
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	58,753			64,352
Intercompany loans receivable	0			3,000
Other assets	0			0
Total assets	58,805			67,402
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	0			0
Accrued compensation	20			3
Accrued income taxes	0			0
Other accrued expenses	25			20
Total current liabilities	45			23
Long-term debt	0			0
Accrued compensation and retirement benefits	0			0
Accrued income taxes	10			10
Intercompany loans payable	6,942			17,278
Deferred tax liabilities	0			0
Other liabilities	0			0
Total liabilities	6,997			17,311
Shareholders’ equity	51,808			50,091
Noncontrolling interests	0			0
Total equity	51,808			50,091
Total liabilities and equity	58,805			67,402
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0			0
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	0			0
Intercompany receivable	42			40
Other current assets	10			10
Total current assets	52			50
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	58,753			64,352
Intercompany loans receivable	0			3,000
Other assets	0			0
Total assets	58,805			67,402
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	0			0
Accrued compensation	20			3
Accrued income taxes	0			0
Other accrued expenses	25			20
Total current liabilities	45			23
Long-term debt	0			0
Accrued compensation and retirement benefits	0			0
Accrued income taxes	10			10
Intercompany loans payable	6,942			17,278
Deferred tax liabilities	0			0
Other liabilities	0			0
Total liabilities	6,997			17,311
Shareholders’ equity	51,808			50,091
Noncontrolling interests	0			0
Total equity	51,808			50,091
Total liabilities and equity	58,805			67,402
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	0			18
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	211			188
Intercompany receivable	8,807			9,407
Other current assets	195			190
Total current assets	9,213			9,803
Property, plant, and equipment, net	1,536			1,480
Goodwill	2,009			2,009
Other intangible assets, net	197			99
Tax assets	508			568
Investment in subsidiaries	75,008			71,123
Intercompany loans receivable	22			21
Other assets	377			216
Total assets	88,870			85,319
Current liabilities:
Current debt obligations	500			500
Accounts payable	507			481
Intercompany payable	21,383			11,971
Accrued compensation	785			913
Accrued income taxes	0			0
Other accrued expenses	287			331
Total current liabilities	23,462			14,196
Long-term debt	9,786			14,418
Accrued compensation and retirement benefits	1,025			1,069
Accrued income taxes	760			692
Intercompany loans payable	9,012			12,613
Deferred tax liabilities	0			0
Other liabilities	262			133
Total liabilities	44,307			43,121
Shareholders’ equity	44,563			42,198
Noncontrolling interests	0			0
Total equity	44,563			42,198
Total liabilities and equity	88,870			85,319
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0			0
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	0			0
Intercompany receivable	0			0
Other current assets	0			0
Total current assets	0			0
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	68,723			39,563
Intercompany loans receivable	3,545			4,119
Other assets	0			0
Total assets	72,268			43,682
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	1,327			1,308
Accrued compensation	0			0
Accrued income taxes	0			0
Other accrued expenses	8			11
Total current liabilities	1,335			1,319
Long-term debt	1,307			1,354
Accrued compensation and retirement benefits	0			0
Accrued income taxes	0			0
Intercompany loans payable	27,048			9,320
Deferred tax liabilities	0			0
Other liabilities	0			0
Total liabilities	29,690			11,993
Shareholders’ equity	42,578			31,689
Noncontrolling interests	0			0
Total equity	42,578			31,689
Total liabilities and equity	72,268			43,682
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	185			1
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	0			0
Intercompany receivable	5			6
Other current assets	2			3
Total current assets	192			10
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	77,989			65,012
Intercompany loans receivable	18,296			27,858
Other assets	0			0
Total assets	96,477			92,880
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	13,599			7,200
Accrued compensation	0			0
Accrued income taxes	0			0
Other accrued expenses	98			53
Total current liabilities	13,697			7,253
Long-term debt	13,522			8,621
Accrued compensation and retirement benefits	0			0
Accrued income taxes	0			0
Intercompany loans payable	9,729			19,682
Deferred tax liabilities	0			0
Other liabilities	0			0
Total liabilities	36,948			35,556
Shareholders’ equity	59,529			57,324
Noncontrolling interests	0			0
Total equity	59,529			57,324
Total liabilities and equity	96,477			92,880
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	185			1
Investments	0			0
Accounts receivable, net	0			0
Inventories, net	0			0
Intercompany receivable	1,333			1,374
Other current assets	3			3
Total current assets	1,521			1,378
Property, plant, and equipment, net	0			0
Goodwill	0			0
Other intangible assets, net	0			0
Tax assets	0			0
Investment in subsidiaries	76,908			63,651
Intercompany loans receivable	18,296			27,858
Other assets	0			0
Total assets	96,725			92,887
Current liabilities:
Current debt obligations	0			0
Accounts payable	0			0
Intercompany payable	13,599			7,199
Accrued compensation	0			0
Accrued income taxes	0			0
Other accrued expenses	104			60
Total current liabilities	13,703			7,259
Long-term debt	13,522			8,621
Accrued compensation and retirement benefits	0			0
Accrued income taxes	0			0
Intercompany loans payable	9,970			19,682
Deferred tax liabilities	0			0
Other liabilities	1			1
Total liabilities	37,196			35,563
Shareholders’ equity	59,529			57,324
Noncontrolling interests	0			0
Total equity	59,529			57,324
Total liabilities and equity	96,725			92,887
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Current assets:
Cash and cash equivalents	3,524			4,374
Investments	7,919			5,455
Accounts receivable, net	6,248			6,222
Inventories, net	4,159			3,792
Intercompany receivable	34,982			19,170
Other current assets	1,838			1,941
Total current assets	58,670			40,954
Property, plant, and equipment, net	3,228			3,195
Goodwill	38,082			37,950
Other intangible assets, net	19,259			20,461
Tax assets	1,764			951
Investment in subsidiaries	0			0
Intercompany loans receivable	21,072			35,398
Other assets	1,819			798
Total assets	143,894			139,707
Current liabilities:
Current debt obligations	344			338
Accounts payable	1,438			1,472
Intercompany payable	8,854			9,452
Accrued compensation	1,104			1,273
Accrued income taxes	457			567
Other accrued expenses	3,170			2,521
Total current liabilities	15,367			15,623
Long-term debt	1,424			1,447
Accrued compensation and retirement benefits	573			582
Accrued income taxes	1,968			2,136
Intercompany loans payable	13,707			16,704
Deferred tax liabilities	1,282			1,278
Other liabilities	1,522			624
Total liabilities	35,843			38,394
Shareholders’ equity	107,906			101,192
Noncontrolling interests	145			121
Total equity	108,051			101,313
Total liabilities and equity	143,894			139,707
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	3,524			4,392
Investments	7,919			5,455
Accounts receivable, net	6,248			6,222
Inventories, net	4,122			3,753
Intercompany receivable	13,623			7,212
Other current assets	2,032			2,131
Total current assets	37,468			29,165
Property, plant, and equipment, net	4,764			4,675
Goodwill	40,091			39,959
Other intangible assets, net	19,456			20,560
Tax assets	2,272			1,519
Investment in subsidiaries	0			0
Intercompany loans receivable	37,018			29,002
Other assets	2,196			1,014
Total assets	143,265			125,894
Current liabilities:
Current debt obligations	844			838
Accounts payable	1,945			1,953
Intercompany payable	72			119
Accrued compensation	1,889			2,186
Accrued income taxes	457			567
Other accrued expenses	3,443			2,834
Total current liabilities	8,650			8,497
Long-term debt	9,903			14,511
Accrued compensation and retirement benefits	1,598			1,651
Accrued income taxes	2,728			2,828
Intercompany loans payable	14,899			17,699
Deferred tax liabilities	1,282			1,278
Other liabilities	1,783			756
Total liabilities	40,843			47,220
Shareholders’ equity	102,277			78,553
Noncontrolling interests	145			121
Total equity	102,422			78,674
Total liabilities and equity	$ 143,265			$ 125,894

Guarantor Financial Informati_5

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	9 Months Ended
	Jan. 24, 2020	Jan. 25, 2019
Operating Activities:
Net cash provided by (used in) operating activities	$ 5,784	$ 4,920
Investing Activities:
Acquisitions, net of cash acquired	(199)	(1,615)
Additions to property, plant, and equipment	(877)	(799)
Purchases of investments	(8,249)	(1,987)
Sales and maturities of investments	5,791	4,159
Capital contribution paid	0	0
Return of capital	0
Other investing activities	(34)	(3)
Net cash provided by (used in) investing activities	(3,568)	(245)
Financing Activities:
Change in current debt obligations, net	17	(696)
Issuance of long-term debt	5,568	3
Payments on long-term debt	(5,606)	(29)
Dividends to shareholders	(2,170)	(2,022)
Issuance of ordinary shares	585	891
Repurchase of ordinary shares	(1,208)	(2,728)
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	0	0
Other financing activities	(74)	10
Net cash provided by (used in) financing activities	(2,888)	(4,571)
Effect of exchange rate changes on cash and cash equivalents	(12)	(70)
Net change in cash and cash equivalents	(684)	34
Cash and cash equivalents at beginning of period	4,393	3,669
Cash and cash equivalents at end of period	3,709	3,703
Consolidating Adjustments | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	9,800	65
Return of capital	0
Other investing activities	0	0
Net cash provided by (used in) investing activities	9,800	65
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	(9,800)	(65)
Other financing activities	0	0
Net cash provided by (used in) financing activities	(9,800)	(65)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	19,449	205
Return of capital	0
Other investing activities	0	0
Net cash provided by (used in) investing activities	19,449	205
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	0	0
Capital contribution received	(19,449)	(205)
Other financing activities	0	0
Net cash provided by (used in) financing activities	(19,449)	(205)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	130	100
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	(18)
Return of capital	10,000
Other investing activities	0	0
Net cash provided by (used in) investing activities	10,000	(18)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(2,170)	(2,022)
Issuance of ordinary shares	585	891
Repurchase of ordinary shares	(1,208)	(2,728)
Net intercompany loan borrowings (repayments)	(7,337)	3,777
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	(10,130)	(82)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	130	100
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	0	(18)
Return of capital	10,000
Other investing activities	0	0
Net cash provided by (used in) investing activities	10,000	(18)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(2,170)	(2,022)
Issuance of ordinary shares	585	891
Repurchase of ordinary shares	(1,208)	(2,728)
Net intercompany loan borrowings (repayments)	(7,337)	3,777
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	(10,130)	(82)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(1,315)	(619)
Investing Activities:
Acquisitions, net of cash acquired	2	0
Additions to property, plant, and equipment	(236)	(207)
Purchases of investments	0	0
Sales and maturities of investments	12	76
Capital contribution paid	0	(47)
Return of capital	0
Other investing activities	(56)	0
Net cash provided by (used in) investing activities	(278)	(178)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	(5,016)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	6,591	793
Capital contribution received	0	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	1,575	793
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	(18)	(4)
Cash and cash equivalents at beginning of period	18	20
Cash and cash equivalents at end of period	0	16
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(497)	(62)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	(9,348)	(187)
Return of capital	0
Other investing activities	0	0
Net cash provided by (used in) investing activities	(9,348)	(187)
Financing Activities:
Change in current debt obligations, net	0	0
Issuance of long-term debt	0	0
Payments on long-term debt	(44)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	588	249
Capital contribution received	9,301	0
Other financing activities	0	0
Net cash provided by (used in) financing activities	9,845	249
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	365	200
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	(9,000)	0
Return of capital	(3,000)
Other investing activities	(5)	0
Net cash provided by (used in) investing activities	(12,005)	0
Financing Activities:
Change in current debt obligations, net	0	(696)
Issuance of long-term debt	5,567	0
Payments on long-term debt	(515)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	6,010	814
Capital contribution received	800	0
Other financing activities	(38)	17
Net cash provided by (used in) financing activities	11,824	135
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	184	335
Cash and cash equivalents at beginning of period	1	1
Cash and cash equivalents at end of period	185	336
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	441	219
Investing Activities:
Acquisitions, net of cash acquired	0	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Capital contribution paid	(9,301)	0
Return of capital	(3,000)
Other investing activities	(5)	0
Net cash provided by (used in) investing activities	(12,306)	0
Financing Activities:
Change in current debt obligations, net	0	(696)
Issuance of long-term debt	5,567	0
Payments on long-term debt	(515)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	6,231	795
Capital contribution received	800	0
Other financing activities	(34)	17
Net cash provided by (used in) financing activities	12,049	116
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	184	335
Cash and cash equivalents at beginning of period	1	1
Cash and cash equivalents at end of period	185	336
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes and Medtronic Luxco Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	6,604	5,239
Investing Activities:
Acquisitions, net of cash acquired	(201)	(1,615)
Additions to property, plant, and equipment	(641)	(592)
Purchases of investments	(8,249)	(1,987)
Sales and maturities of investments	5,779	4,083
Capital contribution paid	(800)	0
Return of capital	(7,000)
Other investing activities	27	(3)
Net cash provided by (used in) investing activities	(11,085)	(114)
Financing Activities:
Change in current debt obligations, net	17	0
Issuance of long-term debt	1	3
Payments on long-term debt	(75)	(29)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(5,264)	(5,384)
Capital contribution received	9,000	65
Other financing activities	(36)	(7)
Net cash provided by (used in) financing activities	3,643	(5,352)
Effect of exchange rate changes on cash and cash equivalents	(12)	(70)
Net change in cash and cash equivalents	(850)	(297)
Cash and cash equivalents at beginning of period	4,374	3,648
Cash and cash equivalents at end of period	3,524	3,351
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	5,710	4,663
Investing Activities:
Acquisitions, net of cash acquired	(199)	(1,615)
Additions to property, plant, and equipment	(877)	(799)
Purchases of investments	(8,249)	(1,987)
Sales and maturities of investments	5,791	4,159
Capital contribution paid	(800)	0
Return of capital	(7,000)
Other investing activities	(29)	(3)
Net cash provided by (used in) investing activities	(11,363)	(245)
Financing Activities:
Change in current debt obligations, net	17	0
Issuance of long-term debt	1	3
Payments on long-term debt	(5,047)	(29)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	518	(4,821)
Capital contribution received	9,348	205
Other financing activities	(40)	(7)
Net cash provided by (used in) financing activities	4,797	(4,649)
Effect of exchange rate changes on cash and cash equivalents	(12)	(70)
Net change in cash and cash equivalents	(868)	(301)
Cash and cash equivalents at beginning of period	4,392	3,668
Cash and cash equivalents at end of period	$ 3,524	$ 3,367

Uncategorized Items - mdt-20200

Label	Element	Value
Parent [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ (33,000,000)	[1]
[1]	See Note 2 to the consolidated financial statements for discussion regarding the adoption of accounting standards during the first quarter of fiscal year 2020.